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1
Chapter 1 - General introduction and outline of 
thesis
1.1 Rheumatoid arthritis – an inflammatory disease
Rheumatoid arthritis (RA) is a common systemic autoimmune disease, 
characterised by inflammation of synovial joints. RA is a complex and het-
erogeneous disease, of which the cause is largely unknown. It is likely that 
risk factors include genetic predisposition, as well as environmental and 
life-style factors 1. Genetic studies in RA patients have identified several 
genetic variants that confer increased risk of RA. However, these risk-al-
leles can only explain about one fifth of the cases, indicating that there are 
many risk factors to be discovered 2. Although there might not be a simple 
explanation for the initial development of RA, in the past decades many 
important factors and pathways have been identified in the pathogenesis 
of synovial inflammation.
Healthy synovial joints have a clear joint space, which is filled with syn-
ovial fluid (SF). SF serves as a lubricant and is produced by the synovi-
al lining: a thin membrane of one or two layers of cells. Inflammation of 
synovial joints is characterised by the influx of immune cells into the joint 
space and a thickening of the synovial lining. Activated immune cells, like 
monocytes, macrophages, neutrophils and lymphocytes, locally produce 
pro-inflammatory cytokines and chemokines. These factors promote car-
tilage damage and bone erosion, either directly through the activation of 
matrix-metalloproteinases (MMPs) and reactive oxygen species, or indi-
rectly by acting as a chemo-attractant for other immune cells 3(Figure 1). 
RA is usually treated with a combination of non-steroidal anti-inflammato-
ry drugs (NSAIDS), such as diclofenac, and disease-modifying anti-rheu-
matic drugs (DMARDS), such as methotrexate 3. Although these drugs 
are generally successful in reducing inflammation and pain by inhibition of 
prostaglandins and suppression of the immune system, there is a need for 
better therapeutics. Recent research has focussed on the development 
of drugs that specifically target important pro-inflammatory mediators 4. 
One such mediator is tumour necrosis factor (TNF), which is elevated 
in SF and serum from RA patients. Specific inhibitors to TNF have been 
developed and are now routinely used in the clinic for patients that need 
additional treatment besides the standard NSAID and DMARD cocktail 1. 
Anti-TNF greatly reduces inflammation and associated clinical parameters 
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in about 70% of patients. There is no indication why the remaining 30% of 
patients do not respond to TNF-blockade, but it is thought that these pa-
tients might benefi t from inhibition of other pro-infl ammatory factors 4. Two 
very recent additions to the list of candidate pro-infl ammatory mediators 
in RA are GM-CSF and IL-17, which are now considered key factors in the 
pathogenesis of RA and other infl ammatory diseases.
Figure 1: Schematic overview of a healthy synovial joint (left) and an 
infl amed arthritic joint (right).
Arthritic joints are characterised by thickening of the synovial lining, formation of pannus tissue 
and an infl ux of infl ammatory cells into the joint space. Cartilage damage is caused by invading 
cells through the production of infl ammatory mediators such as cytokines and matrix-degrading 
enzymes. Infl amed synovium undergoes extensive angiogenesis and promotes the recruitment and 
local differentiation of activated macrophages, dendritic cells, lymphocytes, and mast cells. Locally 
produced pro-infl ammatory cytokines induce differentiation and proliferation of osteoclasts, leading 
to bone erosion.
Healthy joint Arthritic joint
Hyperplastic
synovial lining
Dendritic cell
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1.2 GM-CSF and IL-17 in arthritis
GM-CSF is best known as a haemopoietic growth factor that induces dif-
ferentiation and proliferation of myeloid progenitor cells bearing the GM-
CSF receptor 5. However, GM-CSF also regulates many processes in ma-
ture cells, such as macrophage polarisation, cytotoxicity and induction of 
cytokine production 6. GM-CSF was one of the first factors identified in 
synovial fluid of RA patients7,8. Research aimed at unravelling the role of 
GM-CSF in disease pathogenesis was greatly accelerated by the gener-
ation of mice deficient for GM-CSF or the GM-CSF receptor 9-12. Perhaps 
surprisingly, these mice have relatively normal levels of haemopoietic 
cells, and the development of myeloid cells was largely unaffected by the 
absence of GM-CSF. Regardless, GM-CSF deficient mice are protect-
ed from disease in many animal models for autoimmune inflammation, 
such as collagen-induced arthritis (CIA) 13, acute inflammatory arthritis 
(mBSA/IL-1β model) 14, acute inflammatory peritonitis 15, experimental au-
toimmune encephalomyelitis (EAE, a model for multiple sclerosis) 16 and 
experimental autoimmune myocarditis (EAM) 17. Protection from disease 
could also be achieved by specific inhibition of GM-CSF using neutralising 
antibodies 18,19. These findings suggested that GM-CSF plays an import-
ant role in the initiation and progression of inflammatory processes. Due 
to these observations, GM-CSF is now classified not only as a growth 
factor, but also as a pro-inflammatory cytokine. GM-CSF is produced by 
many cell types (Table 1), and can be induced by other pro-inflammato-
ry cytokines such as IL-1  and TNF. It was suggested that GM-CSF is a 
key player in a cytokine network that allows cross talk between myeloid 
and haemopoietic cells during inflammation 6(see Chapter 2, Figure 1). 
Recently, a surprising new role of GM-CSF was discovered, when it was 
found that GM-CSF was essential for the production of IL-6 and IL-23 by 
dendritic cells (DC) and for the differentiation of pathogenic Th17 cells 17. 
Th17 cells are characterised by the production of IL-17, a pro-inflammatory 
cytokine that was shown to be a crucial mediator of many autoimmune 
and inflammatory processes (Table 1). Like GM-CSF, IL-17 is elevated in 
RA SF, synovial tissue and serum, suggestive of a role in RA pathogen-
esis 20. Animal models for inflammatory arthritis have been instrumental 
in providing insight into the role of IL-17 in RA. IL-17 was shown to cause 
synovial inflammation, cartilage damage and bone erosion after local 
overexpression in knee joints 21. IL-17 can directly activate chondrocytes, 
inhibit matrix synthesis and induce the production of MMPs 22, and IL-17 
induces neutrophil recruitment through the induction of G-CSF and IL-8. 
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In addition, IL-17 promotes osteoclastogenesis 20,23 and the production of 
pro-inflammatory cytokines, chemokines and matrix-degrading enzymes 
in many cell types 22,24-27. Several groups have reported that blockade of 
IL-17 during chronic or acute inflammatory arthritis reduced joint pathol-
ogy 28-31. However, therapeutic blockade of IL-17 during animal models of 
arthritis did not confer complete protection from disease 27,30, suggesting 
that IL-17 alone might not be a dominant pathogenic cytokine. Indeed, the 
potency of IL-17 was strongly increased through synergy with TNF 27,32-35, 
and it is likely that IL-17 can synergise with other pro-inflammatory cyto-
kines 3,36.
The connection between GM-CSF and IL-17 became more defined when 
it was found that GM-CSF-deficient Th17 cells failed to elicit neuro-in-
flammation during EAE 37. This finding suggested that the specific cellular 
source of GM-CSF is important during inflammation, a result supported by 
other recent reports 38,39. T cell-derived GM-CSF induces the production 
of IL-6 and IL-23 in macrophages and DC, providing a positive feedback 
for the further differentiation and maintenance of pathogenic Th17 cells. 
In addition, T cell derived GM-CSF is required for the differentiation of 
inflammatory monocyte-derived DC 38 (Chapter 5 of this thesis).
The research described in this thesis had the following two aims: 1) dis-
secting the role of GM-CSF in experimental inflammation; and 2) clarifying 
the relationship between GM-CSF, IL-17 and Th17 cells in the context of 
inflammation, and in particular during experimental arthritis. 
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1.3 Outline of the thesis
The recently discovered pro-inflammatory properties of GM-CSF and the 
need for better therapeutics for inflammatory conditions such as RA, have 
led to the development of GM-CSF-inhibitors for the clinic. In Chapter 2, 
the background and current state of the art of therapeutic inhibition of GM-
CSF are reviewed.
To specifically study the role of T-cell derived GM-CSF, two different ap-
proaches can be taken: specific overexpression and specific deletion of 
GM-CSF in T cells. In Chapter 3 we investigated the effect of T-cell spe-
cific overexpression of GM-CSF, through the generation of a transgenic 
mouse. Surprisingly, transgenic mice that overexpress GM-CSF in T cells 
developed a condition with many similarities to the human disease Lang-
erhans cell Histiocytosis (LCH). The cause of this rare disease is unclear, 
and hence there is no rational cure. Current treatment options include 
chemotherapy, which is effective but has many unwanted side effects. We 
identified T-cell derived GM-CSF as a potential key player in the patho-
genesis of LCH. In view of the recently developed GM-CSF inhibitors for 
other inflammatory diseases, blockade of GM-CSF might also be an op-
tion for the treatment of LCH.
In Chapter 4 we studied the local development of Th17 cells in a model of 
acute inflammatory arthritis. The mBSA/IL-1β arthritis model is mediated 
by GM-CSF and Th17 cells. We show that differentiation of Th17 cells in 
inflamed synovial joints is induced by the production of IL-1β, IL-6, IL-23 
and TGF-β by synovial macrophages. Interestingly, Th17 differentiation 
was only apparent in the synovium, and not in the draining lymph nodes. 
This suggests that, at least in this arthritis model, there is an influx of naïve 
T cells into the inflamed joint followed by Th17 differentiation, rather than 
a direct influx of circulating Th17 cells.
In Chapter 5 we investigated the role of NF-κB1 during acute inflammato-
ry mBSA/IL-1β arthritis and acute inflammatory peritonitis. We discovered 
that NF-κB1-deficient mice are protected from disease due to a defect in 
GM-CSF production by T cells. We also show that T cell-derived GM-CSF 
is required in these models for the local differentiation of inflammatory DC.
In Chapter 6 we neutralised GM-CSF and IL-17 after onset of CIA and de-
termined the effects on disease progression and joint damage. We found 
a significant improvement on disease parameters when both GM-CSF 
and IL-17 were inhibited. In addition, we used adenoviral vectors to overex-
press GM-CSF and/or IL-17 in naïve knee joints. Although overexpression 
of each of the cytokines caused extensive inflammation and joint damage, 
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combined overexpression had an additive and synergistic effect. An im-
portant finding in this study was that inhibition of each of these cytokines 
affected different inflammatory mediators. Likewise, overexpression of the 
separate cytokines had differential effects on cytokines, chemokines and 
matrix-degrading enzymes. From this study we concluded that there is a 
rationale for the combined inhibition of GM-CSF and IL-17 in inflammatory 
diseases.
In Chapter 7 we give an overview of the background and potential of IL-17 
as a therapeutic target in rheumatoid arthritis and other auto-inflammato-
ry disorders. Chapter 8 contains a summary and brief discussion of the 
results described in this thesis. 
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Abstract 
GM-CSF is a well-known haemopoietic growth factor that is used in the 
clinic to correct neutropenia, usually as a result of chemotherapy. GM-
CSF also has many pro-inflammatory functions and recent data impli-
cates GM-CSF as a key factor in Th17 driven autoimmune inflammatory 
conditions. In this review we summarise the findings that have led to the 
development of GM-CSF antagonists for the treatment of autoimmune 
diseases like rheumatoid arthritis (RA) and discuss some results of recent 
clinical trials of these agents.
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2.1 Biology of GM-CSF
2.1.1. Production of GM-CSF
Granulocyte macrophage colony stimulating factor (GM-CSF, or CSF2) 
was first purified from LPS treated mouse lung-conditioned medium. It 
was subsequently characterised as a haemopoietic growth factor that 
stimulates the proliferation of myeloid cells from bone-marrow progenitors 
1. Human and mouse GM-CSF share a high level of amino acid homology 
2,3, but are species-specific in terms of receptor binding 4. GM-CSF can 
be produced by a wide variety of cell types, including activated T cells, 
B-cells, macrophages, endothelial cells, fibroblasts and tumour cells 5. 
The production of GM-CSF can be stimulated by a range of factors, in-
cluding T cell receptor and co-receptor stimulation 6,7, toll like receptor 
(TLR) agonists, TNFα, IL-1β and prostaglandin E2 8,9 (Figure 1).
2.1.2. Action of GM-CSF on mature cells
Besides the production and differentiation of haemopoietic cells from pre-
cursors, GM-CSF is now recognised to have a range of other functions 
on mature haemopoietic cells, including enhanced antigen presentation, 
induction of complement- and antibody-mediated phagocytosis, and pro-
motion of leukocyte chemotaxis and adhesion 5,10-12. GM-CSF, in combina-
tion with other inflammatory stimuli, can polarise macrophages into “M1-
like” inflammatory macrophages 13,14. M1-macrophages produce a range 
of inflammatory cytokines, such as TNF, IL-6, IL-12p70 and IL-23. In con-
trast, “M2-like” macrophages are maintained in a non-activated state by 
M-CSF, and produce anti-inflammatory factors IL-10 and CCL2 13,14. In the 
central nervous system, GM-CSF can activate resident macrophage-like 
microglia and promote neuro-inflammation through the upregulation of 
TLR4 and CD14 15. In mature neutrophils, the integrin CD11b is upregu-
lated by GM-CSF, which increases adhesion to vascular endothelium and 
tissue entry 16. Priming of neutrophils by GM-CSF increases antimicrobial 
functions, such as phagocytosis and oxidative burst 17,18. GM-CSF can 
have multiple effects on mature DC, such as increased cross-presentation 
19 and increased uptake capacity 20. GM-CSF also induced proliferation of 
CD103+ intestinal dendritic cells in vivo in mice 21. How GM-CSF regulates 
the development and function of dendritic cell subsets is summarised in a 
recent review 22. GM-CSF can also activate non-haemopoietic cells, such 
as endothelial cells and sensory neurons 23,24. Elevated tissue levels of 
GM-CSF have been detected in multiple inflammatory conditions, includ-
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Figure 1: GM-CSF as a therapeutic target for infl ammation and pain
The effects of inhibition of GM-CSF on infl ammation and pain are shown. Inhibition of GM-CSF 
during infl ammation (e.g., joint infl ammation during RA or neuro infl ammation during MS) may in-
hibit differentiation, adhesion, chemotaxis and activation of multiple infl ammatory and immune 
cells such as monocytes, macrophages, neutrophils, DC, microglia and their respective precursors. 
GM-CSF inhibition may therefore reduce the production of other infl ammatory cytokines, such as 
IL-1β, TNF, IL-23 and IL-6. These cytokines are particularly important in shaping the responses of T 
cells, causing differentiation and production of infl ammatory cytokines such as IL-17 and GM-CSF, 
through the activation of transcription factors ROR-γT and NF-κB. DC - dendritic cell; COX2 - cyclo-
oxygenase 2; CNS – central nervous system.
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ing RA, multiple sclerosis (MS), obesity, lung disease and cancer 9.
2.1.3. GM-CSF: a T cell cytokine
Several recent findings have sparked interest in the relationship between 
GM-CSF and T cells. The discovery that GM-CSF promotes the induction 
and survival of Th17 cells via IL-6 and IL-23 and that GM-CSF is required 
for the pathogenicity of Th17 cells in experimental allergic encephalomy-
elitis (EAE), shows that GM-CSF is relevant outside of the myeloid cell lin-
eage 25,26. In these studies, GM-CSF was shown to be induced via ROR-
γt, a lymphocyte-specific transcription factor that was initially described as 
the master regulator for Th17 development 27. Production of GM-CSF by T 
cells is also regulated by the transcription factor NF-κB 28-30. It was shown 
that T cells specifically require the NF-κB1 subunit (p50, most likely as 
part of the active p50/p65 NF-κB heterodimer) for production of GM-CSF, 
and that T cell-derived GM-CSF was crucial for the local differentiation of 
monocyte derived inflammatory dendritic cells in synovial tissue during a 
model of inflammatory arthritis 28. 
2.2 The GM-CSF receptor
The GM-CSF receptor (CSF2R) is a heterodimer, composed of a specific 
ligand-binding α-chain (CSF2Rα), which binds GM-CSF with low affinity 
and a signal-transducing β-chain (CSF2Rβ) 31,32. High affinity binding fol-
lows dimerization of both chains. For signal transduction, the cytoplasmic 
domains of both the α and β chain are required, but it is mainly the β chain 
that binds JAK2 16. Signalling from the CSF2R complex activates the Ras/
MAPK and JAK/STAT/SOCS pathways 16,33,34. Alternative signalling path-
ways, such as the c-fps/fes pathway, have also been suggested 35. The 
CSF2R is expressed on myeloid cells and on some non-haemopoietic 
cells, such as endothelial cells 36,37, but interestingly, not on T cells 38. In 
both mice and humans, the β-subunit is shared with the GM-CSF, IL-3, 
and IL-5 receptors, and is known as the common β chain (βc) 32,39,40. In the 
mouse, an additional IL-3–specific β-chain exists, known as βIL-3 41, which 
is used in preference to βc for signalling by IL-3 42. 
In addition to the membrane-bound form of the CSF2Rα, multiple splice 
variants of soluble CSFR2 have been described, both in vitro and in vivo 
43-45. It is not clear whether these soluble receptors are of functional im-
portance, but they may inhibit the ligand-membrane bound CSFR2 inter-
action 46.
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2.3 Too much or too little?
Abnormalities in GM-CSF production or CSF2R function have been impli-
cated in multiple human pathologies such as RA 47, juvenile myelomono-
cytic leukaemia 48, chronic myelomonocytic leukaemia 49 and pulmonary 
alveolar proteinosis (PAP) 50,51. Many of the features of these human con-
ditions have been studied in mice deficient for GM-CSF or the CSF2R and 
mice that overexpress GM-CSF. In addition, therapeutic blockade of GM-
CSF in animal models using neutralising antibodies has yielded crucial 
pre-clinical information.
2.3.1. GM-CSF and CSF2R knock out mice
Mice have been generated that are deficient in GM-CSF 52. Surprisingly, 
these mice do not have a defect in myeloid cell development, but display 
extensive infiltration of the lungs with lymphocytes and defective matura-
tion of alveolar macrophages 52. As a consequence, there is accumulation 
of lung surfactant, which results in the development of a lung phenotype 
equivalent to idiopathic PAP 52-55. In humans, PAP is a rare lung disease in 
which patients present with an accumulation of surfactant proteins in the 
lungs that interferes with gas exchange. In some patients this can render 
them slightly more susceptible to infections 54. Notably, GM-CSF deficient 
mice have been reported to have a somewhat increased mortality from 
microbial infections 52,53. This suggests that GM-CSF plays an important 
role in the host response to infectious agents, particularly in the lungs, 
possibly through regulating macrophage function 5. More recently it was 
shown that GM-CSF deficient mice also have a defect in the maturation of 
invariant natural killer cells 56, which could be important in innate immunity. 
Mice lacking GMCSF are protected from a wide range of autoimmune 
disease models, such as methylated BSA(mBSA)/IL1 induced arthritis 57, 
collagen induced arthritis (CIA) 58, EAE 59 and experimental autoimmune 
myocarditis (EAM) 60. Intriguingly, these models all require T cells to de-
velop pathology. 
Mice deficient for the β-chain (CSF2Rβ) of the GM-CSF receptor have 
also been generated 61,62. Although the phenotype of these mice cannot 
be attributed to perturbed signalling of GM-CSF alone, due to the acti-
vation of this receptor subunit by IL-3 and IL-5 32,39,40, the phenotype was 
in many aspects similar to that of the GM-CSF deficient mice. CSF2Rβ 
gene knockout mice displayed a lung phenotype resembling PAP, and had 
normal development of haemopoietic cells 62,63. Taken together, the data 
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from GM-CSF gene knockout animals clearly illustrates that GM-CSF and 
the GM-CSF receptor are not essential for steady state haemopoiesis, but 
play more complex biological roles.
2.3.2. Overexpression of GM-CSF
Systemic administration of GM-CSF is used in the clinic for treatment of 
neutropenia after chemotherapy 12, and as an adjuvant in anti-tumour im-
munity 64,65. However, when GM-CSF is administered to patients with Fel-
ty’s syndrome, a flare of RA can occur 66. Likewise, administered GM-CSF 
also exacerbated arthritis in mice 67. In addition, GM-CSF given as an ad-
juvant with a whole-cell melanoma vaccine caused systemic recruitment 
of eosinophils and basophils and was connected with a trend towards 
worse survival 68. These findings illustrate that not only the relative ab-
sence, but also the abundance, of GM-CSF can have significant effects 
on the immune system.
Besides exogenous administration of GM-CSF, there have been numer-
ous studies in which GM-CSF was overexpressed endogenously, either 
transiently using adenoviral vectors 69,70 or constitutively using transgen-
ic mice 71-75. A common feature of these transgenic animal models was 
local macrophage and DC recruitment/differentiation, with phenotypes 
including blindness due to accumulation of macrophages in the eye, my-
elo-proliferation and inflammatory tissue destruction 71, the induction of 
autoimmune gastritis 72, and the development of disseminated histiocy-
tosis 75. These models emphasize the importance of regulating the level 
of bioactive GM-CSF to prevent exaggerated myelopoiesis or a break of 
immune tolerance.
2.3.3. Experimental blockade of GM-CSF
Genetic ablation of GM-CSF or CSF2R has provided many insights into 
the role of GM-CSF and GM-CSF signalling in steady state and emer-
gency haemopoiesis and autoimmunity. However, for the development of 
neutralising GM-CSF therapeutics for inflammatory disorders, it is para-
mount that inhibition is evaluated during pathological processes. For the 
treatment of RA for instance, it is anticipated that GM-CSF blockade might 
be an option for patients who do not respond adequately to convention-
al treatment, so these patients will have pre-existing inflammation. The 
therapeutic effect of GM-CSF blockade after disease onset was shown 
in CIA 76, streptococcal cell wall-induced arthritis (SCW) 77, mBSA/IL-1 78, 
Alzheimer’s disease 79 and LPS-induced lung infection 80. In all of these 
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studies, there was rapid improvement in established disease features. 
An important issue for the development of GM-CSF inhibitors is the pos-
sibility of adverse effects, in particular PAP and increased susceptibility to 
microbial lung infections 51. To date, these effects have not been observed 
in animals treated with anti-GM-CSF. It is not clear if this is due to the 
duration and extent of GM-CSF deficiency, locally controlled regulation of 
GM-CSF during PAP, or because experimental animals are housed under 
controlled conditions and are exposed to a reduced infectious load.  As 
many cytokine inhibitors have been trialled and approved in a broad range 
of inflammatory conditions, physicians and regulatory authorities have a 
strong understanding of managing the risk of opportunistic infections, 
however additional lung monitoring is likely required in human clinical tri-
als of GM-CSF inhibitors in which patients may present with a different 
side effect profile.
2.4 GM-CSF and Th17 cells
Perhaps surprisingly, GM-CSF is actually produced in high levels by T 
cells during inflammation 81-83 and it has been found recently that GM-
CSF is linked to the IL-23/IL-17 pathway 25,26,28,75,84. GM-CSF promoted 
the induction and survival of autoimmune Th17 effector cells in a CD4 T 
cell-mediated model of myocarditis 60. During models of acute inflamma-
tory arthritis or peritonitis, GM-CSF production by T cells was dependent 
on NF-κB1 and was required for the local differentiation of inflammatory 
monocyte derived DCs 28. It was also shown that GM-CSF is essential for 
the pathogenicity of Th17 cells and for the CCR4-dependent production of 
IL-23 by DC in EAE 25,26,84. The production of GM-CSF was regulated not 
only by the transcription factor NF-κB1, but also by ROR-γt 25. As noted in 
paragraph 2, T cells lack GMCSF receptors and so the effect of T cell de-
rived GM-CSF on Th17 mediated inflammation occurs via enhancement 
of IL6 and IL23 production from antigen presenting cells (APC) 26. Through 
binding to their respective receptors on T cells, IL-6 and IL-23 enhance 
GM-CSF production by T cells, creating a positive feedback loop 26. The 
close relationship between GM-CSF and IL-17 in inflammatory conditions 
suggests that therapeutic inhibition of one of these molecules might have 
an effect on the other. It will be interesting to see what happens to the 
level of GM-CSF in patients treated with IL-17 inhibitors that are currently 
in clinical trials 85. Since IL-17 inhibitors reduce the number of Th17 cells 
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in the circulation, one would assume there will also be a reduction in the 
level of GM-CSF production 85. However, it is also possible that the effects 
on Th17-derived GM-CSF are mostly local, at the site of inflammation, 
and difficult to measure due to the generally low levels of GM-CSF in the 
circulation.  Likewise, the levels of IL-17 and the number of Th17 cells are 
likely to be affected in patients treated with GM-CSF inhibitors. The poten-
tial of IL-17 and the IL-17 receptor as therapeutic targets in inflammatory 
conditions has recently been reviewed 86. 
2.5 GM-CSF autoantibodies
Intriguingly, serum GM-CSF in both mice and humans is generally present 
in a complex with GM-CSF autoantibodies 87. Free GM-CSF is maintained 
at very low, often undetectable levels in the serum and tissues 87,88, but is 
nevertheless essential for the maintenance of some myeloid cell functions 
in the lungs. In humans, autoimmune PAP is characterized by high levels 
of auto-antibodies to GM-CSF, or the defective expression of the CSF2R 
50,54,89-92. As described above, the features of human PAP are similar to 
those seen in GM-CSF knockout mice 52. Human GM-CSF autoantibod-
ies inhibit GM-CSF bioactivity 93, thereby reducing GM-CSF–dependent 
cell functions 52-55. GM-CSF autoantibodies are also found at low levels 
in healthy individuals 87. It is possible that these autoantibodies, together 
with soluble CSFR2 molecules, function as additional regulators of GM-
CSF bioactivity in vivo 46,87. To prevent autoimmune pathology and the 
development of PAP, anti-GM-CSF antibodies and the levels of free GM-
CSF need to be maintained in a tightly controlled balance. This balance 
will need to be considered with the introduction of anti-GM-CSF therapeu-
tics for inflammatory conditions 5,87.  
2.6 GM-CSF inhibitors in the clinic
Conventional disease-modifying anti-rheumatic drugs (DMARDS), such 
as methotrexate, are routinely used alone or in combination for the treat-
ment of RA. However, despite the beneficial effect on clinical symptoms 
and joint damage, DMARDS do not yield the desired outcome for some 
patients 94. In the past decade, new biological therapies have been intro-
duced in the clinic or are currently in clinical trials for RA and other inflam-
matory conditions, which has significantly improved clinical outcomes 95. 
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These therapies include TNF inhibitors (infliximab, etanercept, adalimum-
ab, certolizumab and golimumab), a B-cell-depleting anti-CD20 antibody 
(rituximab), an inhibitor of costimulation (cytotoxic T-lymphocyte antigen-4 
fusion (CTLA-4) protein abatacept), an IL-1 receptor antagonist (anakinra) 
and an inhibitor of the IL-6 receptor (tocilizumab) 94,96. However, about 
30% of patients treated with anti-TNF agents show no clinical benefit, and 
only a minority of patients achieve disease remission 96. The other four 
biologicals abatacept, rituximab, anakinra and tocilizumab have now been 
approved for use in RA patients, and have shown variable clinical efficacy 
in reducing disease activity in patients for whom TNF inhibitor therapy 
fails 97. There is great interest in trying to understand the basis for clinical 
response, or lack of response, to these agents in order to better tailor an-
ti-cytokine therapy for individual patients. 
Collectively, a wealth of pre-clinical studies now highlight GM-CSF as a 
key mediator of inflammatory and immune disorders, suggesting it might 
be an excellent candidate for therapeutic intervention 9,98. The action of 
GM-CSF can be inhibited by at least two different approaches: inhibition 
of GM-CSF itself by neutralising antibodies, or the specific blockade of 
GM-CSF binding to its receptor by antibodies against the GM-CSF re-
ceptor α chain. Both approaches have resulted in either humanised or ful-
ly human anti-GM-CSF and anti-CSF2Rα therapeutics that are currently 
being tested in clinical trials. Mavrilimumab, a fully human antibody that 
binds CSF2Rα, thereby preventing signalling through this receptor, has 
now successfully been tested in Phase I and Phase II clinical trials in RA 
patients 99,100. In a recent study of patients with active RA in spite of meth-
otrexate, 55.7% of all participants treated with subcutaneous injection of 
mavrilimumab (every two weeks for 12 weeks) met the primary end point 
of achieving ≥ 1.2 decrease from baseline in the disease activity score 
(DAS28-CRP) at week 12. At the highest dose of mavrilimumab (100mg), 
66.7% of subjects met the primary endpoint compared with 34.7% of pla-
cebo subjects. Treatment responses were often rapid, with differences 
observed between placebo as early as two weeks, and were sustained 
during 12 weeks of follow up. Throughout the duration of this study ad-
verse events were reported as mild or moderate in intensity. Of note is 
that there were no significant pulmonary complications reported during 
the study 100. Likewise, MOR103, another fully human high affinity anti-
GM-CSF monoclonal antibody, has also recently completed evaluation in 
a Phase Ib/2a trial in RA patients, with an acceptable safety profile and 
indications of efficacy 101.  Whilst both clinical studies were different in 
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size, route of administration and duration, it is noteworthy that both report 
a rapid onset of action and provide evidence of clinical efficacy that sup-
port further clinical investigation. In addition to RA, MOR103 is currently 
being tested in a Phase Ib trial for multiple sclerosis (MS) 102.  A panel of 
other GM-CSF inhibitors are also under under investigation, however re-
sults have not yet been reported.  Of particular note is KB003, which is a 
“humaneered” anti GM-CSF antibody that is currently undergoing clinical 
trials in severe asthma 103. Whilst there is compelling evidence that this 
pathway also plays a role in severe respiratory diseases such as asthma 
and chronic obstructive pulmonary diseases (COPD) 104,105, a fine dosing 
balance may have to be achieved so as not to promote additional pulmo-
nary complications.
2.7 GM-CSF and pain
Pain is one of the main symptoms of inflammatory diseases like RA, and 
rated as one of the highest priorities by RA patients 106,107. The relatively re-
cent and surprising finding that functional GM-CSF receptors are present 
on sensory nerves has led to the investigation of GM-CSF as a mediator 
of pain 24. In this study, GM-CSF secreted by tumour cells was linked to 
signal transduction in nociceptors, and directly mediated bone tumour-in-
duced pain. It was suggested that the locally produced GM-CSF at sites 
of inflammation or tumour could sensitise nociceptors. The high levels of 
GM-CSF found in inflammatory synovitis could therefore be linked to joint 
pain experienced by RA patients. This link has recently been examined in 
animal models of inflammatory arthritis and osteoarthritis 108,109, where it 
was shown that GM-CSF was required for arthritic pain. GM-CSF deficient 
mice were completely protected from pain associated with the induction 
of inflammatory arthritis. Interestingly, GM-CSF mediated pain could be 
relieved by the administration of the cyclooxygenase inhibitor indometha-
cin, but this did not have any effect on joint inflammation 109. These results 
raise the possibility that GM-CSF inhibitors might be of particular value in 
relieving pain as well as inflammation. 
2.8 Concluding remarks
There are many facets to GM-CSF biology – haemopoietic growth factor, 
inducer of myeloid and T cell differentiation, pro-inflammatory mediator 
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and neuromodulator. The pre-clinical data provides a strong rationale for 
considering GM-CSF as a potential therapeutic target for inflammatory 
diseases. Recent trials with specific GM-CSF or CSF2R inhibitors prom-
ise improved treatment options for patients with inflammatory conditions. 
Careful monitoring for potential side effects, particularly PAP, remains 
paramount, but we anticipate anti-GM-CSF therapeutics will be of value 
for many autoimmune and inflammatory conditions and perhaps tumour 
associated pain. Continued study of the in vivo consequences of GM-CSF 
inhibition in patients with inflammatory diseases will no doubt provide fur-
ther insights into this fascinating cytokine.
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Abstract
Recent studies highlight surprising roles for granulocyte-macrophage col-
ony stimulating factor (GM-CSF) production by T cells. T cell-derived GM-
CSF is required for the differentiation of monocyte-derived inflammatory 
DC during inflammation and for the pathogenicity of Th17 cells in autoim-
munity. In order to gain further insight into these findings, we engineered 
in vivo over-expression of GM-CSF specifically in T cells, under the con-
trol of the Lck promoter. Lck-GM-CSF transgenic (TG) mice displayed a 
dramatic phenotype, characterized by splenomegaly, lymphadenopathy, 
thymic atrophy and multiple abnormalities in blood cell populations. Thy-
mocyte differentiation was severely affected, and there was a dramatic 
increase in regulatory T cells in the thymus and peripheral lymphoid or-
gans. Lck-GM-CSF TG mice developed a disseminated histiocytosis and 
had increased circulating Th17-related cytokines. The pathology in Lck-
GM-CSF TG mice resembles that of histiocytic human diseases, such 
as Langerhans Cell Histiocytosis (LCH). The etiology of many histiocytic 
disorders is unknown, but our findings suggest that over-production of 
GM-CSF by T cells could be a pathogenic factor and raise the possibility 
that GM-CSF may represent a novel therapeutic target. 
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3.1 Introduction
Although granulocyte macrophage colony stimulating factor (GM-CSF) 
was first described as a haematopoietic regulator that stimulates the ex-
pansion and differentiation of myeloid cells from bone-marrow progeni-
tors, it is now recognized to have multiple functions 1. Interestingly, GM-
CSF is produced by T cells and is transiently upregulated in CD4 and 
CD8 T cells upon stimulation through the T cell receptor and co-stimu-
latory molecules, such as CD28 2. Recently, IL-23 and the transcription 
factor ROR-γt were also found to drive GM-CSF production by Th17 cells 
3. However, GM-CSF is unlikely to act directly on T cells, as these cells 
lack expression of the GM-CSF receptor 4,5.
We recently reported that T-cell derived GM-CSF plays a pivotal role 
in acute inflammatory peritonitis and during acute inflammatory arthri-
tis 6. Production of GM-CSF by murine T cells was NF-κB1 depend-
ent, showing that transcription factors other than ROR-γt can drive 
its production. T cell derived GM-CSF stimulated the differentiation 
of monocyte derived inflammatory dendritic cells (MoDC), most like-
ly through the recruitment of monocyte precursors via CCL2 (MCP-
1). Other recent studies showed that GM-CSF promotes the induc-
tion and survival of Th17 cells via IL-6 and IL-23, and that GM-CSF is 
required for the pathogenicity of Th17 cells in experimental allergic 
encephalomyelitis 3,7. These discoveries, and the knowledge that 
GM-CSF-deficient mice are protected from several T cell dependent ex-
perimental disease models 8,9, suggest that GM-CSF might be of much 
greater importance for T cell function than previously thought.
 
Several models of transgenic over-expression of GM-CSF - either sys-
temically 10, or within non-haematopoietic tissues - have been previously 
described 11-14. A common feature of these models was local macrophage 
and dendritic cell (DC) recruitment/differentiation, with phenotypes includ-
ing blindness due to accumulation of macrophages in the eye 10 and the 
induction of autoimmune gastritis 14. To further dissect the role T cell-de-
rived GM-CSF might play during inflammatory disease, we generated 
transgenic (TG) mice that over-express GM-CSF specifically in T cells, 
using the murine Lck (p56lck) promoter. We found a dramatic phenotype 
in Lck-GM-CSF TG mice, characterized by splenomegaly, lymphade-
nopathy and a remarkable infiltration of both lymphoid and non-lymphoid 
organs by histiocytes. Histiocytes possess hybrid characteristics of DC, 
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macrophages and monocytes and are a classical feature of a range of 
poorly understood human diseases. Our study suggests that increased 
production of GM-CSF by T cells can drive histiocytosis and raise the pos-
sibility that GM-CSF inhibition may be beneficial in some of the histiocytic 
disorders.
3.2 Materials and Methods
Production of lck–GM-CSF transgenic mice
A 446-bp cDNA containing the coding sequence for murine GM-CSF 
(mGM-CSF) was inserted into the BamHI cloning site of the p1017S1 plas-
mid, which is flanked by the T cell-specific murine lck proximal promoter 
and the human growth hormone poly-A tail (hGHpA) 15. A linearized 5715 
bp mGM-CSF transgene construct was injected into the pronucleus of 
fertilized C57BL/6 embryos. Two founder lines of Lck-GM-CSF TG mice 
were generated, with different transgene copy number (as determined by 
Southern Blot, see Figure 1). These founders were designated Lck-GMhi 
and Lck-GMlo, respectively. TG mice were maintained in the heterozygous 
state on a C57BL/6 background. 
Southern Blot for Lck-GM-CSF transgene detection
Genomic DNA from TG mice and wild-type (WT) littermate controls was 
purified from spleen by standard protocols and 5 µg (Lck-GMhi) or 10 µg 
(Lck-GMlo) of DNA was digested overnight with Pst1 at 37°C. DNA was run 
on a 0.8% TAE agarose gel, transferred to Hybond N+ nylon membrane, 
probed with a murine GM-CSF-specific 32P-dATP labeled 446 bp cDNA 
and visualized by a Phospho Imager (BioRad, Gladesville NSW, Austral-
ia).
Quantitative RT-PCR for GM-CSF and ROR-γt expression 
Total RNA was purified using RNeasy columns (Qiagen, Chadstone VIC, 
Australia). Complementary DNA was prepared by reverse transcription. 
Real-time quantitative PCR was performed using an ABI Prism 7900 (Ap-
plied Biosystems, Mulgrave VIC, Australia) instrument and SYBR Green 
reagent, according to manufacturer’s instructions (Qiagen, Chadstone 
VIC, Australia). Results were normalized (ΔCt) for hydroxymethylbilane 
synthase (hmbs) RNA content. ΔΔCt was calculated as ΔCt (TG) - ΔCt 
(WT) for each sample. Primer sequences were: hmbs 5’-CCT-GGT-TGT-
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TCA-CTC-CCT-GA-3’ (forward) and 5’-CAA-CAG-CAT-CAC-AAG-GGT-
TTT-3’ (reverse); GM-CSF 5’-CCA-GCT-CTG-AAT-CCA-GCT-TCT-C-3’ 
(forward) and 5’-TCT-CTC-GTT-TGT-CTT-CCG-CTG-T-3’ (reverse); ROR-
γt 5’-CCG-CTG-AGA-GGG-CTT-CAC-3’ (forward) and 5’-TGC-AGG-AGT-
AGG-CCA-CAT-TAC-A-3’ (reverse).
Mice
Rag1-deficient (Rag1-/-) mice 16 and GM-CSF-deficient (Csf2-/-) mice 17 
(both back-crossed to the C57Bl/6 background for 15 generations) were 
obtained from the Walter and Eliza Hall Institute (WEHI) animal services 
(Kew VIC, Australia).
Cell culture
Single cell suspensions of pooled superficial LN, LN cells enriched for 
CD4+/CD8+ cells by magnetic bead purification (Miltenyi Biotec, Mac-
quarie Park, Australia) or thymocytes were cultured for 3 days at 0.5 x 106 
cells/well in 96-well culture plates at 37°C, 5% CO2 in RPMI containing 
10% FCS, 20µM 2-ME, 2 mM glutamine and 1mM sodium pyruvate (com-
plete medium, CM). Cells were stimulated on plates coated with 10µg/ml 
anti-CD3 (clone 145-2C11; WEHI, Bundoora VIC, Australia) and 2µg/ml 
anti-CD28 (clone 37.51; WEHI, Bundoora VIC, Australia) monoclonal anti-
bodies (mAb). For analysis of cytokine production by histiocytes, purified 
histiocytes (sorted by flow cytometry) were cultured for 10 hours in CM at 
37°C, 5% CO2.
Immune activation in vivo
Mice were injected with 100µL complete Freund’s adjuvant (CFA, Sig-
ma, Castle Hill, Australia) subcutaneously at the base of the tail. Control 
mice received PBS only. Seven days after CFA injection, superficial LN 
were pooled, single cells suspensions prepared, and cells were re-stimu-
lated in vitro with phorbolmyristate ester (PMA [50ng/mL]) and ionomycin 
(1µg/mL), or medium alone (unstimulated) for 4-6 hours. Production of 
cytokines was determined by intracellular flow cytometry. 
Measurement of GM-CSF in supernatants by ELISA
GM-CSF was measured in culture supernatants with the antibody pair 
MP1-22E9 and biotinylated MP1-31G6 (both from BD Pharmingen, North 
Ryde NSW, Australia), used according to manufacturer’s instructions. 
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GM-CSF bio-assay
The bioactivity of GM-CSF in fresh culture supernatant was tested using 
the GM-CSF dependent FDC-P1 cell line (WEHI). Different concentra-
tions of culture supernatant were added to 1000 FDC-P1 cells/well in the 
presence of 10µg/ml neutralizing anti-IL-3 mAb (clone MP2-8F8, WEHI). 
Cells were cultured in 96-well black optical culture plates (Thermo Sci-
entific, Scoresby, Australia) for 2 days at 37°C, 10% CO2 in Dulbecco’s 
modified Eagle’s medium containing 10% FCS. Proliferation was deter-
mined by adding 20µl/well resazurin (Sigma, Castle Hill, Australia) and 
relative fluorescence units (RFU) were measured at 535nm (excitation) 
and 590nm (emission) after 1, 2, 3 and 4 hours. Optimum fluorescence 
was obtained at 4 hrs.
Measurement of multiple analytes in serum and supernatants
Serum or cell supernatant cytokines and chemokines were measured us-
ing the Bio-Plex mouse cytokine 23-plex panel (BioRad, Gladesville NSW, 
Australia), used according to the manufacturer’s instructions. The assay 
was read on a Bio-Plex 200 instrument and analyzed using Bio-Plex Man-
ager V5.0 software.
Antibodies for flow cytometry
The following anti-mouse antibodies were used: Fcγ Receptor II/III (FcR 
Block) 2.4G2, CD3-biotin, CD4-fluorescein isothiocyanate (FITC), CD4-bi-
otin, CD5- phycoerythrin (PE), CD8-Alexa700, CD8-biotin, CD11b-biotin, 
CD11c-FITC, CD24-PE.Cy5, CD25-PE, CD28-Allophycocyanin (APC), 
CD44-FITC, CD103-Alexa700, CD115-FITC, CD205-PE, CD205-Al-
exa700, F4/80-FITC, F4/80-Alexa700, F4/80-Alexa647, H-2Ab-biotin (all 
from WEHI, Bundoora, Australia); CD3-PE, CD207-Alexa647, Foxp3-APC, 
Ly-6C-Peridinin-chlorophyll-protein-Cyanin5.5 (PerCp-Cy5.5) (all from 
eBioscience, Kensington SA, Australia); CD4-PerCp-Cy5.5, CD8-APC, 
CD8-APC-Cyanin7 (APC-Cy7), CD11b-APC, CD11b-PE-Cy7, CD11c-
PE, CD11c-APC, CD40-PE, CD43-biotin, CD62L-APC, CD62L-APC.Cy7, 
CD64-PE, CD207-Alexa647, GM-CSF-PE, IL-17A-APC, c-kit-APC, MH-
CII-PE, NK1.1-biotin, Ly6C/G-APC, Ly6C/G-PE, SiglecF-PE, Streptavi-
din-PE.Cy7 (all from BD Pharmingen, North Ryde NSW, Australia); CD62L-
PE-TexasRed (Invitrogen, Mulgrave VIC, Australia); CD25-Alexa-700, 
Ly6C-Pacific Blue (PacBlue), F4/80 PacBlue, Qa2-biotin, TCRβ-PE.Cy7 
(from BioLegend, Karrinyup WA, Australia); CX3CR1-PE, CCR2-APC, 
GM-CSFRα-APC, GM-CSFRβ-APC (all from R&D systems, East Bris-
bane QLD, Australia).
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Flow cytometry
Single cell suspensions were prepared by passing organs through a 
70µM cell strainer, or by density gradient as described below. Erythro-
cytes were lysed and cells were then washed with PBS containing 2mM 
ethylenediaminetetraacetic acid (EDTA) and 1% fetal calf serum, treated 
with FcR block (10µg/mL) and stained for flow cytometric analysis. Dead 
cells were excluded by propidium iodide, Fluoro-Gold or Aqua live/dead 
(Invitrogen, Mulgrave VIC, Australia) staining. For intracellular staining of 
CD207, cells were treated with BD Cytofix/cytoperm (BD Biosciences, 
North Ryde NSW, Australia), according to manufacturer’s instructions. For 
intracellular staining of IL-17A and GM-CSF, cells were cultured for 4-6 
hours in CM containing Monensin and Brefeldin (Golgistop, Golgiplug, BD 
Pharmingen, North Ryde NSW, Australia) according to manufacturer’s in-
structions, followed by fixation in Cytofix/cytoperm as above. An LSRII or 
LSR Fortessa instrument was used for flow cytometry (BD BioSciences, 
North Ryde NSW, Australia). Histiocytes were sorted on a MoFlo automat-
ed cell sorter (Beckman-Coulter, Gladesville NSW, Australia).
Enrichment of DC in superficial LN 
To enrich for DCs, light density cells (LDC) were purified as previously 
described 18. Cells were then stained for flowcytometric analysis of DC 
populations and divided into subpopulations based on surface- and intra-
cellular markers, as previously described 19,20. 
Histological analysis of organs and cytospins
TG mice and WT littermates (2 males and 2 females of each genotype at 
6 weeks of age) were analyzed independently (through Australian Phe-
nomics Network, by pathologist Dr. John Finnie, Adelaide, Australia, who 
is expert in the diagnosis of lymphoma; and at WEHI [DM]). 5µM tissue 
sections were stained with haematoxylin and eosin (H&E) and scanned 
using a Zeiss Mirax digital slide scanner (Zeiss, North Ryde NSW, Aus-
tralia). Cells were cytospun onto poly-lysine coated slides, stained with 
May-Grunwald Giemsa or Diff Quick stain (Lab Aids, Narrabeen NSW, 
Australia) and examined using a Zeiss Axioplan 2 microscope, fitted with 
an AxioCam HR camera (Zeiss, North Ryde NSW, Australia). AxioVision 
software (Zeiss, North Ryde NSW, Australia) was used for all analyses of 
microscopic images.
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Differential cell counts of blood and peripheral lymphoid 
organs
Blood was collected by retro-orbital bleed in sodium-EDTA tubes. Spleen, 
LN and thymus were depleted of erythrocytes using ammonium chloride. 
Automated differential cell counts were performed using an ADVIA 120 in-
strument calibrated for murine hematopoietic cells (Siemens, Bayswater, 
Australia). 
In vitro clonogenic analysis of bone marrow and spleen cells
Colony formation by bone marrow and spleen cells was performed as 
previously described 21. 
In vivo phagocytosis of fluorescent latex beads
Phagocytic cells were labeled in vivo, as described 22. Briefly, mice were 
injected intravenously with 250µL 1:25 diluted 0.5-1.0µM YG fluorescent 
latex beads (PolySciences, Gymea NSW, Australia). Organs were analyz-
ed for the presence of latex beads by flow cytometry, as described above.
Figure 1:  (right page) Generation of Lck-GM-CSF transgenic (TG) 
mice.
(A) DNA construct used to inject fertilized C57Bl/6 embryos. (B) Agarose gel and Southern Blot of 
genomic DNA from wildtype (WT) or lck-GM-CSF transgenic mice probed with a 32P labeled trans-
gene-specific probe. (C) Survival curves of male and female TG and WT mice (n = 10-20 mice/group). 
(D) Production of GM-CSF by thymocytes or LN cells, unstimulated, or following 3 days of in vitro 
stimulation with anti-CD3 and anti-CD28 (CD3/CD28). ND = not detected. Results representative of 
two independent experiments. n=2 mice/group. (E) Bioactivity assay for GM-CSF.  Proliferation was 
measured (by fluorescence) of FDC-P1 cells. Cells were incubated with 1/1000 diluted culture su-
pernatant of anti-CD3/anti-CD28 stimulated thymocytes or CD4+/CD8+ LN cells, in the presence of 
anti-IL-3. Results representative of two independent experiments. n=2 mice/group. (F) Quantitative 
RT-PCR for GM-CSF on purified mRNA from thymocytes, total LN cells, sorted LN CD4+ or CD8+ T 
cells and sorted LN CD3- non-T cells. ΔCt was determined by normalization for expression of the 
hmbs gene. ΔΔCt was defined as ΔCt TG – ΔCt of the corresponding WT cell population. Results are 
representative of two independent experiments. n=1-3 mice/group. Mean values ± SEM are shown. 
(G) GM-CSF levels measured by BioPlex in serum from Lck-GM TG mice. n=16 mice per group. 
*p<0.05, unpaired t-test.
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Mixed Leukocyte Reaction (MLR)
Splenic antigen presenting cell (APC) populations from Lck-GMhi mice 
were sorted by flow cytometry, based on expression of F4/80, CD11b and 
CD11c. Where indicated, cells were fixed with 2% PFA for 30 minutes on 
ice. CD3+ responder T cells from BALB/c spleen were purified by magnetic 
bead sorting (AutoMacs, Miltenyi Biotec, North Ryde NSW, Australia), us-
ing anti-CD3-phycoerythrin (PE) labeled antibody (BD Pharmingen, North 
Ryde NSW, Australia) and anti-PE magnetic beads (Miltenyi Biotec, North 
Ryde NSW, Australia), according to manufacturer’s instructions. Sorted 
TG splenocytes were co-cultured with 1 x 105 CD3+ responder cells in a fi-
nal volume of 200µL for 4 days at 37°C/5% CO2. Tritiated thymidine (1µCi/ 
well; Amersham BioSciences, Rydalmere NSW, Australia) was added for 
the final 24 hours of culture, then the supernatant was removed and cells 
were harvested onto glass fiber filters for determination of tritiated thymi-
dine incorporation using a Topcount scintillation counter (Perkin Elmer, 
Glen Waverley VIC, Australia).
Statistical analyses
p-values were determined by Mann-Whitney or Student’s t test, as indicat-
ed in the table and figure legends.
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3.3 Results
Generation and validation of transgenic mice
TG mice were generated by injecting a construct comprising the murine 
proximal Lck promoter, mGM-CSF cDNA and the hGHpA site into fertil-
ised mouse embryos (Figure 1A). TG mice were identified by PCR using 
primers spanning the hGHpA/mGM-CSF junction. Two founders were se-
lected and transgenic offspring confirmed by Southern Blot analysis of 
genomic DNA (Figure 1B). One founder had a higher copy number of in-
tegrated transgene DNA, as judged by a more intense band for the trans-
gene, despite lower loading of DNA (Figure 1B). Founders were therefore 
designated Lck-GMhi and Lck-GMlo. The probe for GM-CSF could also 
detect endogenous GM-CSF, which served as a loading control (Supple-
mental Figure 1). Survival analysis showed that Lck-GMhi mice appeared 
healthy for up to about 23 weeks, then gradually succumbed to spleno-
megaly and anemia (Figure 1C). Lck-GMlo mice appeared healthy for over 
12 months and did not show increased mortality (Figure 1C). 
To assay expression of the Lck-GM-CSF transgene, we cultured thymo-
cytes and LN cells, with or without anti-CD3 and anti-CD28 antibodies. 
Three days later, GM-CSF levels in the supernatant were measured by 
ELISA. Unstimulated thymocytes from both TG lines and unstimulated LN 
cells from the Lck-GMhi line showed increased production of GM-CSF, 
compared to WT cells. Stimulated thymocytes and LN cells from both trans-
genic lines showed markedly increased production of GM-CSF compared 
to WT cells (Figure 1D). To verify the bioactivity of GM-CSF produced by 
Lck-GM TG lymphocytes, these supernatants were diluted and added to 
GM-CSF dependent FDC-P1 cells. Possible interference from IL-3, which 
is also a growth factor for FDC-P1 cells, was blocked by the addition of 
neutralizing anti-IL-3 antibodies.  FDC-P1 cells displayed a dose-depen-
dent proliferation after incubation with T cell cell-supernatants, and this 
was greater with TG supernatants, demonstrating that the Lck-GM-CSF 
transgene produced functional protein (Figure 1E). Increased production 
of GM-CSF was also confirmed using quantitative RT-PCR on unstimu-
lated Lck-GMhi thymocytes and purified LN cell populations (Figure 1F). 
We found a clear increase in GM-CSF transcript (shown by an increase 
in -ΔΔCt) in thymocytes, total LN cells and purified CD8+ LN cells, a slight 
increase in purified CD4+ LN cells, but no increase in CD3- non-T cells. 
Together, these data show that Lck-GM mice express increased levels of 
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functional GM-CSF specifically in the T-cell lineage, with the strongest 
expression in thymocytes and peripheral CD8+ T cells.
Lymphoid abnormalities in Lck-GM-CSF TG mice
To determine the effects of increased T-cell derived GM-CSF on the lym-
phoid system, spleen, LN and thymus were harvested from 6-week-old 
WT and TG mice. Although TG mice and WT littermate had comparable 
body weights (not shown), the weight, cellularity and size of the spleen 
and LN of Lck-GMhi mice were increased, compared to WT littermates 
(Figure 2, Table 1). In contrast, these parameters were reduced in the 
thymus (Figure 2A, Table 1). Some of these differences were also present 
(spleen and LN weight and cell numbers), but were less pronounced, in 
Lck-GMlo mice (Table 1), consistent with a lower transgene copy number 
(Figure 1B). Analysis of the main cell subsets (neutrophils, lymphocytes, 
monocytes, eosinophils and basophils) in spleen and LN revealed that the 
increase in total white cells of spleen and LN included all subsets (Table 
1). Eosinophil numbers were increased dramatically in the spleen, in ac-
cordance with other reports of GM-CSF overexpression 10. Likewise, the 
reduction in cellularity of the thymus was caused by decreased numbers 
of each subset, with the exception of monocytes (Table 1).
Analysis of T-cell subsets in these organs revealed relatively normal 
proportions of CD4+ and CD8+ T-cells in the spleen and lymph nodes of 
Lck-GMhi mice (Figure 2B, left panels). However, a substantial increase 
in the number of CD4+Foxp3+ regulatory T cells was observed in the TG 
mice, as well as a switch from naïve to effector/memory phenotype (Fig-
ure 2B, center and right panels), consistent with a systemic inflammato-
ry process 23. In the TG thymus, thymocyte differentiation was severely 
impaired, with the proportion of immature DP decreased, while DN and 
mature SP subsets were increased (Figure 2C). To examine whether an 
early block in thymocyte differentiation might explain the lower numbers of 
cells, we analysed progression through the CD3/CD4/CD8 triple negative 
(TN) stages.  There was an increase in TN1 cells, suggestive of an early 
differentiation block, but some progression through the TN stages was 
observed (Figure 2C), including β-selection (as judged by CD28 upregu-
lation in the TN3 subset [not shown]).  The distribution of the semi-mature 
and mature single positive thymocytes was severely altered, with large 
proportional increases of the most mature SP cells (defined as CD24lo/
Qa2hi), at the expense of the semi-mature SP cells. We also observed a 
substantial increase in the proportion of CD4+Foxp3+ regulatory T cells 
in the thymus. In the context of markedly reduced thymocyte cellulari-
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ty, these changes are consistent with a severe (but incomplete) block in 
thymic lymphopoiesis, with some recirculation of mature T cells.
Table 1: Weight and absolute numbers of main cell subsets in peripher-
al lymphoid organs 
Spleen LN Thymus
LckGMhi LckGMlo WT LckGMhi LckGMlo WT LckGMhi LckGMlo WT
Weight 
(g) 0,37 ± 0,04 0,11 ± 0,01 0,09 ± 0,01 0,1 ± 0,02 0,05 ± 0,02
0,03 ± 
0,004 0,03 ± 4 0,06 ± 0,01 0,07 ± 0,01
WBC* 2920,5 ± 396,8 616 ± 121,9
479,6 ± 
53,9 88,2 ± 19,9 16,5 ± 4,8 27,7 ± 12,2 21,6 ± 6,7
460,1 ± 
152,2
401,2 ± 
93,9
Neut† 104 ± 20,1 6,6 ± 2,6 3,3 ± 0,77 1,5 ± 0,18 0,64 ± 0,18 1,1 ± 0,38 0,7 ± 0,22 2 ± 1,2 1,5 ± 0,66
Lymph‡ 2023,6 ± 191,8
581,7 ± 
113,5 463,2 ± 51 78,7 ± 17,9 15,1 ± 4,9 25,9 ± 11,7 18,6 ± 5,8
452,2 ± 
147,3
395,5 ± 
91,3
Mono§ 69,5 ± 16,2 2,5 ± 1,5 1,3 ± 0,41 0,46 ± 0,08 0,27 ± 0 0,28 ± 0,02 0,16 ± 0,12 2,3 ± 0 0,64 ± 0,56
Eos¶ 530,8 ± 185 9,8 ± 7,2 3 ± 0,43 1,5 ± 0,26 1,6 ± 1 0,43 ± 0,06 0,77 ± 0,12 2,2 ± 1 1,7 ± 0,6
Baso** 105,4 ± 
13,7 8 ± 1,9 6,4 ± 1,2 1,1 ± 0,33 ND†† 0,3 ± 0 0,87 ± 0,25 33 ± 8,4 29 ± 5,3
* white blood cells; † neutrophils; ‡ lymphocytes; § monocytes; ¶ eosinophils; ** basophils; †† 
Not detected, below detection limit;  n = 4-7 mice/group. Mean values x 10-6/mL ± SEM (standard 
error of the mean).
Increased Th17-pathway cytokines and expression of 
retinoic acid receptor-related orphan receptor γt (ROR-γt) in 
thymocytes and LN cells
In light of the recently reported role for GM-CSF in the differentiation of 
effector Th17 cells 3, we analysed serum from mice aged between 6 and 
12 weeks by Bio-Plex bead array. Of the 23 cytokines and chemokines 
measured, IL-1β, IL-2, IL-5, IL-12p40, GM-CSF and IL-17A were markedly 
increased in TG mice, when compared to WT littermate controls (Table 2). 
All of these cytokines, except for IL-5, are implicated in the Th17 pathway 
7. These findings suggest there might be enhanced Th17 (CD4+) or Tc17 
(CD8+) differentiation in the Lck-GM-CSF TG mice. In contrast, serum 
concentrations of other cytokines and chemokines (IL-1α, IL-3, IL-4, IL-9, 
IL-10, IL-12(p70), IL-13, Eotaxin, G-CSF, IFN-γ, KC, CCL2 (MCP-1), CCL3 
(MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES) and TNFα) were no different 
to WT littermates (not shown).
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Table 2: BioPlex analysis of serum cytokines 
Analyte (pg/ml)
Mouse IL-1β IL-2 IL-5 IL-6 IL-10 IL-17 GM-CSF CCL2 CCL4 TNF
LckGMhi 60.7 ± 13.3
24.1 ± 
2.9
11.4 ± 
1.6
26.8 ± 
12
14.2 ± 
2.7 7.3 ± 1.4
32.7 ± 
6.6
254 ± 
39.4
54.4 ± 
14
372 ± 
68.4
WT 22.6 ± 5 15.7 ± 2.9 6.7 ± 0.8 1.1 ± 0.6 10 ± 3.3 3.4 ± 1.5 10 ± 3.3
156 ± 
34 19.3 ± 8
204 ± 
76.6
p 0.008 0.04 0.037 0.2 0.23 0.019 0.002 0.083 0.074 0.091
p value: two-tailed Mann Whitney test. n = 12-14 mice/group. Mean values ± SEM.
To formally assess Th17 and Tc17 differentiation in LckGM TG mice during 
global immune activation, we injected mice with Complete Freund’s Ad-
juvant (CFA). LN cells were re-stimulated in vitro and we compared the 
percentage of IL-17 and IFN-γ producing CD4+ and CD8+ cells (Figure 
2D). The percentage of CD4+ IL-17 or IFN-γ-producing T cells in the TG 
mice was increased upon in vitro re-stimulation, regardless of CFA injec-
tion. CFA injection boosted the number of CD4+ IL-17-producing T cells by 
~2-fold. Surprisingly, when stimulated in this manner, the percentage of 
CD8+ IL-17 producing T cells increased ~3-fold in the LckGMlo mice when 
primed with CFA. This increase was not seen in the LckGMhi mice. In con-
trast, the percentage of CD8+ IFN-γ producing T cells was independent of 
CFA injection, and was increased ~2 and ~10-fold in the LckGMlo and Lck-
Figure 2: (right page) Splenomegaly, lymphadenopathy, thymic 
atrophy, perturbed CD8/CD4 T cells in the thymus and increased 
ROR-γt expression in thymocytes and T cells of Lck-GM-CSF TG mice
(A) Photographs of spleen, LN and thymus of Lck-GMhi TG and WT controls at 6 weeks of age. Scale 
bar = 1cm. (B) Flow cytometric analysis of T cell populations in spleen and LN. Single cell suspen-
sions were stained for TCRβ, CD4, CD8, Foxp3, CD25, CD44 and CD62L. Cells were gated on TCRβ+. 
Treg were defined as CD4+Foxp3+. Naïve T cells were defined as CD62Lhi/CD44lo. Effector/memory T 
cells (eff/mem) were defined as CD62Llo/CD44hi (C) Single cell suspensions from thymus were ana-
lysed by flow cytometry for mature/immature CD4+ and CD8+ T cell populations and triple negative 
(CD3/CD4/CD8-) differentiation. Mature CD4+ T cells were defined as CD24-Qa2+. Mature CD8+ T cells 
were defined as TCRβ+CD24-Qa2+. Lineage- TN1, TN2, TN3 and TN4 were defined by the expression of 
CD44 and CD25 as shown. Mean ± SEM shown.  (D) Intracellular flow cytometry for the detection of 
IL-17 and IFN-γ in CD4+ and CD8+ T cells after priming with CFA and re-stimulation of LN cells (PMA/
Ionomycin) in vitro. (E) Quantitative PCR for ROR-γt expression on RNA from purified thymocytes 
and LN cell populations. Expression in TG cells is shown as –ΔΔCt, normalized for expression of the 
hmbs gene and normalized for ROR-γt expression of the corresponding WT cells.
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GMhi mice respectively. We also assessed the production of GM-CSF in 
this experiment (supplemental Figure 2). As expected, GM-CSF produc-
tion was stronger in the LckGMhi mice, in particular in stimulated CD8+ T 
cells. This result suggests a link between IFN-γ and GM-CSF production 
following stimulation.
Quantitative PCR (QPCR) for ROR-γt, which is a transcription factor re-
quired for Th17 differentiation 24, was performed. We found markedly in-
creased ROR-γt mRNA in TG thymocytes, total LN cells and purified CD8+ 
LN cells (Figure 2E), suggesting an increased population of Tc17 cells in 
these organs (Figure 2E). In keeping with this possibility, LN cells from 
both lines produced more IL-17, as well as GM-CSF, when stimulated with 
anti-CD3 and anti-CD28 (not shown). Interestingly, the mRNA expression 
of ROR-γt in purified TG CD4+ LN cells was unchanged. Although these 
cells displayed a clear increase in GM-CSF mRNA, this increase was 
modest when compared to purified CD8+ LN cells (Figure 1E), suggesting 
a quantitative relationship between GM-CSF expression and ROR-γt ex-
pression. 
Peripheral blood cell populations are altered in Lck-GM-CSF 
TG mice
To analyse whether other hematopoietic cell types were affected by in-
creased GM-CSF production by T-cells, TG mice and WT littermates 
from both lines were bled at 6 weeks of age. Absolute numbers of total 
white blood cells were no different between WT and TG mice (not shown), 
however, TG mice had markedly increased percentages of neutrophils, 
eosinophils, and large myeloid cells (identified by absence of the typical 
physical features of common blood cell populations) (Figure 3A). Accord-
ingly, there were reduced percentages of lymphocytes, monocytes and 
reduced platelets in TG mice. These changes in blood cell populations 
were observed in both lines, but were more pronounced in Lck-GMhi mice. 
The Lck-GMhi mice were also anaemic (haematocrit 60 ± 0.8% for WT vs 
46.3 ± 6.4% for TG). We therefore chose Lck-GMhi mice for more detailed 
analysis.
Decreased colony forming potential in bone marrow, but 
increased colony forming potential in spleen in Lck-GMhi mice
In light of the perturbations to TG myeloid populations, we performed 
colony-forming assays to assess myeloid precursors in the bone marrow 
and spleen (Table 3 and Table 4). TG bone marrow cells had decreased 
granulocyte, granulocyte/macrophage, macrophage, eosinophil and meg-
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Figure 3: Lymphopenia, monocytopenia, thrombocytopenia, 
neutrophilia, eosinophilia and an increase in large myeloid cells in 
peripheral blood of Lck-GM-CSF TG mice
Peripheral blood from TG mice and littermate controls between 6-12 weeks of age, analysed by 
automated differential cell count. * p<0.05; ** p<0.001, unpaired t test.
akaryocyte colony forming potential (Table 3). Cell counts of bone marrow 
revealed normal cellularity, but increased percentages of mature neutro-
phils (not shown). In contrast, TG splenocytes displayed increased colony 
forming potential (Table 4), suggesting extramedullary myelopoiesis. We 
confirmed this result by manual differential cell counts of splenocytes (not 
shown). Assays with saline alone did not yield any colonies from cultures 
of bone marrow or spleen. 
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Table 3: Colony formation by bone marrow cells 
Mouse Stimulus
Number of colonies/25,000 bone marrow cells
Blast G * GM † M ‡ Eo § Meg ¶
TG
GM-CSF 0 11 ± 4 2 ± 1 24 ± 5 1 ± 1 0
G-CSF 0 8 ± 2 0 0 0 0
M-CSF 0 3 ± 2 1 ± 1 32 ± 17 0 0
IL-3 3 ± 4 13 ± 6 8 ± 4 12 ± 3 2 ± 2 3 ± 1
SCF ** 4 ± 1 6 ± 2 3 ± 1 2 ± 1 0 0
SCF+IL-3+EPO †† 10 ± 3 20 ± 4 12 ± 5 20 ± 9 2 ± 0 12 ± 5
IL-6 0 7 ± 3 0 0 0 0
Saline 0 0 0 0 0 0
WT
GM-CSF 0 27 ± 4 11 ± 11 45 ± 6 4 ± 3 0
G-CSF 0 16 ± 5 0 0 0 0
M-CSF 0 4 ± 3 11 ± 1 63 ± 13 0 0
IL-3 2 ± 1 42 ± 2 22 ± 1 24 ± 11 5 ± 0 11 ± 1
SCF 9 ± 4 24 ± 7 2 ± 3 2 ± 0 0 0
SCF+IL-3+EPO 8 ± 1 47 ± 1 23 ± 3 37 ± 1 5 ± 4 36 ± 11
IL-6 0 6 ± 7 1 ± 0 1 ± 1 0 0
Saline 0 0 0 0 0 0
* Granulocyte; † Granulocyte/macrophage; ‡ Macrophage; § Eosinophil; ¶ Megakaryocyte; ** SCF 
= stem cell factor; †† EPO = erythropoietin;  n = 2 mice/group. Mean values ± standard deviation 
(SD).
Table 4: Colony formation by spleen cells 
Mouse Stimulus
Number of colonies/50,000 spleen cells
Blast G * GM † M ‡ Eo § Meg ¶
TG
GM-CSF 0 2 ± 1 2 ± 1 5 ± 4 0 0
M-CSF 0 0 0 5 ± 4 0 0
SCF+IL-3+EPO **†† 20 ± 0 4 ± 5 2 ± 2 6 ± 2 1 ± 1 11 ± 6
Saline 0 0 0 0 0 0
WT
GM-CSF 0 0 0 0 0 0
M-CSF 0 0 0 1 ± 1 0 0
SCF+IL-3+EPO 1 ± 1 0 1 ± 0 3 ± 2 0 5 ± 1
Saline 0 0 0 0 0 0
* Granulocyte; † Granulocyte/macrophage; ‡ Macrophage; § Eosinophil; ¶ Megakaryocyte; ** SCF 
= stem cell factor; †† EPO = erythropoietin; n = 2 mice/group. Mean values ± SD.
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Altered lymphoid organ architecture due to histiocytic
infi ltration in Lck-GMhi mice
Histopathological analysis of the spleen and LN of TG mice revealed 
marked effacement of the normal architecture by histiocyte-like cells, al-
though a follicular pattern was still discernible (Figure 4). The spleen dis-
played an increase in nucleated erythroid cells, consistent with extra-med-
ullary erythropoiesis. Occasional multi-nucleated giant cells (MGC) were 
observed, suggesting fusion of histiocytes and/or tissue macrophages. 
The TG thymus lacked normal lobes and had an atrophic appearance. 
There was effacement of the thymic medulla (“M” in Figure 4) by his-
tiocytes, as observed in spleen and LN, and the cortex was markedly 
reduced in size (“C” in Figure 4), consistent with the severe defects we 
observed in thymocyte differentiation. TG lungs showed multiple nodules, 
consisting of poly-morphonuclear cells and histiocytes (Figure 4). There 
was an absence of mitotic fi gures in these nodules, arguing against neo-
plastic transformation. TG BM showed a marked reduction in lymphocytes 
and an increase in granulocytes (Figure 4), in agreement with the differ-
Figure 4
WT TG WT TG
S
p
le
en
L
N
L
u
n
g
T
hy
m
u
s C C
M
M
B
M
F F F
F
Figure 4: Histiocytic inﬁ ltrates in organs of Lck-GM-CSF TG mice
Organs and bone from Lck-GMhi mice were collected at 6 weeks of age and sections stained with 
haematoxylin and eosin. F=follicle, C=Cortex, M=Medulla. Original magnifi cation 50x (LN, thymus) 
and 100x (spleen, lung, BM).
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ential cell counts. Non-lymphoid organs, including lung, kidney and liver 
showed varying degrees of infiltration by histiocytes and poly-morphonu-
clear cells (Figure 4 and data not shown). In summary, the histological 
findings in Lck-GM-CSF TG mice were consistent with a disseminated 
histiocytosis.
Lck-GMhi histiocytes have hybrid features of monocytes, 
macrophages and DC 
Analysis of myeloid markers revealed dramatic expansion of CD11b+ 
F4/80int/+ cells in the lymphoid organs of TG mice (Figure 5). In TG blood 
and BM, these cells were F4/80lo (not shown). This population could be 
further divided, based on CD11c staining and on morphology. The CD11c+ 
population (histiocytes) was preferentially expanded in Lck-GMhi mice (Fig-
ure 5B and 5C, right panel). Histiocytes were extensively immuno-pheno-
typed by flow cytometry. These cells also expressed CD115, MHCII, and 
low levels of CCR2 and CD62L, but not CD43, CD205, Ly6C or CX3CR1, 
and thus showed hybrid features of monocytes, macrophages and DC 
(Table 5).  Histiocytes also expressed GM-CSFRα and GM-CSFRβ (Fig-
ure 5D) and intracellular CD207, which is a hallmark of Langerhans cells 
(Figure 5E). CD11b+ F4/80int/+CD11c- cells expressed the eosinophil mark-
er SiglecF and were morphologically identical to eosinophils (Figure 5C, 
left panel).
We next evaluated the production of cytokines and chemokines by Lck-GM-
hi histiocytes, in vitro. CD11b+ F4/80int/+CD11c+ histiocytes produced high 
levels of CCL4 and CCL5, suggesting that these cells might engender an 
autocrine loop for recruitment of monocyte/macrophage and DC precur-
sors (Figure 5F). In contrast, under these conditions, histiocytes did not 
produce nitric oxide (data not shown).
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Table 5: Surface phenotype of CD11b+ F4/80int/+CD11c+ histiocytes
Cell type
Membrane marker
C
D
11
b
C
D
11
c
C
D
43
C
D
62
L
C
D
11
5
C
D
20
5
C
D
20
7
Ly
6C
F
4/
80
C
X
3C
R
1
C
C
R
2
M
H
C
II
S
ig
le
cF
G
M
-C
S
F
R
α
G
M
-C
S
F
R
β
Histiocyte + + - +/- + - lo¶ - int** - lo + - + +
Eosinophils + - +/- +/- +/- - - +/- int + lo - + + +
Res mono* + + + - + - - - lo + - - - + +
Infl mono† + - + + + - - + lo + + - - + +
cDC‡ +/- ++ - - - - - - - int - + - + +
Langer-
hans + + - - + ++ ++ - - - + ++ - + +
Infl mac§ + - - - - - - + + + + +/- + + +
* Resident monocyte;  †Inflammatory monocyte; ‡Conventional DC; § Inflammatory macrophage; 
** Intermediate levels; ¶ Low levels; +/- = both positive and negative cells observed. Surface phe-
notypes of monocytes, DC and macrophages from references 4,20,53.
Histiocytes from Lck-GMhi mice can mature to become 
functional APC 
To determine whether histiocytes can stimulate naïve T cells, purified his-
tiocytes and eosinophils were co-cultured with purified allogeneic CD3+ 
Balb/c T cells for 4 days. Histiocytes, but not eosinophils, could stimulate 
alloreactive T cells (Figure 5G). Histiocytes that were fixed with 2% PFA 
prior to culture could not stimulate T cells, showing that cell maturation in 
vitro is required, as is the case for immature DC. Immature DC can also ef-
ficiently take up antigens for processing and presentation 25. We therefore 
tested the ability of histiocytes to phagocytose latex beads in vivo (Figure 
5H). Approximately 10% of histiocytes phagocytosed latex beads (Figure 
5H), whereas, as expected, eosinophils did not.
Increased Langerhans DC in LN from Lck-GMhi mice 
The human disease LCH is characterized by tissue infiltration with Langer-
hans-type cells, commonly referred to as “LCH cells” to distinguish them 
from Langerhans cells (LC) 26. LCH cells express LC antigens CD207 and 
CD1a, as well as the monocyte markers, CD68 and CD14. Expression 
of CD205, which is present on mature LC, has been detected on tissue 
sections of human LCH lesions, but to our knowledge, the co-expression 
of CD207 and CD205 has not specifically been addressed in human LCH 
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Figure 5:  (left page) Characterization of histiocytes from TG mice
(A) Flow-cytometric analysis of CD11b and F4/80 expression on leukocytes from spleen, 
LN and thymus of Lck-GMhi mice. (B) Histiocytes can be distinguished from eosinophils 
by CD11c expression. Numbers represent percentage of live cells. (C) Cytospins of CD11b+ 
F4/80int/+CD11c- eosinophils (left panel) and CD11b+ F4/80int/+CD11c+ histiocytes (right pan-
el) cells, sorted from TG spleen. Cells were stained with May-Grünwald Giemsa stain. Orig-
inal magnification 1000x. (D) Detection of GM-CSFRα (left panel) and β (right panel) on 
CD11b+F4/80+ cells from TG spleen (black line) by flow cytometry. Control (grey line): unstained cells. 
(E) Detection of CD207 (Langerin) on histiocytes (CD11c+, clear histogram) and eosinophils (CD11c-, 
shaded histogram) by flow cytometry. Control (grey line): unstained cells. (F) Analysis of cytokines 
and chemokines in culture supernatant from purified histiocytes from TG spleen by BioPlex bead 
array. n=2 mice.  (G) Mixed leukocyte reaction of purified, unfixed histiocytes (CD11c+, open circles) 
or eosinophils (CD11c-, closed squares), or PFA-fixed histiocytes (grey circles), with purified splenic 
Balb/c CD3+ T cells. Proliferation after 4 days was measured by 3H thymidine incorporation. CPM = 
counts per minute. Pooled data from 2 experiments shown, n=2 mice per experiment. * p < 0.05, 
unpaired t-test (H) Uptake of fluorescent labeled latex beads in vivo by CD11b+ F4/80int/+CD11c+ histio-
cytes. Beads were injected intravenously and spleen cells were analysed by flow cytometry.
Figure 6: Flow cytometric analysis of DC populations
Light density spleen cells were stained for CD11b and CD11c, CD8, CD205 and CD207. (A) CD11chi/
CD11bhi cells were gated and (B) further analysed for the expression of CD8, CD205 and CD207. (C) 
% of CD8+, CD8- conventional DC and Langerhans DC in WT and TG LN. Representative plots shown 
from two separate experiments. Mean and range from one experiment given in (C). n = 2-3 mice per 
genotype per experiment. His = histiocyte/histiocyte precursor population.
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cells 26. In the mouse, functionally mature LC in the LN share a pheno-
type similar to human LC and express CD207, CD11b and CD205 20. TG 
histiocytes expressed low levels of CD207 and were negative for CD205 
(Figure 5D). To determine if DC populations were skewed in TG mice, 
we enriched for DCs via a density gradient. The absolute number of light 
density cells per mg of tissue was marginally increased in the TG mice, 
but this did not reach statistical significance (not shown). However, DC 
populations of TG mice did differ from those in WT littermates (Figure 6). 
In the spleen, there was an increase in the percentage of CD11c+CD11b- 
(resident DC or migratory CD11b- DC) and CD11b+CD11c+ DC in the light 
density fraction (Figure 6A, top panels). With these markers we could also 
distinguish CD11cintCD11b+ histiocytes/histiocyte precursors (and possibly 
DC precursors), which were absent in the WT spleen (“His” in Figure 6A). 
The DC were further analysed for CD205 and CD207 expression (Figure 
6A, bottom panels). This revealed the presence of Langerhans cells in the 
TG spleen, defined by the expression of CD205 and CD207. LC are nor-
mally only present in LN 20. In addition, TG mice displayed reduced CD8+ 
DC in the spleen (Figure 6B). The proportion of CD8- DC was comparable 
to WT spleen. In the LN, there was a slight reduction in CD8+ DC and an 
increase in CD8- DC (Figure 6C). The percentage of Langerhans cells 
was variable, but there was a trend towards an increase of these cells. In 
contrast, CD11c+CD11b- DC were reduced in Csf2-/- mice (not shown), con-
sistent with a direct effect of GM-CSF on at least some DC populations in 
peripheral lymphoid organs. 
Histiocytosis can be transferred to lymphopenic mice by ma-
ture Lck-GMhi T cells and thymocytes 
To examine whether the histiocytosis observed in TG mice was due direct-
ly to over-production of GM-CSF by T cells, we transferred purified TG or 
WT CD3+CD4+ (CD4+ T cells), CD3+CD8+ (CD8+ T cells) and CD3- (non-T) 
LN cells, or unfractionated thymocytes, into Rag1-/- mice. A week after 
transfer, mice that received either TG CD4+, CD8+ T cells or TG thymo-
cytes had altered peripheral blood populations, which were very similar to 
the changes found in TG mice. Recipient mice had a markedly increased 
percentage of large myeloid cells in the peripheral blood, which increased 
over time (Figure 7A). Histiocytes could be identified on histological anal-
ysis of spleens from mice injected with TG CD4+ or CD8+ T cells (not 
shown) and thymocytes, but not in spleens from mice that received non-T 
cells (Figure 7B). In addition, spleens from mice injected with TG thymo-
cytes or CD8+ T cells were larger than spleens from mice injected with WT 
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cells or TG CD3- non-T cells (Figure 7C). This effect was not seen when 
mice were injected with CD4+ T cells, most likely reflecting the difference 
in GM-CSF production between these cell types (Figure 1). 
Differential cell counts of the spleen showed that the population of large 
myeloid cells was specifically expanded (Figure 7D), and these cells were 
CD11b+F4/80+ (shown for mice transferred with TG thymocytes in Fig-
ure 7E). In contrast, mice that received WT cells or TG non-T cells, and 
non-injected Rag1-/- mice (not shown) did not accumulate histiocytes and 
had normal splenic architecture. These data demonstrate that histiocyto-
sis is a cell intrinsic consequence of the TG T cells.
3.4 Discussion
Recent studies highlight the importance of GM-CSF production by T cells 
in mediating immunity and inflammation 3,6,7. Following our earlier work 6, 
we hypothesized that increased production of GM-CSF by T cells might 
expand monocyte-derived inflammatory DC (MoDC) during inflammation 
and cause increased differentiation of Th17 cells. We tested this hypoth-
esis by over-expressing GM-CSF specifically in T cells, under the control 
of the Lck promoter. We show strong expression of the Lck-driven GM-
CSF transgene in the thymus as well as expression in peripheral lym-
phoid organs, in accordance with earlier reports using this promoter 27-29. 
Transgenic mice displayed a dramatic phenotype, characterized by sple-
nomegaly, lymphadenopathy, thymic atrophy and multiple abnormalities 
in thymic and blood cell populations. LckGM-CSFhi mice had a decreased 
life span, which was due to splenomegaly (caused by histiocyte infiltra-
tion and extra-medullary haematopoiesis) and anaemia. LckGM-CSF TG 
mice developed disseminated histiocytosis, with an increased Foxp3+ 
T-cell population, increased levels of ROR-γt mRNA and increased circu-
lating Th17-related cytokines. The increase in CD4+ IL17+ cells was even 
more obvious when LckGM-CSF mice were injected with CFA, linking 
GM-CSF production in the context of global immune activation with Th17 
differentiation. Interestingly, basal expression of GM-CSF was strongest 
in thymocytes and CD8+ T cells, suggesting the increase in circulating 
Th17 cytokines in naïve LckGM-CSF mice is most likely the result of more 
Tc17 cells, rather than Th17 cells. In vitro stimulated Lck-GM TG CD4+ and 
CD8+ T cells produced high levels of IFN-γ, which was increased to up to 
~10 fold in the LckGM-CSFhi mice compared to WT. These findings sug-
gested that a link exists between the T-cell-derived production of GM-CSF 
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Figure 7: Histiocytosis can be transferred to Rag1-/- mice by TG thy-
mocytes and LN T cells 
Thymocytes or purified LN CD4+ T cells, CD8+ T cells or non-T (CD3-) cells were transferred to Rag1-
/- mice by i.v. injection (1x106/mouse). (A) Percentages of large myeloid cells were determined in pe-
ripheral blood by automated differential cell counts weekly following transfer; n=2-3 mice per group 
per time point (B) H&E stained spleen sections from Rag1-/- recipients receiving thymocytes or non-T 
cells. Original magnification 200x. n = 3 mice per group. Data from one experiment representative of 
two experiments is shown. R = red pulp; W = white pulp; H = histiocytes; E = eosinophils. (C) Spleen 
weight and blood cell populations of Rag1-/- mice on day 28 after transfer of donor cells and differ-
ential counts of splenocytes; n=2-6 mice per group. (D) Percentage of large myeloid cells in spleen 
determined by differential cell count on day 28 after transfer. Mean ± SEM; n=3 mice per group. (E) 
Flow-cytometric analysis of CD11b and F4/80 expression on splenocytes from Rag1-/- mice on day 28 
after transfer of WT or TG thymocytes. * = p < 0.05, t-test (Holm-Sidak method).
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and the production of IL-17 and IFN-γ by T cells. In view of our findings in 
CD8+ T cells, it is possible that GM-CSF plays a role in the development 
of Tc17/IFN-γ cells – these cells have been shown to have potent anti-tu-
mour properties, which could partly explain the absence of tumours in the 
Lck-GM TG mice 30. In addition, infiltrating IFN-γ secreting T cells induce 
macrophage activation, inflammation, and tissue damage, and play a sig-
nificant role in end organ damage in the context of autoimmunity 31, and 
increased IFN-γ was implicated in the pathophysiology of certain severe 
histiocytic disorders 32.
Histiocytic disorders encompass a range of malignant and non-malignant 
conditions that are incompletely understood, partly through lack of suita-
ble animal models. LCH is a clonal proliferative disease, characterized by 
tissue infiltration with Langerhans-like cells (as recently reviewed 33) and 
mutations in BRAF 34,35. Not all cases of LCH are aggressive, and some 
have a better prognosis 33,36. A previous model of histiocytosis was gener-
ated by infecting mice with malignant histiocytosis sarcoma virus, leading 
to transitional macrophage/DC sarcoma 37. Another experimental model 
was induced by transgenic expression of the SV40 T oncogene in DC 38. 
These mice developed infiltration of spleen, liver, bone marrow, thymus, 
and mesenteric lymph node with CD11c+CD8+CD207+ DC, resembling the 
aggressive form of LCH. Mice in both these models invariably died early 
from the disease. 
In TG mice, we found large numbers of infiltrating cells that expressed 
CD115, F4/80, and CD11b in the lymphoid organs, peripheral blood, BM 
and in non-lymphoid organs, such as the kidney, lung and liver. These 
cells were phenotypically similar to immature monocytic Langerhans cell 
precursors 39. A subpopulation of these cells expressed CD11c and low 
levels of CD207, but not CD205. Although these markers are not exclu-
sively expressed by LC 19, the presence of CD11b suggests TG histiocytes 
are more similar to LC than to other DC types. In WT mice, LC are only 
found in the LN, but we found mature CD205+CD207+ LC in the spleen 
of TG mice. This finding may suggest that LCH in the TG mice might 
involve immature monocytic Langerhans cell precursors. Spleen and LN 
showed dramatically increased size and cellularity, but with preserved fol-
licular structure. High levels of chemokines, such as CCL2, CCL4 and 
CCL5 were produced by MoDC 6 and by TG histiocytes, which could act 
as chemo-attractants for histiocytic precursors to enter tissues and differ-
entiate under the influence of local GM-CSF. The histiocytes of Lck-GM-
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CSF Tg mice express GM-CSFRα and β, CD207, low levels of MHCII, can 
phagocytose latex beads in vivo, and freshly isolated cells do not stimu-
late naïve T cells in MLR, suggesting an immature antigen presenting cell 
(APC) phenotype. Human LCH histiocytes also resemble DC held in an 
immature state in vivo by extrinsic factors, such as IL-10 40. We show that 
in vitro, Lck-GM-CSF-derived histiocytes can mature to become function-
al APC and also observed marginally higher serum IL-10 in Lck-GM-CSF 
mice. Collectively, these observations in Lck-GM-CSF TG mice are also 
reminiscent of human LCH. The clinical and histological features, the ab-
sence of mitotic figures and of spontaneous cellular proliferation in our 
model, thus suggest a non-neoplastic process in Lck-GMhi mice, which 
has many similarities to LCH. 
Transgenic expression of GM-CSF in non-haematopoietic tissue has been 
shown to cause local accumulation of macrophages and neutrophils 10-14. 
GM-CSF is a potent growth factor for eosinophils 41 and increased num-
bers of these cells were observed in another GM-CSF transgenic mouse 
10. We also found increased eosinophils and show that expression of GM-
CSF in T cells causes accumulation of histiocytes, which has not been 
observed in previous GM-CSF transgenic mice. Interestingly, eosinophils 
and histiocytes can be found together in eosinophilic granuloma of bone 
42. We therefore hypothesize that histiocytes differentiate in tissues that 
provide proximity to GM-CSF producing T cells. This hypothesis is sup-
ported by earlier studies that showed increased serum levels of GM-CSF 
in LCH patients, expression of the GM-CSF receptor on LCH cells and 
increased production of GM-CSF by T cells, macrophages and LCH cells 
in LCH lesions 43-45.  
In contrast to increased cellularity in peripheral LNs, the thymi of Lck-GMhi 
mice were atrophic and had a severely reduced cortex. However, thymo-
cyte differentiation appeared to still proceed, but was severely impaired. 
Increased local GM-CSF might favour retention of mature thymocytes in 
the medulla, or perhaps more likely, promote the recirculation of periph-
eral T cells. A direct effect of GM-CSF on thymocytes is unlikely due to 
the absence of GM-CSF receptors on T cells 46, and the observation that 
GM-CSF receptor-deficient mice did not display an overt T cell phenotype 
47. In the thymus and LN, we also observed a major increase in the propor-
tion of CD4+Foxp3+ regulatory T cells. Treg differentiation in the thymus 
requires both high avidity TCR interactions and an additional signal from 
IL-2, or other γ-chain cytokines 48. Treg expansion in the LckGM TG mice 
is most likely due to increased recirculation from the periphery, but could 
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be secondary to locally increased IL-2, TNF or TGFβ expression, caused 
by GM-CSF. Of potential relevance, we detected elevated IL-2 and slightly 
increased TNF in the serum. Interestingly, increased Treg numbers have 
been detected in lesions and peripheral blood from LCH patients 49. Treg 
were detected in proximity of LCH cells, and it was suggested that LCH 
cells could be involved in Treg differentiation 49. Our findings in the Lck-
GM TG thymus support this conclusion. We hypothesize that overproduc-
tion of GM-CSF by T cells induces the local differentiation of LCH cells 
that produce cytokines or chemokines that promote Treg, Tc17 and Th17 
differentiation. Expansion of Treg might explain why Lck-GMhi mice are 
not overtly sick in spite of the infiltrates in many organs. Elevated serum 
levels of Th17-related cytokines (IL-1β, IL-2, IL-12p40) is also consistent 
with a contribution of T-cell derived GM-CSF to the Th17 pathway 7, and 
is most likely the result of increased GM-CSF production by CD8+ T cells, 
driving cytokine production by macrophages and DC. However, whether 
the IL-17 family plays a direct role in the pathogenesis of LCH remains 
controversial 50,51.
In the bone marrow, histiocytes might compete with myeloid progen-
itor cells for a common bone marrow niche, which might explain the 
decreased colony forming potential we found from that site, and the in-
creased extra-medullary haemopoiesis seen in the spleen. Administration 
of exogenous GM-CSF in itself does not cause histiocytosis 52, suggesting 
a requirement for direct cellular interaction. Our observation that transfer 
of Lck-GM TG T cells into lymphopenic recipients causes histiocytosis, 
illustrates how this T cell cytokine might affect myeloid differentiation. Our 
previous study showed that NF-κB1 deficient mice, which had reduced 
GM-CSF production in CD4+ T cells, also had a decrease in inflamma-
tory monocyte-derived DC 6. Our results therefore shed new light on the 
possible in vivo consequences of GM-CSF production by T cells and are 
important for two reasons. First, the Lck-GM-CSF TG mice provide a nov-
el murine model for histiocytosis. This heterogeneous group of human 
diseases has been very difficult to understand and to treat.  We provide 
evidence that over-production of GM-CSF by T cells could be a pathogen-
ic factor in histiocytic disorders, and LCH in particular. Finally, and most 
importantly, our results raise the possibility that specific inhibitors of GM-
CSF should be considered in the management of histiocytic disorders. 
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Supplemental Figure 2: Intracellular flowcytometry for GM-CSF on 
LN cells 7 days after priming with CFA.
Increased numbers of GM-CSF producing CD4+ T cells were observed in the LckGMhi mice only. 
Increased numbers of GM-CSF producing CD8+ T cells were observed in both lines.
Supplemental Figure 1: Southern Blot of genomic DNA from wildtype 
(WT) or lck-GM-CSF transgenic mice. 
Blot was probed with a 32P labelled GM-CSF-specific probe. Endogenous GM-CSF was detected in 
all samples, transgene GM-CSF was detected in de TG samples only.
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Abstract
Objective
To examine the generation of pro-inflammatory Th17 cells at the site of 
tissue inflammation and in draining lymph nodes using an interleukin-17 
(IL-17)-dependent model of acute inflammatory arthritis.
Methods
Arthritis was elicited in mice by intra-articular injection of methylated bo-
vine serum albumin (mBSA) into the knee and subcutaneous injection of 
IL-1β. Anti-IL-17 or control antibodies were administered during arthritis 
induction. Cytokine expression was evaluated by intracellular cytokine 
staining of synovial lymphocytes, by polymerase chain reaction analysis of 
RNA extracted from lymph node cells, and by enzyme-linked immune-sor-
bent assay of cell culture supernatants. Th17 differentiation of naive CD4+ 
T cells was assessed in co-cultures with macrophages from arthritic mice.
Results
Anti-IL-17 antibody administered during acute arthritis markedly reduced 
disease, indicating that the model is IL-17 dependent. IL-17 messenger 
RNA (mRNA), but not protein, was detected in draining lymph node CD4+ 
T cells and preceded joint inflammation. In addition, mRNA for Th17 
cell-stimulatory cytokines (transforming growth factor β, IL-6) and Th17 
cell-inhibitory cytokines (interferon-γ, IL-4) was detected in lymph nodes 
following injection of mBSA and IL-1β. Th17 cells were clearly identified 
in the inflamed synovium at the peak of disease. Synovial macrophages 
supported Th17 cell generation from naive CD4+ T cell precursors stimu-
lated via CD3 in vitro and produced high levels of IL-6. In contrast, perito-
neal macrophages failed to induce Th17 cell differentiation and produced 
less IL-6.
Conclusion
These results suggest that Th17 cell differentiation is initiated in draining 
lymph nodes but that IL-17-producing cells are restricted to the inflamed 
synovium, being generated in response to local cytokines produced by 
inflammatory macrophages. 
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4.1 Introduction
The Th1/Th2 paradigm postulates that CD4+ T cells are polarised upon 
activation to produce distinct subpopulations based on cytokine produc-
tion and effector function. Th1 cells produce cytokines such as interfer-
on-γ (IFN-γ) and drive macrophage activation and delayed type hypersen-
sitivity responses, whereas Th2 cells promote antibody production by B 
cells via the production of interleukin-4 (IL-4), IL-5, and IL-6. Although the 
Th1/Th2 paradigm provides a framework by which to explain immune re-
sponses to infection, T cell responses within the context of autoimmunity 
are harder to accommodate within this model. A new subset of pro-inflam-
matory CD4+ T cells characterised by the production of IL-17 has been 
recently identified 1,2. IL-17-producing T cells (Th17 cells) have been shown 
to mediate models of autoimmune diseases (for review, see 3), including 
experimental autoimmune encephalomyelitis 4 and collagen-induced ar-
thritis (CIA) 5. IL-17 (IL-17A) is a member of a cytokine family comprised of 
six homologous molecules (IL-17A to IL-17F) that are produced predomi-
nantly by activated T cells 6. IL-17 has potent pro-inflammatory effects that 
may promote the development of inflammatory arthritis 7. These include 
the induction of other inflammatory cytokines and chemokines, recruit-
ment of neutrophils 8,9, induction of osteoclastogenesis by up-regulating 
the expression of RANKL on osteoclast precursors 10,11, and stimulation of 
matrix metalloproteinase production 12. Direct injection of IL-17 into knee 
joints or adenovirus-mediated overexpression of IL-17 in joints was shown 
to deplete proteoglycans in articular cartilage 13,14. The severity of CIA in 
mice deficient in IL-17 was reduced due to inhibition of T cell priming, 
which suggests a role for IL-17 in early T cell activation 15. Treatment of 
mice with anti-IL-17 after the onset of CIA inhibited disease and protected 
against joint inflammation and cartilage and bone destruction 16, raising 
the possibility that blockade of IL-17 could be therapeutically useful in in-
flammatory diseases such as rheumatoid arthritis.
In vitro differentiation of Th17 cells is dependent on stimulation of naive 
T cells with the cytokines transforming growth factor β (TGF-β), IL-6, and 
IL-23 via induction of the transcription factor retinoic acid-related orphan 
receptor-γt (ROR-γt) 17. In addition, IL-21 functions to amplify the Th17 cell 
response through an autocrine loop 18-20. Although IL-23 was originally 
described as the pivotal cytokine required for Th17 cells, initial stimulation 
of naive CD4+ T cells with TGF-β and IL-6 is required to induce expression 
of the IL-23 receptor 21, which renders the cells responsive to stimulation 
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with IL-23 and promotes Th17 cell expansion and survival. The production 
of Th17 cells in response to stimulation with IL-23 in vitro is enhanced by 
the addition of IL-1β 22. Differentiation of conventional Th1 and Th2 T cell 
subsets inhibits the generation of Th17 cells, via the secretion of IFN-γ 
and IL-4, respectively 23,24. IL-2 has also been shown to inhibit Th17 cell 
differentiation 25, although IL-1β may overcome IL-2-mediated inhibition of 
Th17 cells 26. The requirements for activation and expansion of Th17 cells 
are therefore quite different from those of other CD4+ T cell subsets. The 
generation of Th17 cells in vitro requires the presence of TGF-β, IL-6, and 
IL-23 but the relative absence of IL-2, IL-4, and IFN-γ. Given these unusu-
al differentiation requirements, it is not clear what in vivo circumstances 
might favour the generation of Th17 cells over Th1 or Th2 cells.
We used the methylated bovine serum albumin (mBSA)/IL-1 model of 
acute inflammatory arthritis to investigate the differentiation of Th17 cells 
in vivo. This model is induced by a single intra-articular (IA) injection of 
mBSA into the knee joint, followed by 3 daily subcutaneous (SC) injec-
tions of the cytokine IL-1β 27. Mice that have received this treatment rapidly 
develop an acute mono-arthritis in the injected knee joint, which peaks 7 
days after the initial mBSA injection and typically resolves by day 21. The 
advantages of this model of arthritis are that disease develops rapidly, 
occurs reproducibly, and is localised to the injected knee joint, allowing 
detailed histological analysis. Intriguingly, the model is entirely dependent 
on CD4+ T cells as well as synovial macrophages and neutrophils but is in-
dependent of CD8+ T cells and B cells 28-30. Although the mBSA/IL-1 model 
requires CD4+ T cells, several features are not consistent with the Th1/Th2 
paradigm. Disease incidence and severity are independent of IFN-γ, while 
there is only a minor reduction in disease severity in the absence of IL-4 
30,31. Furthermore, mBSA elicits a poor proliferative response in vitro when 
used to stimulate draining lymph node (LN) cells obtained at the peak of 
disease, while injection of mBSA into the knee joint, in combination with 
systemic IL-1β, is capable of inducing florid inflammatory arthritis in only 7 
days. These findings suggest that disease is not caused by a conventional 
CD4+ T cell response elicited by immunisation with mBSA.
In this study, we found that Th17 cells are present within the inflamed 
synovium at the peak of disease, and that blockade of IL-17 results in a 
marked reduction in disease severity. We also found that the cytokine 
micro- environment in draining LNs is unfavourable for the development 
of Th17 cells, but that synovial macrophages isolated at the peak of dis-
ease support the generation of Th17 cells from naïve T cells in an IL-6-de-
pendent manner. These results suggest that differentiation of Th17 cells is 
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maintained at the site of tissue inflammation by the local cytokine milieu 
produced by synovial macrophages.
4.2 Material and Methods
Mice.
C57BL/6 mice were obtained from The Walter and Eliza Hall Institute of 
Medical Research (WEHI) Animal Supplies (Kew, Victoria, Australia). All 
mice were at least 8 weeks old at the time of experimentation. All animal 
procedures were approved by the Animal Ethics Committee of Melbourne 
Health (Parkville, Victoria, Australia).
Induction of acute inflammatory arthritis with mBSA and IL-1β.
Acute inflammatory arthritis was induced as previously described 28. 
Briefly, mice were injected IA with 200μg of mBSA into the knee joint, 
followed by 3 daily subcutaneous (SC) injections of 250ng of IL-1β. For 
antibody neutralisation experiments, mice were injected intraperitoneally 
(IP) on days 0, 2, 4, and 6 following the initial mBSA injection with 50μg 
of anti-IL-17 (clone 50104; R&D Systems, Melbourne, Victoria, Australia) 
or rat IgG2a isotype control (clone 4H1; WEHI) 32. The anti-IL-17 antibody 
recognises murine IL-17A and does not cross-react with mouse IL-17E or 
IL-17F. In vitro, this antibody has been shown to inhibit the IL-17-stimulated 
secretion of IL-6 by NIH3T3 cells 33.
Histologic assessment.
Mice were sacrificed at various times following induction of acute inflam-
matory arthritis, and the knee joints were removed and processed for his-
tology as described previously 28. Severity of arthritis was assessed using 
five features of joint disease (exudate, synovitis, pannus, and cartilage 
and bone destruction), each of which was graded on a scale of 0 (normal) 
to 5 (severe) by an investigator (IKC) who was blinded to the experimental 
groups. 
Flow cytometric analysis.
Cells were stained for flow cytometric analysis with fluorescein isothiocy-
anate (FITC)-, phycoerythrin (PE)-, or biotin-labelled antibodies to CD45 
(clone 104), CD19 (clone 1D3), CD44 (clone 1M7), CD25 (clone PC61), or 
L-selectin (CD62L; clone MEL14) (all from BD PharMingen, North Ryde, 
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New South Wales, Australia); CD11b (clone M1/70), CD4 (clone CT-CD4), 
or CD8 (clone CT-CD8a) (all from Invitrogen, Mt. Waverley, Victoria, Aus-
tralia); or GR-1 (clone RB6-8C5; WEHI). Biotinylated antibodies were de-
tected using streptavidin-TriColor (Caltag) or streptavidin-allophycocyanin 
(APC; BD PharMingen). For intracellular cytokine staining, cells were cul-
tured with 1μM monensin A for 4 hours, stained for surface markers, and 
further processed using a BD Cytofix/Cytoperm and BD Perm/Wash kit 
(BD Biosciences, North Ryde, New South Wales, Australia). Cells were 
then stained with PE conjugated antibodies to IL-17 (clone TC11-18H10), 
IFN-γ (clone XMG1.2), or rat IgG1 (clone R3-34) as an isotype control (all 
from BD PharMingen). Analysis was performed on a FACScan flow cy-
tometer using CellQuest software version 3.3 (BD Immunocytometry Sys-
tems, North Ryde, New South Wales, Australia). For cell sorting experi-
ments, a MoFlo instrument (DakoCytomation, Botany, New South Wales, 
Australia) or DiVa flow cytometer (BD Immunocytometry Systems) was 
used.
Purification of CD4+ and CD8+ T cells from lymphoid tissues.
CD4+ and CD8+ T cells were purified from spleen or inguinal and popliteal 
LNs by staining with FITC-labelled anti-CD4 and PE-labelled anti-CD8, 
followed by incubation with anti-FITC or anti-PE microbeads (Miltenyi Bi-
otec, North Ryde, New South Wales, Australia). Cells were positively se-
lected using an AutoMACS instrument (Miltenyi Biotec). Cell purity was 
determined by flow cytometry and was routinely ≥ 90%.
Isolation of cells from synovial tissue.
Inflamed synovial tissue was dissected from the knee joints of arthritic 
mice on day 7 following mBSA injection, and single-cell suspensions were 
prepared as previously described 31. For flow cytometric analysis, syno-
vial cells were cultured for 4 hours in the presence of 20ng/ml of phorbol 
myristate acetate, 0.1μg/ml of ionomycin, and 1μM monensin A (all from 
Sigma, Melbourne, Victoria, Australia) prior to staining.
Isolation of macrophages.
Macrophages were purified on day 7 either from synovial tissue (CD45+CD-
11b+GR-1-) following enzymatic digestion 31 or from peritoneal washes 
(CD45+CD11b+GR-1-CD19-) of arthritic mice by flow cytometry. In some in-
stances, peritoneal macrophages were derived (day 7) from non-arthritic 
mice that had been injected IP with 200μg of mBSA (day 0) and injected 
SC in the footpad with 250ng of IL-1β (days 0, 1, and 2).
Proefschrift Annemarie.indb   88 13-10-2013   22:35:36
Page 89
Chapter 4
4
Polymerase chain reaction (PCR) analysis.
Total RNA was isolated from purified T cells, synovial macrophages, and 
peritoneal macrophages before and after in vitro culture. Complementary 
DNA was prepared by reverse transcription. RNA expression levels were 
determined by real-time quantitative PCR using a LightCycler (Roche, 
Castle Hill, New South Wales, Australia) or an ABI Prism 7900 (Applied 
Biosystems, Scoresby, Victoria, Australia) instrument and SYBR Green 
reagent (Qiagen, Doncaster, Victoria, Australia). Expression levels were 
normalised for β-actin or hydroxymethylbilane synthase (hmbs) RNA con-
tent.
Primer sequences were as follows: for β-actin, 5’- ATC-GTG-CGT-
GAC-ATC-AAA-GAG-A-3’ (forward) and 5’-CCA-CAG-GAT-TCC-ATA-
CCC-AAG-A-3’ (reverse); for IL-17A, 5’-CCG-CAA-TGA-AGA-CCC-TGA-
TAG-A-3’ (forward) and 5’-CAG-CAT-CTT-CTC-GAC-CCT-GAA-A-3’ 
(reverse); for TGF-β, 5’-GAT-CCC-CCT-AGC-CTC-TCA- TC-3’ (forward) 
and 5’-GCA-CAA-GCA-GGA-TTG- AGT-GA-3’ (reverse); for IL-6, 5’-AGT-
TGC-CTT-CTT- GGG-ACT-GA-3’ (forward) and 5’-CAG-AAT-TGC-CAT- 
TGC-ACA-AC-3’ (reverse); for IFN-γ, 5’-CAG-CTC-TTC- CTC-ATG-GCT-
GTT-T-3’ (forward) and 5’-GTC-ACC- ATC-CTT-TTG-CCA-GTT-C-3’ 
(reverse); for IL-4, 5’-GCA- ACG-AAG-AAC-ACC-ACA-GAG-A-3’ (forward) 
and 5’- GAT-GAA-TCC-AGG-CAT-CGA-AAA-G-3’ (reverse); for hmbs, 
5’-CCT-GGT-TGT-TCA-CTC-CCT-GA-3’ (forward) and 5’-CAA-CAG-CAT-
CAC-AAG-GGT-TTT-3’ (reverse); and for ROR-γt, 5’-CCG-CTG-AGA-
GGG-CTT-CAC-3’ (forward) and 5’-TGC-AGG-AGT-AGG-CCA-CAT-
TAC-A-3’ (reverse).
In vitro differentiation of Th17 cells. 
Purified macrophages (105) and naive splenic CD62L+CD25-CD44-CD4+ T 
cells (105) were cultured for 3 days in 200μl of RPMI 1640 supplemented 
with 10% fetal calf serum, 0.1mM non-essential amino acids (Gibco, Mul-
grave, Victoria, Australia), and 50μM 2-mercapto-ethanol in the presence 
or absence of 10μg/ml anti-CD3 (clone 145-2C11; WEHI). For IL-6 neutral-
isation, 10μg/ml of an anti-IL-6 antibody (clone MP5-20F3; Bio-Express, 
Kaysville, UT) was added for the duration of the culture. Supernatants 
(day 3) were assayed for IL-6 and IL-17 production by enzyme-linked im-
munosorbent assay (ELISA), using matched antibody pairs (BD PharMin-
gen). Cells were re-stained with anti-CD4 and were then either stained for 
intracellular IL-17 or sorted by flow cytometry for RNA analysis.
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4.3 Results
Dependence of inflammatory arthritis on IL-17 and involvement 
of Th17 cells. 
Inflammatory arthritis was induced by IA injection of mBSA into the knee 
joints, followed by 3 daily SC injections of IL-1β. A neutralising antibody to 
IL-17 or an isotype control antibody was administered every second day. 
Knee joints were removed on day 7, and histology sections were scored 
for disease severity. Treatment with antibody to IL-17 resulted in significant 
protection against inflammatory arthritis, as compared with mice treated 
with isotype-matched control antibody (Figure 1A). The mean ± SEM total 
histology score decreased from 17.2 ± 1.3 (maximum 25) in mice that re-
ceived an isotype control antibody to 7.3 ± 0.9 in mice that received injec-
tions of the anti-IL-17 antibody (p ≤ 0.0001 by Mann-Whitney 2-tailed test). 
The severity of all histologic features of disease (joint exudate, synovitis, 
pannus formation, cartilage degradation, and bone destruction) was sig-
nificantly reduced with anti-IL-17 antibody treatment (Figures 1A and B). 
Neutralisation of IL-17 over the course of mBSA/IL-1-induced inflammatory 
arthritis therefore markedly protects against disease, demonstrating that 
this model is dependent on the production of IL-17.
The presence of Th17 cells within the inflamed synovium at the peak of 
disease (day 7) was evaluated by flow cytometry. Since the enzymatic 
digestion protocol used to obtain single-cell suspensions from inflamed 
synovium strips CD4 molecules from the cell surface, lymphoid cells were 
defined as CD45+ (hematopoietic) CD11b- (non-myeloid) cells 31. These 
cells were small and non-granular according to the forward/side light- 
scatter profile, consistent with lymphocytes. At the peak of inflammatory 
arthritis, ~7% of synovial lymphoid cells stained for IL-17 (Figure 1C). No 
staining was seen when an isotype control antibody was used. Minimal 
IFN-γ staining was detected in synovial lymphoid cells, consistent with 
the mBSA/IL-1 model of acute inflammatory arthritis being independent 
of IFN-γ 31.
IL-17 messenger RNA (mRNA) production in CD4+ T cells in 
draining LNs before the development of acute inflammatory 
arthritis. 
In order to correlate the production of IL-17 with the onset of inflammation, 
knee joints were obtained from mice at various times following IA injection 
of mBSA, and histology sections were examined for features of inflamma-
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Figure 1: Inhibition of the development of mBSA/IL-1–induced 
inflammatory arthritis by neutralisation of IL-17.
Acute inflammatory arthritis was induced with mBSA and IL-1β, and mice were treated with anti-IL-17 
or isotype control antibodies as described in Materials and Methods. (A) Histology scores. Joint 
sections were scored for features of arthritis using a 0–5-point scale (0=normal; 5=severe). Values 
are the mean and SEM of 20 joints per group (pooled from 2 independent experiments). *=p<0.0001 
versus control, by Mann-Whitney 2-tailed test. (B) Histologic features of mouse knee joints fol-
lowing treatment with isotype control (i) or anti-IL-17 (ii) antibodies. Frontal sections of knee joints 
harvested on day 7 were stained with haematoxylin and eosin (original magnification 100x). Repre-
sentative sections are shown. (C) Detection of Th17 cells in inflamed synovium following intracellu-
lar cytokine staining. Synovial cells were isolated at the peak of disease (day 7) and cultured for 4 
hours in the presence of phorbol myristate acetate, ionomycin, and monensin A. Cells were stained 
for CD45 and CD11b and intracellular cytokines (isotype control, IL-17, and interferon-γ [IFN-γ]) and 
analysed by flow cytometry. The profiles shown are gated on synovial lymphoid cells, defined as 
CD45+CD11b-. Values in the upper right compartment are the percentages of cytokine-producing 
cells.
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tory arthritis. A transient cellular joint exudate was detected in the knee 
joints on day 1 post-injection that was due to the IA injection (Figure 2A). 
Histological features had essentially returned to normal on day 2, with 
minimal signs of inflammation in the joints on day 4. By day 7, a florid in-
flammatory arthritis had developed in the injected knee joint, which was 
characterised by the presence of joint exudate and synovitis (Figure 2A) 
and IL-17+ lymphoid cells in the inflamed synovium (Figure 1C).
Draining popliteal and inguinal LNs from arthritic mice were examined to 
determine the kinetics of Th17 cell differentiation. CD4+ and CD8+ T cells 
were purified, and RNA was extracted. Expression of mRNA specific for 
IL-17 was determined by real-time quantitative PCR analysis, and the rela-
tive expression of IL-17 mRNA was evaluated by normalising against β-ac-
tin. IL-17 mRNA was not detected in CD4+ T cells from the draining LNs of 
naïve mice, nor from mice in the first 2 days following the mBSA injection 
(Figure 2B). Production of IL-17 mRNA by CD4+ T cells was detected on 
day 4 in the draining LNs, but this declined by day 7. No IL-17 mRNA was 
detected in CD8+ T cells purified from the draining LNs at any time follow-
ing induction of disease, which is consistent with the mBSA/IL-1 model of 
inflammatory arthritis being independent of CD8+ T cells. Production of 
IL-17 mRNA in draining LN cells therefore precedes the onset of inflam-
matory arthritis, a finding consistent with inflammatory arthritis requiring 
the generation of Th17 cells.
Although IL-17 mRNA was detected in CD4+ T cells in the draining LNs 
following induction of inflammatory arthritis, we were unable to detect 
IL-17-producing LN cells by intracellular cytokine staining at any stage 
(data not shown). In addition, supernatants from draining LN cells cul-
tured either alone or in the presence of mBSA did not contain detectable 
levels of IL-17 (detection limit 20pg/ml) (data not shown). Induction of in-
flammatory arthritis therefore results in the expression of IL-17 mRNA, but 
minimal production of protein in CD4+ T cells in the draining LNs. This is 
in marked contrast to lymphocytes present in the inflamed synovium on 
day 7, which do produce IL-17 protein, as detected by intracellular cytokine 
staining (Figure 1C).
Cytokine milieu within draining LNs unfavorable for Th17 cell 
development. 
Differentiation of Th17 cells is induced by TGF-β and IL-6 but is inhibited 
by IFN-γ and IL-4 23,24. We examined whether these cytokines were in-
duced in draining LN CD4+ T cells following induction of inflammatory ar-
thritis. Real-time quantitative PCR analysis for TGF-β, IL-6, IFN-γ, and IL-4 
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was performed on RNA isolated from LNs obtained at various times fol-
lowing injection of mBSA (Figure 2C). Injection of mBSA and IL-1β induced 
the production of both TGF-β and IL-6 mRNA on day 2, although this 
decreased to undetectable levels by day 4. IFN-γ and IL-4, which inhibit 
differentiation of Th17 cells, were also induced following injection of mBSA 
and IL-1β, being first detected on day 1 and peaking on day 2. Cytokine 
production during the first two days may have been due to the exogenous 
IL-1β given at that time. IL-23p19 mRNA was not detected in RNA isolated 
from LN cells at any time over the course of disease (data not shown). 
Injection of mBSA and IL-1β therefore induces the transient production of 
Figure 2: Occurrence of cytokine production in draining lymph nodes 
(LNs) before the onset of acute inflammatory arthritis.
(A) Knee joints were harvested at various stages after the initial injections of methylated bovine 
serum albumin and interleukin-1β (IL-1β). Knee joints were harvested on days 1, 2, 4, and 7, and 
frontal sections were stained with haematoxylin and eosin. The synovium (S) was not inflamed on 
days 1-4, but synovial inflammation occurred by day 7. Cellular exudate (E) was also present in the 
joints on day 7 but was minimal at all other times, except for a transient exudate that occurred on 
day 1 (original magnification 40x). (B) Total RNA was isolated from CD4+ and CD8+ T cells purified 
from LN cells by magnetic sorting. Real-time quantitative polymerase chain reaction (PCR) analysis 
of IL-17 and β-actin was performed on cDNA prepared from mRNA samples. IL-17 mRNA production 
by T cells was normalised against β-actin. Results are representative of 3 experiments. (C) Real-time 
quantitative PCR analysis of transforming growth factor β (TGF-β), IL-6, interferon-γ (IFN-γ), and 
IL-4 was performed on RNA isolated from draining LN cells. Results were normalised against the 
expression of β-actin. Values in B and C are the mean ± SEM.
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TGF-β and IL-6, which promote the differentiation of Th17 cells. However, 
these effects may be counterbalanced by the production of IFN-γ and IL-
4, as well as the lack of IL-23. The local cytokine microenvironment within 
the draining LNs is therefore not optimal for the generation of Th17 cells.
Induction of Th17 differentiation of naive CD4+ cells by 
synovial, but not peritoneal, macrophages. 
Th17 cells were detected in the synovium at the peak of inflammatory ar-
thritis (Figure 1C), and disease did not develop until after IL-17 mRNA was 
detected in CD4+ T cells in the draining LNs. However, we were unable 
to detect production of IL-17 protein in the draining LNs. Differentiation of 
Th17 cells in vivo may therefore require further stimuli produced by cells 
at the site of local inflammation. To evaluate this, synovial and peritoneal 
macrophages from arthritic mice were compared for cytokine production, 
as well as for their capacity to induce Th17 differentiation of naive CD4+ 
T cells. Peritoneal macrophages from mice that had received IP mBSA 
and SC IL-1β were also evaluated. Cells were purified by flow-cytome-
try, and mRNA was isolated to determine the cytokine profiles by reverse 
transcription-PCR analysis, both before and after in vitro culture. Fresh-
ly isolated synovial macrophages produced mRNA for cytokines that are 
essential for Th17 induction: IL-1β, IL-23p19, IL-6, and TGF-β. In contrast, 
freshly isolated peritoneal macrophages produced mRNA for IL-1β and 
TGF-β, but IL-23p19 and IL-6 were markedly reduced (Figure 3A). Since 
synovial macrophages produce mRNA for cytokines that are required for 
the generation of Th17 cells, we next determined whether these cells could 
support the differentiation of Th17 cells from naïve precursors in vitro. 
Synovial or control macrophages were co-cultured for 3 days with naïve 
CD4+ T cells in the presence of 10μg/ml of anti-CD3. The T cells were 
then stained for the presence of intracellular IL-17, and supernatants were 
assayed for IL-17 and IL-6 by ELISA. Addition of synovial macrophages 
to CD4+ T cells, in the presence of anti-CD3, resulted in the generation 
of IL-17–producing CD4+ T cells, with ~4% of cells staining positive for IL-
17 by flow cytometry. In contrast, peritoneal macrophages isolated from 
arthritic mice or mice that received IP mBSA, were much less efficient at 
inducing Th17 differentiation (Figure 3B). ELISA of culture supernatants 
confirmed that IL-17 production was greatest when naïve CD4+ T cells 
were co-cultured with synovial macrophages (Figure 3C). Naive CD4+ T 
cells cultured either alone, with anti-CD3, or with synovial macrophages 
in the absence of any further stimuli failed to differentiate into IL-17-pro-
ducing cells (data not shown). Since IL-6 is essential for Th17 induction, 
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Figure 3: Induction of the differentiation of Th17 cells from naive 
T cells by synovial, but not peritoneal, macrophages. 
(A) The presence of macrophage RNA for transforming growth factor β (TGF-β), interleukin-6 (IL-6), 
IL-1β, and IL-23p19, cytokines that are essential for Th17 differentiation, was determined by reverse 
transcription-polymerase chain reaction analysis. Beta-actin was included as a loading control. RNA 
was extracted from freshly isolated macrophages derived from the synovium of arthritic mice (lane 
1), the peritoneum of naïve mice (lane 2), and the peritoneum of arthritic mice (lane 3). Lane 4 con-
tains water control. (B) Macrophage stimulation of IL-17 production by CD4 T cells was determined 
by flow cytometry. Macrophages from the synovium of arthritic mice, the peritoneum of mice inject-
ed intra-articularly (IA) with methylated bovine serum albumin (mBSA), and the peritoneum of mice 
injected intra-peritoneally (IP) with mBSA (see Materials and Methods for details) were cultured with 
equal numbers of naive CD4+ T cells in the presence of anti-CD3. Cells were then stained for intracel-
lular IL-17. The profiles shown are gated on CD4+ T cells. Values in the upper right compartment are 
the percentages of Th17 cells. (C) and (D) Culture supernatants were assayed for the presence of IL-
17 (C) and IL-6 (D) by enzyme-linked immunosorbent assay. Values are the mean ± SEM and are rep-
resentative of 3 independent experiments. *= p < 0.01 versus synovium, by Student’s 2-tailed t-test.
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it was evaluated by ELISA of co-culture supernatants. In contrast to the 
results obtained by PCR on freshly isolated synovial and peritoneal mac-
rophages, IL-6 production was found in all co-cultures. However, there 
was significantly more IL-6 in synovial macrophage co-cultures than in 
peritoneal macrophage co-cultures (Figure 3D). These experiments show 
that there is production of some IL-6 in peritoneal macrophage co-cultures 
with naive CD4+ T cells, but macrophages from this site still fail to support 
Th17 differentiation.
Th17 induction by synovial macrophages prevented by IL-6 
blockade. 
To evaluate the role of synovial macrophage-derived IL-6 in the induction 
of Th17, a neutralising anti-IL-6 antibody was used in the macrophage 
co-cultures described above. Anti-IL-6 dramatically inhibited Th17 induc-
tion by synovial macrophages, reducing the percentage of positive-stain-
ing cells from ~4% to ~1% (Figures 3B and 4A, respectively). T cells from 
co-cultures with peritoneal macrophages that also contained anti-IL-6 are 
shown as a control in Figure 4A. IL-17 ELISA of supernatants from co-cul-
tures containing synovial macrophages confirmed the inhibition of Th17 
induction by anti-IL-6 (Figure 4B).
To determine whether IL-6 blockade of Th17 induction acts at the level of 
transcription or translation, RNA was purified from T cells re-sorted from 
co-cultures on day 3. IL-17 and ROR-γt mRNA levels were determined by 
real-time quantitative PCR. The addition of anti-IL-6 in culture inhibited 
the expression of both IL-17 and ROR-γt mRNA to levels similar to those 
in naïve T cells (Figures 4C and D, respectively). IL-6 blockade therefore 
inhibited Th17 induction by synovial macrophages at the transcriptional 
level.
4.4 Discussion
Th17 cells are important mediators of host protection and initiate inflam-
mation in response to infection (for review, see 3). Since IL-17 is a po-
tent pro-inflammatory cytokine, it seems likely that mechanisms would 
exist to ensure that IL-17 production is restricted in order to avoid wide-
spread systemic inflammation. The mBSA/IL-1-induced model of arthritis 
is a CD4+ T cell-dependent model of acute inflammatory arthritis. Since 
the incidence and severity of disease are not substantially affected by 
the absence of IFN-γ or IL-4 in this model 30,31, we investigated whether 
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Figure 4: Th17 induction by synovial macrophages prevented by 
inhibition of interleukin-6 (IL-6). 
Macrophages from different sources were cultured with equal numbers of naive CD4+ T cells in the 
presence of anti-CD3 and anti-interleukin-6 (anti-IL-6) (10µg/ml). (A) Macrophage stimulation of IL-
17 production by CD4+ T cells was determined by flow cytometry. Macrophages from the synovium 
of arthritic mice, the peritoneum of mice injected intra-articularly (IA) with methylated bovine serum 
albumin (mBSA), and the peritoneum of mice injected intra-peritoneally (IP) with mBSA (see Materi-
als and Methods for details) were cultured with equal numbers of naive CD4+ T cells in the presence 
of anti-CD3 and a neutralising anti-IL-6 antibody. Cells were then stained for intracellular IL-17. The 
profiles shown are gated on CD4+ T cells. Values in the upper right compartment are the percentages 
of Th17 cells. (B) Supernatants from synovial macrophages (MΦ) cocultured with naive CD4+ T cells 
in the presence or absence of anti-IL-6 were assayed for IL-17 by enzyme-linked immunosorbent 
assay. (C) and (D) CD4+ T cells were purified from the spleens of naive mice or from co-cultures with 
synovial macrophages, with or without the addition of anti-IL-6, and real-time quantitative poly-
merase chain reaction analysis of IL-17 (C) and retinoic acid–related orphan receptor γt (ROR-γt) (D) 
was performed. Results were normalised against the expression of hydroxymethylbilane synthase. 
Values in B-D are the mean ± SEM and are representative of 3 independent experiments.
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inflammatory arthritis was dependent on the generation of pro-inflamma-
tory Th17 cells. Administration of a neutralising antibody against IL-17 to 
mice over the course of disease resulted in a marked reduction in disease 
severity, demonstrating that this model is dependent on IL-17 production. 
Although we were able to detect IL-17 gene transcription by CD4+ T cells 
in draining LNs following injection of antigen into the joint, IL-17-producing 
cells were found only at the site of inflammation (Figures 1 and 2). In con-
trast, lymphoid cells producing IFN-γ were not detected in the synovium. 
Since IFN-γ is known to inhibit the differentiation of Th17 cells, the lack of 
IFN-γ-positive cells at the site of inflammation is consistent with the local 
emergence of Th17 cells following induction of inflammatory arthritis. Pro-
duction of TGF-β and IL-6 in draining LNs may therefore promote the initial 
polarisation of Th17 cells by inducing the expression of ROR-γt and the 
IL-23 receptor on naïve precursors. Further differentiation may be limited 
by the relative absence of IL-23 and the presence of inhibitory cytokines 
such as IFN-γ and IL-4. It is also possible that other, as-yet-unidentified, 
inhibitory factors could block efficient translation of IL-17 mRNA in the LN 
environment.
Migration of Th17 cells or immediate precursors thereof from LNs to sites 
of tissue infection or inflammation may permit IL-17 production because 
of the presence of a favourable cytokine milieu and the relative absence 
of inhibitory cytokines or other factors. Consistent with this hypothesis, 
synovial macrophages isolated at the peak of inflammatory arthritis, in 
conjunction with antigen stimulation via the T cell receptor, were able to 
induce the differentiation of naïve CD4+ T cell precursors into IL-17-pro-
ducing cells and produced IL-6, IL-23, IL-1β, and TGF-β. In contrast, peri-
toneal macrophages, whether from naïve mice, arthritic mice, or mice that 
had been injected IP with mBSA, were much less capable of inducing IL-
17 production. This may be due to the failure of peritoneal macrophages 
to produce sufficient levels of cytokines such as IL-6, which is essential 
for the generation of Th17 cells, but other possible explanations include 
intrinsic differences in tissue macrophage populations and the response 
of these populations to systemic IL-1β. Our results in this experimental 
model show that only synovial macrophages derived from the site of in-
flammation support the differentiation of Th17 cells.
The ability of local antigen-presenting cells to induce Th17 cells may there-
fore depend on the initial stimulus, the cytokines produced, and the local 
micro- environment. Lamina propria macrophages have recently been 
shown to induce regulatory T cell responses, while dendritic cells induced 
Th17 cells 34. Similarly, dendritic cells isolated from the central nervous 
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system of mice following the induction of experimental autoimmune en-
cephalomyelitis were shown to produce the cytokines TGF-β, IL-6, and 
IL-23 and to induce the polarisation of Th17 cells from naïve precursors 
35,36. Following infection with Candida albicans, binding of fungal cell wall 
components to dectin-1, a C-type lectin, induced the production of IL-23 
and the generation of Th17 cells 37. Similarly, methylation of BSA may re-
sult in recognition by pattern-recognition receptors expressed by synovial 
antigen-presenting cells that, in combination with the IL-1β that is adminis-
tered in the early stages of the model, can initiate a Th17-type response.
In summary, we have shown that mBSA/IL-1-induced acute inflammato-
ry arthritis is dependent on the production of IL-17, and that Th17 cells 
are present at the site of tissue inflammation, but not in draining LNs. In 
addition, we have shown that synovial macrophages, but not peritoneal 
macrophages, support the generation of Th17 cells in an IL-6-dependent 
manner. The data presented here are consistent with a model in which the 
initial differentiation of Th17 cells occurs within draining LNs, but the gen-
eration of mature IL-17-producing cells requires stimulation with cytokines 
that are produced by synovial tissue macrophages at the site of inflamma-
tion. Such a model would restrict the production of IL-17 to non-lymphoid 
sites involved in an inflammatory response and limit systemic inflamma-
tion. These data add to the case for considering both IL-6 and IL-17 as 
therapeutic targets in inflammatory disease.
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Abstract
Rel/NF-κB transcription factors regulate inflammatory and immune re-
sponses. Despite possible subunit redundancy, NF-κB1-deficient (Nfkb1-/-
) mice were profoundly protected from sterile CD4 T cell-dependent acute 
inflammatory arthritis and peritonitis. We evaluated CD4 T cell function 
in Nfkb1-/- mice and found increased apoptosis and selectively reduced 
GM-CSF production. Apoptosis was blocked by expression of a Bcl-2 
transgene without restoring a disease response. In contrast with wild-type 
cells, transfer of Nfkb1-/- or GM-CSF-deficient CD4 T cells into RAG-1-de-
ficient (Rag1-/-) mice failed to support arthritis induction. Injection of GM-
CSF into Nfkb1-/- mice fully restored the disease response, suggesting that 
T cells are an important source of GM-CSF during acute inflammation. 
In antigen-induced peritonitis, NF-κB1-dependent GM-CSF production in 
CD4 T cells was required for disease and for generation of inflammatory 
monocyte-derived dendritic cells (MoDC), but not conventional dendrit-
ic cells. MoDC were identified in inflamed synovium and draining lymph 
nodes during arthritis. These MoDC produced high levels of MCP-1, a 
potent chemo-attractant for monocytes. This study revealed two important 
findings: NF-κB1 serves a critical role in the production of GM-CSF by 
activated CD4 T cells during inflammatory responses, and GM-CSF de-
rived from these cells drives the generation of MoDC during inflammatory 
disease.
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5.1 Introduction
Dendritic cells (DC) are crucial for the generation of immune responses 
and comprise several subsets in mice. In the absence of overt infection 
or inflammation (steady-state conditions), these include the resident and 
migratory conventional DC (cDC), plasmacytoid DC, and Langerhans 
DC 1,2. After exposure to inflammatory stimuli, monocytes are recruited 
and differentiate into inflammatory monocyte-derived DC (MoDC), in a 
GM-CSF-dependent manner 3-5. Although numerous lymphoid and mye-
loid cell types can produce GM-CSF in vitro, it is unclear how the GM-CSF 
required for MoDC differentiation is provided in vivo.
The Rel/NF-κB family of transcription factors has been shown to contrib-
ute to the development and differentiation of multiple cell types 6, and reg-
ulate the expression of multiple gene products that are likely to contribute 
to human rheumatoid arthritis (RA) 7. The REL subunit has recently been 
identified in genome-wide association studies as a genetic risk factor for 
RA 8. However, few in vivo studies have examined individual Rel/NF-κB 
subunits in relevant experimental models of inflammatory disease.
There are five mammalian Rel/NF-κB proteins: NF-κB1 (p50 and its pre-
cursor, p105), NF-κB2 (p52 and its precursor, p100), RelA (p65), RelB, 
and c-Rel 6. Rel/NF-κB proteins form homodimers and heterodimers, with 
the most common transcription factor comprising a dimer of NF-κB1 and 
RelA. In most cells, the majority of Rel/NF-κB is maintained as inactive 
cytoplasmic complexes by a family of inhibitor proteins (IκB). In response 
to multiple immune stimuli that include cytokines, TCR stimulation, and 
TLR ligands, IκB proteins are phosphorylated and targeted for proteas-
ome-mediated degradation. In the case of NF-κB1, proteolytic process-
ing of p105 produces p50, which homodimerizes or heterodimerizes be-
fore translocating to the nucleus and binding κB elements found in the 
transcriptional regulatory regions of target genes 6. However, control of 
gene transcription by NF-κB family members is complex, and a number 
of modulating cofactors have been identified 9. NF-κB1 lacks an intrinsic 
transactivation domain, and NF-κB1 homodimers generally inhibit tran-
scription via the histone deacetylase, HDAC1 10,11. NF-κB1 activates gene 
transcription through interaction with its major trans-activating dimer part-
ners RelA and c-Rel, or by interacting with the co-activators, Bcl-3 12 and 
CREB-binding protein 13.
We previously reported that NF-κB1-deficient (Nfkb1-/-), but not c-Rel–
deficient (Rel-/-), mice were protected from CD4+ T cell-dependent acute 
inflammatory arthritis 14. We also previously reported that MoDC differen-
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tiated from monocyte precursors in the spleen during acute inflammatory 
peritonitis 3. In this study, we show that Nfkb1-/- mice are also protected 
from acute inflammatory peritonitis, and that protection in these models of 
acute inflammation was due to a critical requirement for the NF-κB1 sub-
unit in CD4+ T cells. Protection from disease was not due to enhanced T 
cell apoptosis or to the failure to upregulate cellular activation markers or 
cytokine receptors, but to a relatively selective defect in the production of 
GM-CSF. We also show that the differentiation of MoDC, which could be 
identified in inflamed synovial tissue, draining lymph nodes (LN), and the 
spleen during both inflammatory arthritis and peritonitis, was dependent 
on the expression of NF-κB1 in CD4+ T cells, and T cell-derived GM-CSF. 
Our data provide direct experimental evidence that NF-κB-mediated pro-
duction of GM-CSF by activated CD4+ T cells is pivotal for MoDC differen-
tiation in inflammatory conditions.
5.2 Materials and Methods
Mice
Mice were backcrossed onto C57BL/6 (B6), as indicated. Nfkb1-/- mice 15 
and IL-1R1-deficient (IL1r-1-/-) mice 16 had eight and six crosses, respective-
ly. RAG-1-deficient (Rag1-/-) mice 17 (15 crosses), GM- CSF-deficient (GM-
CSF-/-) mice 18 (8 crosses), B6.Ly5.1, and CD11c-Diphtheria toxin receptor 
(DTR) transgenic (Tg) mice 19 were obtained from the Walter and Eliza Hall In-
stitute (WEHI) animal services (Kew, VIC, Australia). Nfkb1-/-/OT-II mice and 
Nfkb1-/-/vav-Bcl2 mice were generated by crossing Nfkb1-/- mice with OT-
II 20 and vav-Bcl2 Tg B6 mice 21, respectively. B6 mice were used as wild-
type (WT) controls in all experiments. All mice were 7 weeks old. All an-
imal procedures were approved by the WEHI animal ethics committee.
Acute monoarticular arthritis
As previously described 14, on day 0, mice were injected intra-articular-
ly (i.a.) into the knee joint with 200μg methylated BSA (mBSA; Sigma). 
Human recombinant IL-1β (250ng; PeproTech) was injected subcutane-
ously into the footpad on days 0, 1, and 2. In some experiments, mice 
were injected intra-peritoneally (i.p.) three times daily for seven days with 
120,000 units murine recombinant GM-CSF (specific activity 1x108 U/mg; 
WEHI), beginning on day 0. Mice were sacrificed on day 7 and the knees 
processed for histological assessment. Sections were graded from 0 (nor-
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mal) to 5 (severe) for 5 histological features of arthritis (maximum total 
score of 25) by a blinded assessor.
Induction of acute peritonitis
Acute peritonitis was induced as described previously 3,22. On days 0 and 
14, mice were injected intra-dermally at the base of the tail with 100μl 
mBSA (1mg/ml in CFA). On day 21, mice were injected i.p. with 100μg 
mBSA to induce inflammation. Peritoneal exudate and spleen were ana-
lysed by flow cytometry on day 23.
Isolation of CD4 T cells
Single-cell suspensions from spleen were incubated with FITC-conju-
gated anti-CD4 mAb (Caltag) followed by anti-FITC microbeads (Miltenyi 
Biotec). Magnetically labelled cells were positively selected using an Au-
tomacs Magnetic Cell Sorter (Miltenyi Biotec). Sorted cell purity was >95% 
determined by flow cytometry.
CD4 T cell transfer to Rag1-/-  and irradiated Nfkb1-/- mice
CD4+ T cells (5x106) were injected intravenously (i.v.) into either non-ir-
radiated Rag1-/- mice or sub-lethally gamma-irradiated (4.0 Gy) WT or 
Nfkb1-/- mice. Thirty minutes before cell transfer, mice were injected i.p. 
with anti-CD8 mAb (0.3mg each of YTS169 and 53-6.7) to deplete any 
co-transferred CD8 cells. After 4-5 weeks, donor T cells were assessed 
in the peripheral blood of recipients by flow cytometry and acute arthritis 
was induced. In experiments with WT or Nfkb1-/- mice (each Ly5.2), evalu-
ation of CD4 reconstitution was facilitated by the use of Ly5.1 donor CD4 
T cells.
In vitro stimulation of CD4 T cells
CD4 T cells were cultured in 96-well plates at 37°C, 5% CO2 in RPMI con-
taining 10% FCS, 20μM 2-ME, 2mM glutamine, and 1mM sodium pyru-
vate. One or more of the following stimuli were added: human rIL-2 (1000 
U/ml; Cetus), 1-5 mg/ml anti-CD3 (clone 145-2C11; WEHI; adsorbed to the 
wells for 2h at 37°C), and 1-10μg/ml anti-CD28 (clone 37.51; WEHI) mAb. 
For Th17 polarizing conditions, cultures included anti-CD3, anti-CD28, 
human rTGF-β1 (5ng/ml; R&D Systems), human rIL-6 (20ng/ml; R&D Sys-
tems), anti-IFN-γ (10μg/ml; clone R4-6A2; WEHI), and anti-IL-4 (10μg/ml; 
clone 11B11; WEHI). Cell surface activation marker expression was deter-
mined by flow cytometry using PE-conjugated mAb to CD25 (clone PC61; 
Pharmingen) or CD69 (clone H1.2F3; Pharmingen). Dead cells were ex-
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cluded by propidium iodide staining (Calbiochem).
RNase protection analysis
Total RNA from 1x107 cells was analysed using the RiboQuant RNase 
Protection System (Pharmingen) with the murine cytokine receptor tem-
plate set mCR-1. Dried polyacrylamide gels were visualized after an over-
night exposure by PhosphorImager (Molecular Dynamics) using Image 
Quant software.
Intracellular cytokine staining
CD4 T cells (1x105) were cultured with 10μg/ml anti-CD3 and 2μg/ml an-
ti-CD28. For Th17 conditions, 5μg/ml anti-CD3 and 1μg/ml anti-CD28 
were used, and TGF-β1, IL-6, anti-IFN-γ, and anti-IL-4 were added, as 
described earlier. Monensin A (1μM; Sigma) was added during the last 4 
h of culture. Cells were restained for CD4, then fixed, permeabilised, and 
stained for intracellular cytokines using the Cytofix/ Cytoperm kit (BD Bio-
sciences) and PE-labelled Ab (Pharmingen).
Cytokine production by naïve CD4 T cells
Splenic CD4 T cells were prepared from naïve mice, further stained with 
anti-CD25-PE (clone PC61), anti-CD44-PE (clone 1M7), anti-CD62L-bi-
otin (clone MEL-14), and streptavidin-allophycocyanin (all from Pharmin-
gen), and sorted by flow cytometry (MoFlo Cytomation) to obtain naïve 
CD4+CD44-CD62L+CD25- T cells. Cells (1x105) were cultured in a 96-well 
plate in the presence of 10μg/ml anti-CD3 + 2μg/ml anti-CD28. Culture 
supernatants were removed after 72 h and evaluated for cytokines and 
chemokines using the Bio-Plex mouse cytokine 23-plex panel (Bio-Rad 
Laboratories) according to the manufacturer’s instructions. The assay was 
read on a Bio-Plex 200 instrument and analysed using the Bio-Plex Man-
ager V5.0 software.
Nuclear and cytoplasmic extracts, EMSA, and Western blot
Nuclear and cytoplasmic extracts were prepared and EMSA performed 
as previously described 23. In brief, 1.5μg nuclear extracts were incubat-
ed with [32P]-labelled double-stranded κB3 probe (5’-CGTAAGCAGCGG- 
GAAATCCCCC-3’) 23 on ice for 20 min. Antibodies (2μg; Santa Cruz Bio- 
technology) specific to NF-κB1 (sc-1192X), RelA (sc-372X), c-Rel (sc-71X), 
NF-κB2 (sc-298X), and RelB (sc-226X) were added for a further 20 min 
on ice. Reactions underwent electrophoresis at 250V for 2 hours on a 5% 
non-denaturing polyacrylamide gel. Gels were dried onto 3MM paper and 
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exposed to film.
For Western blots, the NuPage system (Invitrogen) was used with 10μg 
extract per lane. Bands were transferred to a PVDF membrane using iBlot 
(Invitrogen) and the membrane was incubated with rabbit anti-c-Rel Ab 
(sc-71X), followed by HRP-conjugated sheep anti-rabbit IgG (Chemicon). 
Bands were visualised using the ECL Western blotting detection system 
(Amersham Biosciences).
Depletion of CD11c+ DC during acute inflammatory arthritis
Lethally irradiated (2 x 500 rad) WT mice were injected i.v. with CD11c-
DTR Tg 19 or WT bone marrow cells. Mice were allowed to reconstitute for 
5 weeks. Conventional CD11c+ DC were depleted by i.p. injection of 100ng 
Diphtheria toxin on days -1 to 4 of the acute arthritis model. Control mice 
received saline. DC depletion was >60%.
Detection and sorting of DC in lymphoid and synovial tissues
Light density cells were purified as previously described 24. In brief, spleens 
or LN were digested with DNase I (0.1%; Roche Molecular Biochemicals) 
and collagenase (1mg/ml, type II; Worthington Biochemical); synovial tis-
sue was digested as described previously 25 and centrifuged in Nycodenz 
medium (density 1.082 g/cm3; Axis-Shield, Norway). Light density cells 
were then stained for flow cytometric analysis using Ab against CD11b, 
CD11c, Ly6C, and MHCII (all from Pharmingen). Dead cells were excluded 
by propidium iodide staining. For experiments with sorted DC, cDC (CD-
11chiCD11b+/-Ly6C-MHCIIhi) and MoDC (CD11cintCD11bhiLy6C+/hiMHCIIhi) 
were sorted using a DIVA automated cell sorter (BD Biosciences).
Cytokine production by cDC and MoDC purified from inflamed 
synovial tissue
DC were sorted from inflamed synovial tissue, obtained at the peak of 
acute inflammatory arthritis (day 7) as described earlier. Cells (5x104) were 
cultured in 200μl RPMI containing 10% FCS, 20μM 2-ME, 2mM glutamine 
and 1mM sodium pyruvate for 16 h at 37°C, 5% CO2, in triplicate. Culture 
supernatants were removed and evaluated for cytokines and chemokines 
using the Bio-Plex mouse cytokine 23-plex panel (Bio-Rad Laboratories). 
The assay was read on a Bio-Plex 200 instrument and analyzed using the 
Bio-Plex Manager V5.0 software.
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Measurement of apoptosis
For analysis of apoptosis, cells were washed in PBS and resuspended 
in hypotonic buffer containing 50μg/mL propidium iodide, 0.1% trisodium 
citrate (Merck chemicals, Kilsyth, VIC, Australia) and 0.1% Triton X-100 
(Calbiochem), and incubated at 4°C for > 2h. Flow cytometry was used to 
determine the percentage of DNA fragmentation as described previously 
26.
MLR and presentation of OVA by DC
For MLR, splenic cDC from WT or Nfkb1-/- mice were mixed with CD4 T 
cells (1x105 cells/well) from BALB/c mice. For the reciprocal MLR, CD4 T 
cells from WT or Nfkb1-/- mice were mixed with BALB/c irradiated (20 Gy) 
stimulator splenocytes. For Ag-specific presentation, WT and Nfkb1-/- mice 
were injected i.v. with 3 mg OVA (Sigma) or PBS. After 16 h, spleens were 
harvested and cDC were purified as described previously 27. OVA-specif-
ic CD4 T cells were purified from spleens of OT-II mice and co-cultured 
(1x104 cells/well) with increasing numbers of DC. In reciprocal experi-
ments, WT cDC from OVA-injected mice were cultured with WT or Nfkb1-
/- OT-II CD4 T cells. For each assay, 1 μCi/ well [3H]thymidine (Amersham 
Biosciences) was added for the final 8 h of culture, cells were harvested 
onto glass fibre filters, and radioactive incorporation was counted on a 
scintillation counter as a measure of CD4 T cell proliferation.
Statistics
For histological scores, the Mann-Whitney two-sample rank test was used 
to determine the level of significance between means of groups. For other 
comparisons, two-way ANOVA and Student t test were used, as indicated. 
Tests were two-tailed, and p<0.05 was considered statistically significant.
5.3 Results
A critical role for NF-κB1 in CD4 T cells during acute 
inflammatory arthritis
To investigate the selective protection of Nfkb1-/- mice from mBSA/IL-1 
acute inflammatory arthritis, a CD4 T cell-dependent model 25, we trans-
ferred purified WT or Nfkb1-/- splenic CD4 T cells into Rag1-/- mice, which 
have normal APC function 28. There were similar percentages of WT and 
Nfkb1-/- CD4 T cells in the peripheral blood of recipient Rag1-/- mice imme-
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Figure 1: CD4 T cells require NF-κB1, but not responsiveness to IL-1, 
for acute inflammatory arthritis.
WT, Nfkb1-/-, and IL1r-1-/- splenic CD4 T cells were transferred to Rag1-/- mice as described in Materi-
als and Methods. Acute inflammatory arthritis was induced after 5 wks and the joints examined 7 d 
later. Representative H&E-stained sections (original magnification 3200x) of knee joints from  Rag1-
/- mice that had received (A) no cells, (B) WT cells, or (C) Nfkb1-/- cells. (D) Disease in a WT B6 mouse 
is shown for comparison. (E) Total histological scores (mean ± SEM; n = 7 joints) for Rag1-/- mice 
receiving either WT or Nfkb1-/- cells. Mice receiving no cells had similar scores to those transferred 
with Nfkb1-/- cells (not shown). *p ≤ 0.05. Results are representative of three experiments. (F) Total 
histological scores (mean ± SEM; n = 20 joints, pool of 3 experiments) are shown for Rag1-/- mice 
receiving either WT or IL1r-1-/- cells. (G) Restoration of disease susceptibility in Nfkb1-/- mice by 
transfer of WT CD4 T cells. Total histological scores (mean 6 SEM; n = 20 joints) are shown for 
sublethally irradiated WT or Nfkb1-/- mice receiving WT cells.
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diately before arthritis induction (% of total leukocytes: 18.4 ± 2.7 versus 
17.3 ± 2.2, respectively; mean ± SEM; n = 4). As expected, arthritis could 
not be induced in naïve Rag1-/- mice (Figure 1A); however, Rag1-/- mice 
that received WT CD4 T cells (Figure 1B) developed acute arthritis, with 
features and severity similar to those of B6 mice (Figure 1D). In contrast, 
Rag1-/- mice receiving Nfkb1-/- CD4 T cells had markedly reduced disease 
compared with recipients of WT CD4 T cells, with very mild histologi-
cal features (Figure 1C, 1E) that resembled the minor pathology seen in 
Nfkb1-/- mice 14.
A link between IL-1R signalling and NF-κB, coupled with the ability of IL-1β 
to stimulate T cells, raised the possibility that the reduced disease re-
sponse in Rag1-/- mice injected with Nfkb1-/- CD4 T cells might be because 
Figure 2: Increased apoptosis in TCR-stimulated Nfkb1-/- CD4 T cells 
is prevented by vav-Bcl2 Tg but has no effect on acute arthritis. 
(A) CD4 T cells from (i) WT, (ii) Nfkb1-/-, (iii) vav-Bcl2 Tg, and (iv) Nfkb1-/-/ vav-Bcl2 Tg mice were 
cultured for 72 h with anti-CD3 + anti-CD28. Propidium iodide-stained cells were evaluated by flow 
cytometry. Representative histogram plots are shown with the percentage of cells exhibiting DNA 
fragmentation (apoptosis) indicated. (B) Mean percentages of apoptotic cells (6 SEM; n = 8 mice). 
Representative of three experiments. *p ≤ 0.0001, Student t test. (C) Acute inflammatory arthritis 
was induced in WT and Nfkb1-/-/vav-Bcl2 Tg mice and evaluated 7 d later. Results show total histo-
logical scores (mean ± SEM; n = 10 joints) and are representative of two experiments. †p ≤ 0.0001.
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of the inability of these cells to respond to IL-1. IL1r-1-/- CD4 T cells were 
therefore transferred into Rag1-/- mice and arthritis was induced. Compa-
rable disease between mice receiving IL1r-1-/- and WT CD4 T cells (Fig-
ure 1F) indicated that direct CD4 T cell responsiveness to IL-1 was not 
required.
To confirm the exclusive requirement for NF-κB1 expression in CD4 T 
cells, we injected sublethally irradiated Nfkb1-/- mice with WT CD4 T cells, 
which restored a normal disease response in the mice (Figure 1G). Col-
lectively, these data demonstrate that NF-κB1 function in CD4 T cells is 
essential for the induction of mBSA/IL-1 acute arthritis, via a pathway that 
does not involve IL-1 acting directly on CD4 T cells.
Arthritis is not restored in Nfkb1-/- mice by the pro-survival 
protein Bcl2
The Rel/NF-κB family is important for cell survival through the inhibition of 
apoptosis, and indeed, we found that cell death was greater in activated 
Nfkb1-/- CD4 T cells compared with WT CD4 T cells (Figure 2Ai, 2Aii, 2B). 
To address whether increased apoptosis could account for the failure of 
Nfkb1-/- mice to succumb to acute arthritis, we intercrossed Nfkb1-/- mice 
with mice that expressed a Bcl2 Tg in all leukocytes 21. Although Bcl2 Tg 
expression prevented the enhanced apoptosis seen in activated Nfkb1-
/- CD4 T cells in vitro (Figure 2Aiv, 2B), it was unable to restore disease 
in vivo (Figure 2C), thereby excluding reduced CD4 T cell survival as the 
explanation for the protection of Nfkb1-/- mice.
Nuclear induction of NF-κB1 after CD4 T cell activation
To understand how NF-κB1 signaling might contribute to CD4 T cell func-
tion after cellular activation, we performed EMSA on nuclear extracts of 
stimulated WT and Nfkb1-/- CD4 T cells. Because of the low frequency of 
mBSA-specific T cells in the acute arthritis model 25, these studies were 
performed using nuclear extracts isolated from CD4 T cells after activa-
tion with anti-CD3 + anti-CD28 mAb in culture. Three low-abundance 
complexes that bound specifically to a canonical κB site were detected 
in unstimulated WT CD4 T cells (Figure 3A). Based on Ab supershifts, 
these complexes were NF-κB1/RelA heterodimers and NF-κB1 homodi-
mers (Figure 3A, upper panel). After activation, nuclear levels of NF-κB1 
homodimers were markedly increased, as were NF-κB1/c-Rel heterodi-
mers, albeit to a lesser extent (Figure 3A, lower panel). Consistent with 
previous findings 29, NF-κB2 and RelB were undetectable in CD4 T cell 
nuclei. Nuclear extracts from unstimulated Nfkb1-/- CD4 T cells only bound 
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weakly to the κB site (Figure 3A, upper panel). However, a c-Rel complex 
was upregulated in stimulated Nfkb1-/- CD4 T cells (Figure 3A, lower pan-
el), which may represent c-Rel homodimers. The presence of enhanced 
levels of c-Rel in the nuclei of stimulated WT and Nfkb1-/- CD4 T cells was 
confirmed by Western blot (Figure 3B). Together, these data suggest that 
NF-κB1/c-Rel heterodimers and NF-κB1 homodimers are the major NF-
Figure 3: NF-κB1 in activated CD4 T cells.
(A) Subunit composition of Rel/NF-κB complexes in WT and Nfkb1-/- splenic CD4 T cells. Nuclear 
extracts of CD4 T cells that were unstimulated (top panel), or stimulated for 72 h with anti-CD3 + 
anti-CD28 (bottom panel) mAb, were examined by EMSA in the presence and absence of specific 
Ab to Rel/NF-κB subunits. Arrows indicate supershifts (SS). (B) Western blot of c-Rel expression in 
the nuclear extracts and cytoplasm of WT (+/+) and Nfkb1-/-  (-/-) CD4 T cells that were unstimulated 
or stimulated for 72 h with anti-CD3 + anti-CD28 mAb. All results are representative of two or more 
experiments.
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Figure 4: Activation marker expression and cytokine production by 
Nfkb1-/- CD4 T cells.
(A) and (B) Normal CD4 T cell activation markers and cytokine receptor expression in the absence of 
NF-κB1. (A) WT or Nfkb1-/- CD4 T cells were cultured for 24h in the absence (-) or presence (+) of an-
ti-CD3 + anti-CD28 mAb, then stained with Ab to CD25 or CD69 and analysed by flow cytometry. (B) 
RNase protection analysis for cytokine receptor mRNA expression by WT (+/+) and Nfkb1-/- (-/-) CD4 
T cells stimulated for 48 h with anti-CD3 + anti-CD28. L32 and GAPDH were RNA loading controls. 
(C) and (D) Reduced GM-CSF production by CD4 T cells in the absence of NF-κB1. (C) WT and Nfkb1-
/- CD4 T cells were cultured for 72h with anti-CD3 + anti-CD28, either without additives or under Th17 
conditions (TGF-β+IL-6+anti-IFN-γ+anti-IL-4). The production of cytokines critical for arthritis devel-
opment (IL-2, IL-17, and GM-CSF) was evaluated by intracellular cytokine staining. Representative 
flow cytometry plots are shown; values are the percentage of cytokine-producing CD4 T cells. (D) 
Naïve WT and Nfkb1-/- CD4 T cells (CD4+CD44-CD62L+CD25-) were cultured for 72h with anti-CD3 + 
anti-CD28, and cytokine production was evaluated in culture supernatants by Bio-Plex assay. Values 
show the mean (± SEM; n = 3 mice) concentrations in pg/ml. *p ≤ 0.05, †p ≤ 0.01, Student t test. All 
results are representative of two or more experiments.
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κB subunits that are normally induced in activated CD4 T cells, and that in 
the absence of NF-κB1, c-Rel homodimers predominate.
Reduced production of the arthritogenic cytokine GM-CSF by 
Nfkb1-/- CD4 T cells
Involvement of NF-κB in the regulation of proinflammatory cytokine 
gene transcription is well documented. In addition to IL-1, we and oth-
ers have shown that the acute arthritis model is critically dependent on 
the T cell-derived cytokines IL-2, GM-CSF 30,31, and IL-17 32. We therefore 
evaluated the effect of NF-κB1 deficiency on expression of early activa-
tion markers and cytokine receptors, and production of the key arthri-
togenic cytokines IL-2, GM-CSF, and IL-17 by CD4 T cells. Flow cyto-
metric analysis of Nfkb1-/- CD4 T cells after stimulation with anti-CD3 + 
anti-CD28 mAb showed normal expression of CD25 (IL-2Rα) and CD69 
(Figure 4A), and RNase protection analysis showed normal levels of 
mRNA for the cytokine receptors IL-2R α- and β-chains, the IL-4Rα-chain, 
and the γ common chain (Figure 4B). Intracellular cytokine staining of 
Nfkb1-/- CD4 T cells after stimulation with anti-CD3 + anti-CD28 mAb or 
under Th17 polarizing conditions showed normal or enhanced expression 
of IL-17 and IL-2, respectively, but a marked reduction in GM-CSF (Figure 
4C).
Cytokine production was further evaluated in the culture supernatants of 
stimulated naïve CD4 T cells (CD4+CD44-CD62L+CD25-) by Bio-Plex assay. 
In accordance with the intracellular cytokine staining, the supernatants of 
Nfkb1-/- CD4 T cells had a 5.8-fold reduction in GM-CSF production (Fig-
ure 4D). These data also confirmed the relatively specific effect of NF-
κB1 deficiency on naïve CD4 T cell cytokine production, with normal or 
enhanced production of IL-2, IFN-γ, and TNF. There was also 1.7- fold less 
IL-3 production by the Nfkb1-/- CD4 T cells, and the Th2 cytokines IL-5 and 
IL-13 were reduced (2.6- and 1.8-fold, respectively), as previously reported 
for Nfkb1-/- CD4 T cells 33, but the latter were minor products compared 
with GM-CSF (log scale shown in Supplemental Figure 1 (online)).
Critical dependence of acute joint inflammation on NF-κB1– 
dependent GM-CSF production by CD4 T cells
Collectively, our findings suggested that Nfkb1-/- mice were protected from 
acute arthritis through the inability of CD4 T cells to produce the critical ar-
thritogenic cytokine, GM-CSF 34. To further evaluate the relation between 
CD4 T cells and GM-CSF in acute arthritis, we transferred WT or GM-
CSF-/- CD4 T cells to Rag1-/- mice and arthritis was induced. A substantial 
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reduction in the disease response was observed in mice that received 
GM-CSF-/- CD4 T cells, indicating CD4 T cell-derived GM-CSF is indeed 
essential for full disease expression (Figure 5A). Because the effect was 
not as profound as NF-κB1 loss in CD4 T cells, and IL-3 could also be 
involved, we sought to confirm the importance of GM-CSF in disease de-
velopment in Nfkb1-/- mice. Injection of GM-CSF throughout the 7 days 
of the model fully restored a normal response in the Nfkb1-/- mice, for all 
features of disease (Figure 5B).
Antigen presentation by DC is required for the induction of 
acute joint inflammation
The dependence of acute arthritis on CD4 T cells infers that APC are 
essential to disease. To establish the importance of DC in this model, we 
used DTR Tg mice that were depleted (by >60%) of CD11chi cells, as previ-
ously described 19. Arthritis was markedly reduced in the CD11c-depleted 
mice, but some residual disease was present (Figure 6A). In this system, 
Diphtheria toxin preferentially depletes CD11chi cells (i.e., cDC) over CD-
11cint cells (i.e., plasmacytoid DC and MoDC) 35, suggesting that cDC are 
Figure 5: NF-κB1 and GM-CSF production by CD4 T cells are critical 
for acute inflammatory arthritis.
(A) WT and GM-CSF-/- CD4 T cells were transferred to Rag1-/- mice (see Materials and Methods). 
Arthritis was induced after 5wk and the joints examined 7d later. Total histological scores (mean ± 
SEM; n = 24–25 joints) are shown for Rag1-/- mice receiving either WT or GM-CSF-/- cells. Data are 
pooled from two experiments. *p ≤ 0.001. (B) Arthritis was induced in WT and Nfkb1-/-mice that were 
also injected thrice daily with either GM-CSF (Nfkb1-/-mice only) or vehicle. Results show the mean 
histological scores (± SEM; n = 10 joints) for arthritis features at day 7. GM-CSF injections fully re-
stored the disease response in Nfkb1-/-mice (p ≤ 0.001, compared with vehicle-treated Nfkb1-/- mice).
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necessary but not sufficient for a complete disease response and that CD-
11cint inflammatory MoDC could be responsible for the residual disease. 
To establish the role of NF-κB1 itself in cDC, we evaluated Nfkb1-/- cDC in 
vitro for allogeneic (MLR) and Ag-specific (OVA) T cell stimulation (Figure 
Figure 6: DC are essential for acute inflammatory arthritis, but DC 
function is not dependent on NF-κB1.
(A) Dependence of acute arthritis on CD11c+ DC. Arthritis was induced in WT mice reconstituted with 
DTR-CD11c or WT bone marrow. DC were depleted by i.p. injection of 100 ng Diphtheria toxin on 
days 21 to 24. Control mice received saline. Data show the total histological scores (mean ± SEM; n 
= 14 joints, pool of 2 experiments). *p ≤ 0.001. (B) and (C) MLR. (B) BALB/c CD4 T cells cocultured 
with purified cDC isolated from WT or Nfkb1-/-mice, or (C) CD4 T cells from WT or Nfkb1-/- mice 
cocultured with irradiated splenocytes from BALB/c mice. (D) and (E) Purified splenic cDC were iso-
lated from (D) OVA- or vehicle-injected WT and Nfkb1-/- mice and cultured with OT-II CD4 T cells, or 
from (E) OVA-injected WT mice and cultured with WT or Nfkb1-/-OT-II CD4 T cells (n=3 mice). For all 
experiments, T cell proliferation was assessed by [3H]thymidine (TdR) incorporation. Results show 
the mean cpm (± SEM; n = 6) and are representative of three experiments. p ≤ 0.0001 (C) and p ≤ 
0.001 (E), by two-way ANOVA, for Nfkb1-/- versus WT cells.
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6B-D). In agreement with previous studies 36,37, we found that Nfkb1-/- cDC 
were similar to WT cDC in both assays. In contrast, when we crossed OT-
II mice to Nfkb1-/- mice, OVA-specific, Nfkb1-/- CD4 T cells were unrespon-
sive to stimulation in vitro with splenic WT cDC that had been loaded with 
OVA in vivo (Figure 6E).
To address the involvement of GM-CSF-dependent MoDC (defined as 
CD11cintCD11bhiLy6C+/hiMHCIIhi) in acute inflammatory arthritis, we disso-
ciated inflamed synovial tissue on day 7 of disease. Flow cytometry re-
vealed that MoDC comprise 85% of the CD11c+ cell population in inflamed 
synovial tissue, and these cells were also found in the draining popliteal 
LN at the peak of disease in WT mice (Figure 7A, 7C). In contrast, MoDC 
could not be detected in popliteal LN from naïve mice. The number of 
these cells was markedly reduced in popliteal LN from GM-CSF-/- mice on 
day 7 of inflammatory arthritis, demonstrating that differentiation of these 
cells during inflammation in vivo is dependent on GM-CSF (Figure 7A, 
Figure 7: MoDC are present in draining LN and inflamed synovial 
tissue from WT mice but not GM-CSF-/- mice in acute inflammatory 
arthritis.
Single-cell suspensions of draining popliteal LN from WT mice, or GM-CSF-/- mice (A), or light den-
sity cell suspensions of inflamed synovial tissue (C) at the peak of acute inflammatory arthritis (day 
7) were stained with Ab for CD11b, CD11c, Ly6C, and MHCII, and analysed by flow cytometry. Naïve 
WT mice were used as a control. CD11cintCD11b+Ly6C+MHCII+ MoDC could be detected in inflamed 
tissue, but not naïve tissue or GM-CSF-/- tissue. (B) Numbers of MoDC detected in popliteal LN from 
WT or GM-CSF-/- mice at the peak of acute inflammatory arthritis (day 7). Mean ≤ SEM, n = 5-6/ 
group. *p ≤ 0.05, compared with mBSA-treated WT mice, Student t test. Experiment was performed 
twice. (D) Cytokine production by purified cDC and MoDC from inflamed synovial tissue of WT mice 
(pg/ml).
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7B). To establish that the MoDC in synovial tissue can drive arthritis, we 
purified these cells, as well as cDC, from digested synovial tissue of 10 
WT mice on day 7 of arthritis. Analysis of cytokine production after a short 
period of in vitro culture by Bio-Plex revealed that compared with cDC, 
MoDC produce more of the arthritogenic cytokine IL-6 and high levels of 
the chemokine MCP-1. Production of MCP-1 by these cells suggests a 
positive amplification loop to recruit more monocytes and MoDC to the 
site of inflammation (Figure 7D).
NF-κB1 in CD4 T cells is required for the induction of acute 
peritonitis
To determine whether these findings in experimental arthritis apply to oth-
er models of T cell-dependent inflammation, and to access tissue-infiltrat-
ing cells more readily, we examined Ag-induced peritonitis. This model 
is also dependent on GM-CSF 22, and we established in an earlier study 
that MoDC differentiate in the spleen from monocyte precursors during 
this response 3. Rag1-/- mice were reconstituted with purified CD4 T cells 
derived from WT or Nfkb1-/- mice, and acute peritonitis was induced. Mice 
were primed and boosted with mBSA in CFA, challenged by i.p. injec-
tion of mBSA 7 days later, and evaluated after 48 h. Mice that received 
Nfkb1-/- CD4 T cells developed markedly reduced peritoneal exudate (total 
white blood cells and neutrophils) compared with mice receiving WT CD4 
T cells, indicating that NF-κB1 was required in CD4 T cells for disease 
(Figure 8A). Evaluation of cytokines in the peritoneal exudate showed re-
duced levels of pro-inflammatory cytokines (IL-6, IL-1β, TNF) in mice that 
received Nfkb1-/- CD4 T cells, in particular, GM-CSF (Figure 8B), which 
Figure 8:  (left page) NF-κB1 in CD4 T cells is critical for acute 
inflammatory peritonitis and the differentiation of MoDC, but not 
cDC, in the spleen.
WT or Nfkb1-/- CD4 T cells were transferred into Rag1-/- mice, acute peritonitis was induced (control 
mice received saline), and peritoneal exudate was evaluated after 48h. (A) Number of white blood 
cells (WBC; left panel) and neutrophils (right panel) in peritoneal washes (mean ± SEM; n=10-13 
mice). *p ≤ 0.05, Student t test, compared with mBSA-treated WT mice. Data pooled from four 
experiments. (B) Analysis of cytokines in peritoneal exudates. Results show the mean (± SEM; n=4 
mice/group) concentration of cytokines as measured by Bio-Plex array. (C) Splenic DC were exam-
ined by flow cytometry 48h after i.p. challenge. Light density spleen cells were gated for CD11b+CD-
11cint/+. MoDC were defined as Ly-6C+MHCII+ and cDC as Ly-6C-MHCII+. Ungated cells are monocytes. 
(D) Numbers of splenic MoDC (left panel) and cDC (right panel). Results show the mean ± SEM 
(n=15-16 mice/group, pool of 4 experiments). *p ≤ 0.05.
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was one of the most prevalent cytokines detected. Therefore, NF-κB1 in 
CD4 T cells, as well as GM-CSF, is required in both models of acute tissue 
inflammation (i.e., arthritis and peritonitis).
NF-κB1 is required for generation of inflammatory DC
We showed previously that CD11cintCD11bhiLy6C+/hiMHCIIhi MoDC, which 
we detected in inflamed joints during arthritis, also appear in the spleens 
of mice with mBSA-induced acute peritonitis 3. To evaluate the importance 
of NF-κB1 in CD4 T cells in the generation of MoDC in this model, we 
reconstituted Rag1-/- mice with purified CD4 T cells derived from WT or 
Nfkb1-/- mice, and acute peritonitis was induced. Splenic MoDC numbers 
were consistently reduced in mice reconstituted with Nfkb1-/- CD4 T cells. 
In contrast, the number of cDC, although more variable over multiple ex-
periments, was not statistically different (Figure 8C, 8D).
5.4 Discussion
The NF-κB family is of central importance to immune responses and in-
flammation, but there has been relatively little in vivo evaluation of the 
contributions of individual subunits. This study of NF-κB1 in inflammatory 
arthritis and peritonitis revealed two important findings: NF-κB1 serves a 
critical role in the production of GM-CSF by activated CD4 T cells during 
inflammatory responses, and GM-CSF derived from these cells prefer-
entially drives MoDC development during inflammatory disease. Altered 
Nfkb1-/- CD4 T cell function was shown to be responsible for resistance 
to two models of acute inflammation: arthritis and peritonitis. Rag1-/- mice, 
which were rendered susceptible to disease by transfer of WT CD4 T 
cells, remained refractory when engrafted with Nfkb1-/- CD4 T cells. Ar-
thritis susceptibility was restored in Nfkb1-/- mice by injection of WT CD4 
T cells, indicating the defect was T cell intrinsic and that trans-endothelial 
migration and leukocyte recruitment to joints was not impaired in Nfkb1-/- 
mice. Although both CD4 T cells and IL-1 are essential components of this 
arthritis model, they are not directly interdependent. We found that CD4 
T cells do not require a response to IL-1 in acute inflammatory arthritis, 
because IL1r-1-/- CD4 T cells could transfer disease susceptibility when 
injected into Rag1-/- mice.
One potential explanation for the reduced function of Nfkb1-/- CD4 T cells 
would be globally impaired activation. However, after strong polyclon-
al stimulation, Nfkb1-/- CD4 T cells displayed a normal activation profile 
Proefschrift Annemarie.indb   126 13-10-2013   22:35:47
Page 127
Chapter 5
5
(CD69, CD25) and cytokine receptor (IL-2R, IL-4R, γc) expression. It has 
been proposed that persistent Rel/NF-κB activation and inhibition of ap-
optosis contributes to the chronic inflammatory synovitis of human RA 38. 
The diminished [3H]thymidine incorporation we observed for both alloanti-
gen and Ag-specific stimulation of Nfkb1-/- CD4 T cells could be explained 
by enhanced T cell apoptosis. However, we found that enforced expres-
sion of Bcl-2 in the haemopoietic compartment did not influence acute 
arthritis susceptibility in Nfkb1-/- mice, although it did improve the viability 
of activated T cells in vitro. Although reduced CD4 T cell survival involving 
the Bcl-2–dependent pathway does not therefore account for the reduced 
disease response in Nfkb1-/- mice, we cannot exclude enhanced Nfkb1-/- 
CD4 T cell apoptosis via the extrinsic, death receptor pathway contribut-
ing to disease resistance in this model.
A notable further finding was reduced cytokine production by activated 
Nfkb1-/- CD4 T cells, particularly GM-CSF. Remarkably, this was relatively 
selective, and activated Nfkb1-/- CD4 T cells actually showed enhanced 
production of TNF and IFN-γ compared with WT cells. Rag1-/- mice re-
constituted with GM-CSF-/- CD4 T cells developed markedly less inflam-
matory arthritis than mice given WT cells, and injection of GM-CSF fully 
restored the disease response in Nfkb1-/- mice. Although NF-κB1 has a 
role in GATA3 expression and Th2 differentiation 33, there is only a minor 
contribution to mBSA/IL-1-induced arthritis from the Th2 cytokine IL-4 31. 
In contrast, disease is markedly dependent on endogenous GM-CSF, IL-2 
30,31, and IL-17 32. Given that IL-2 production by Nfkb1-/- CD4 T cells was 
enhanced and IL-17 expression was unchanged, the reduced GM-CSF 
production by Nfkb1-/- CD4 T cells raised the possibility that this source of 
GM-CSF could be pivotal in the arthritis model. Although IL-3 production 
was reduced in Nfkb1-/- CD4 T cells, and thus could also account for the 
mild disease response in Nfkb1-/- mice, injection of GM-CSF alone was 
sufficient to restore a normal disease response. It is interesting to note 
that the T cells of Rel-/- mice also have reduced GM-CSF production 39, 
whereas these mice exhibited a normal disease response in the acute ar-
thritis model 14. A possible explanation lies in the markedly enhanced GM-
CSF production by activated Rel-/- peritoneal macrophages 39, which may 
provide sufficient GM-CSF for a disease response. Interestingly, each of 
the genes for the cytokines that were deficient in Nfkb1-/- CD4 T cells (GM-
CSF, IL-3, and the Th2 cytokines IL-4, IL-5, and IL-13) map within a 0.7-Mb 
region on mouse chromosome 11 (and an orthologous region on human 
chromosome 5). In contrast, under the same conditions, the production 
of the Th2 cytokine IL-10, which maps to mouse chromosome 1, was nor-
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mal in Nfkb1-/- CD4 T cells. It is therefore tempting to speculate that in 
activated CD4 T cells, NF-κB1 may directly or indirectly interact with non-
coding elements responsible for the coordinate regulation of these genes 
on chromosome 11. There is evidence for such control regions in human 
chromosome 5, which are phylogenetically conserved 40,41.
Our data show that cytoplasmic c-Rel was able to translocate to the nu-
cleus in stimulated Nfkb1-/- CD4 T cells, suggesting that NF-κB1 is not 
required for nuclear shuttling of this NF-κB subunit. Although c-Rel was 
detected in the nuclei of stimulated Nfkb1-/- CD4 T cells and could bind to 
a consensus κB site, it was unable to effectively activate gene transcrip-
tion in the absence of NF-κB1. GM-CSF was one of the most abundantly 
produced cytokines in WT CD4 T cells and was proportionally the most 
severely reduced in Nfkb1-/- CD4 T cells. In T cells, GM-CSF production is 
mainly controlled at the transcriptional level, is usually transient, and de-
pends on activation through the TCR and co-stimulatory molecules, such 
as CD28 42,43. These findings are consistent with the demonstration of NF-
κB1 and c-Rel binding to the GM-CSF promoter 44,45. We conclude that the 
most likely reason for the Nfkb1-/- phenotype in the inflammation models is 
lack of NF-κB1/c-Rel heterodimer transcriptional activity in activated CD4 
T cells. However, p50 homodimers have been reported to promote gene 
transcription in some circumstances 13, so we cannot exclude NF-κB1 ho-
modimers as transcriptional activators in CD4 T cells.
Although originally described as a haemopoietic cell growth factor, GM-
CSF can have numerous pro-inflammatory effects on mature myeloid cells 
(reviewed in 34), and GM-CSF is a potent inducer of DC differentiation. In a 
peritonitis model that is dependent on CD4 T cells and GM-CSF, we found 
reduced splenic MoDC numbers in Rag1-/- mice injected with Nfkb1-/- CD4 
T cells. These mice had normal splenic cDC levels, suggesting that this 
cell type is unable to drive inflammation in the absence of sufficient MoDC. 
This possibility is supported by our observation that the disease response 
in acute inflammatory arthritis was markedly reduced, but not abolished, 
when CD11chi cells were depleted using the CD11c-DTR system. GM-CSF 
is also critical for the development of experimental autoimmune encepha-
litis, and in this model, GM-CSF production by effector T cells was shown 
to activate microglial cells 46. Interestingly, IL-23 stimulated the production 
of GM-CSF, as well as IL-17 by murine T cells 47, which may help explain 
earlier findings with GM-CSF-/- T cells 48. GM-CSF promoted the induction 
and survival of autoimmune Th17 effector cells in a CD4 T cell-mediated 
model of myocarditis 49. T cells appear to lack GM-CSF receptors; thus, 
this effect was most likely via enhancement of IL-6 and IL-23 production 
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from APC. Although it was previously thought that GM-CSF-/- mice had 
normal DC 50, GM-CSF was recently found to be required for the accu-
mulation of Langerin+ CD103+ DC 51, and GM-CSF production by CD8+ T 
cells, in combination with microbial stimuli, was postulated as a “licensing 
factor” for DC 52.
GM-CSF can be produced by macrophages but, interestingly, apparently 
not by DC 49. In vivo, on-going DC recruitment and differentiation in the 
setting of tissue inflammation may be highly dependent on other cell types 
28 and the supply of critical cytokines such as GM-CSF 51,52. Transfer of 
WT CD4 T cells into Nfkb1-/- mice was sufficient to restore a normal dis-
ease response to these mice, indicating that APC function was not lim-
iting. DC function in Nfkb1-/- mice was normal for Ag-specific (OVA) and 
allogeneic (MLR) T cell stimulation, indicating that Ag uptake, processing, 
and presentation by cDC was not impaired in Nfkb1-/- mice. These data 
confirm and extend the findings of previous reports 36,37 that show normal 
cDC development and function in Nfkb1-/- mice, with a marginal reduction 
in numbers being the main difference to WT mice. Importantly, we found 
MoDC in the directly involved joint tissue of WT mice with inflammatory 
arthritis, and MoDC were identified as a likely target for CD4 T cell-de-
rived GM-CSF. MoDC may be especially relevant during persistent tissue 
inflammation 53. It has been suggested that, in such conditions, these cells 
may even be superior APC, as steady-state cDC have been exposed to 
the immunosuppressive tissue environment 4. In a recent study, MoDC 
arising in response to an infectious challenge were found to localize to 
the T cell areas in LN, favouring functional interaction. These MoDC were 
found to produce a strong MLR and were actually superior to cDC in Ag 
presentation, including cross-presentation 54. Our finding that MoDC de-
rived from inflamed synovial tissue produce high levels of MCP-1, a potent 
chemo-attractant for monocytes, also suggests that MoDC might provide 
a positive amplification loop through which monocytes are recruited to 
sites of inflammation and then differentiate into DC. Collectively, these 
data raise the intriguing possibility of a positive feedback loop between 
CD4 T cells and DC, whereby NF-κB signalling in CD4 T cells that initially 
encounter Ag presented by cDC causes GM-CSF production that specifi-
cally promotes the recruitment or development of MoDC from monocytes 
(Supplemental Figure 2 (online)).
The important role the Rel/NF-κB transcription factors serve in regulating 
immune and inflammatory responses makes this pathway an excellent po-
tential target for therapeutic intervention in inflammatory diseases such as 
RA. Indeed, inhibition of NF-κB in T cells has been shown to alleviate col-
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lagen-induced arthritis 55. However, global inhibition of Rel/NF-κB, even 
within a single cell type, may severely compromise the immune system. 
Anti-GM-CSF clinical trials are planned or under way in several candidate 
diseases, including RA; thus, it is vital to understand where, when, and 
how GM-CSF production is controlled. Our findings show that NF-κB1 de-
letion alone is sufficient to markedly reduce GM-CSF production by acti-
vated CD4 T cells, and also demonstrate the importance of T cell-derived 
GM-CSF in promoting MoDC development and inflammatory disease.
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Abstract
Objective
To study changes in inflammatory mediators during combined IL-17- and 
GM-CSF-blockade during experimental arthritis and during local overex-
pression of IL-17 and GM-CSF in synovial joints.
Methods
Collagen-induced arthritis (CIA) was elicited in DBA/1J mice. Mice were 
treated for two weeks with antibodies against IL-17, GM-CSF, or a combi-
nation of these. Severity of arthritis was defined by macroscopic scores, 
X-ray and histology. For overexpression studies, adenoviral vectors for 
IL-17, GM-CSF or a combination of these were injected intra-articularly. 
Joints were taken at 4 hours, day 1, day 4 and day 7 after injection for 
analysis. For both sets of experiments, joint washouts and synovial cell- 
and lymph node cultures were analysed for cytokine, chemokine and ma-
trix metallo-proteinase (MMP) production by Luminex analysis, flow cy-
tometry and quantitative PCR.
Results
Combined therapeutic treatment of mice during CIA ameliorated disease 
progression, and significantly improved macroscopic scores and joint 
damage, compared to treatment with anti-IL-17 or anti-GM-CSF alone. 
Anti-IL-17 specifically reduced the transcription of IL-23 in the synovium, 
whereas anti-GM-CSF reduced the transcription of MMPs and Receptor 
Activator of NF-κB Ligand (RANKL). Overexpression of IL-17 and GM-
CSF in the knee joint elicited extensive inflammatory infiltrate, cartilage 
damage and bone destruction. Combined overexpression of IL-17 and 
GM-CSF had a synergistic effect on the production of MMPs, RANKL and 
IL-23 in the synovium. 
Conclusion
IL-17 and GM-CSF influence different aspects of the inflammatory pro-
cesses in the synovial joints. Combined blockade during inflammatory ar-
thritis reduces inflammation through inhibition of the Th17/IL-23/GM-CSF 
axis and reduces cartilage destruction and bone erosion by inhibition of 
MMP and RANKL production. Overexpression of IL-17 and GM-CSF in the 
joint causes extensive inflammation and damage through additive as well 
as synergistic effects.
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6.1 Introduction
Rheumatoid arthritis (RA) is systemic disease, characterized by chron-
ic inflammation of synovial joints. The etiology of RA remains unclear, 
but the pathogenesis has been studied extensively in patients as well as 
animal models 1,2. In RA, inflammatory cells such as neutrophils, natural 
killer cells and T and B lymphocytes infiltrate the synovial membrane, con-
tributing to bone and cartilage degradation. Of the T cells in the inflamed 
synovium, the CD4+ T cell is the most abundant. CD4+ T cells can differ-
entiate into Th1, Th2, Th17 or regulatory T cells (Treg), depending on the 
local cytokine milieu 3. Originally RA was classified as a Th1-mediated 
disease, but it is now well established that Th17 cells play a crucial role in 
RA pathogenesis 4. 
Th17 cells are important mediators of inflammatory disease, and are iden-
tified by the production of IL-17 5,6. Th17 cells are the main pathogenic 
cell type in many models of autoimmunity, including experimental autoim-
mune encephalomyelitis (EAE) 7, acute inflammatory arthritis (mBSA/IL-1 
arthritis) 8 and collagen-induced arthritis (CIA) 9. Pathogenic Th17 cells 
have also been identified in inflamed synovium of rheumatoid arthritis 
(RA) patients 10. Neutralisation of IL-17 during CIA showed that IL-17 plays 
a role both in the early and late stages of CIA, and that IL-17 directly and 
indirectly influences joint inflammation and joint destruction by the upreg-
ulation of inflammatory cytokines and matrix metalloproteinases (MMPs) 
11,12. Mice deficient in the IL-17 receptor show reduced sensitivity to inflam-
mation induction 13.
Naïve T cells differentiate into Th17 cells when activated in the presence 
of transforming growth factor-β (TGF-β) and IL-6 14-16. IL-23 is required for 
functional maturation and pathogenicity of Th17 cells, via Ror-γt-mediated 
induction of GM-CSF production 17-20. However, GM-CSF in its turn also 
induces IL-23 production by DC via CCR4, thereby creating a positive 
feedback loop for the production of these two cytokines 21. Interestingly, 
GM-CSF-deficient mice are resistant to many Th17-dependent models of 
autoimmune disease, including CIA, mBSA/IL-1, EAE and experimental au-
toimmune myocarditis (EAM) 8,22-24, and GM-CSF-deficient Th17 cells are 
unable to induce EAE upon adoptive transfer 19. In addition, NF-κB1-defi-
cient mice, that have a relatively selective defect in GM-CSF production 
by T cells, were protected from acute inflammatory arthritis and peritonitis 
25. Mice that overexpress GM-CSF specifically in T cells develop dissem-
inated histiocytosis and have increased Th17-related cytokines in the se-
rum (van Nieuwenhuijze et al, unpublished data; chapter 3 of this thesis). 
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These recent data illustrate that GM-CSF, which was initially described 
as a hematopoietic growth factor for myeloid bone marrow progenitors 26, 
plays a crucial role in mediating T cell function in inflammatory conditions.
Discovery of the important roles of GM-CSF and IL-17 in inflammation has 
prompted the development of therapeutic inhibitors for these cytokines. 
Neutralising humanised antibodies against GM-CSF an Il-17 have been 
successfully tested in clinical trials for RA 27-29. Although there is no doubt 
that both IL-17 and GM-CSF play indispensible roles in the pathogenesis 
of RA, the question remains how the local or systemic levels of these 
cytokines might influence each other. We sought to answer this question 
using two approaches: i) by combined neutralisation of GM-CSF and IL-17 
during established CIA; and ii) by combined local adenoviral over-expres-
sion of GM-CSF and IL-17 in the knee joint. We show that administration 
of neutralising antibodies to both GM-CSF and IL-17 greatly reduced the 
progression of established CIA, and that combined treatment was supe-
rior to inhibition of these cytokines alone. In contrast, overexpression of 
GM-CSF and IL-17 induced extensive inflammation and bone- and carti-
lage-damage in the synovial joint. 
6.2 Materials and Methods
Mice
8 to 10-week old male DBA1/J mice (Janvier, Saint Berthevin, France) 
were allowed to acclimatize for a minimum of 7 days in the Central An-
imal Laboratory (CDL) of the Radboud University Medical Center. The 
animals were kept in conventional filter-top cages (for the neutralisation 
experiment) or in specialized individually ventilated cages (IVC, for the 
adenoviral overexpression experiment), with a maximum of 11 animals per 
cage. Food and water was provided ad libitum and mice were subjected 
to 12-hour cycles of light and darkness.
Induction of arthritis
Mice were immunized at the base of the tail with 100 μg of bovine type II 
collagen (CII) prepared as previously described 30 and diluted in 0.05 M 
acetic acid to a concentration of 2  mg/ml. CII was emulsified in equal 
volumes of Freund’s complete adjuvant (2 mg/ml Mycobacterium tuber-
culosis, strain H37Ra; Difco, Detroit, MI, USA). On day 21, mice received 
an intraperitoneal booster injection of 100  μg of CII dissolved in phos-
Proefschrift Annemarie.indb   142 13-10-2013   22:35:53
Page 143
Chapter 6
6
phate buffered saline (PBS). Joint inflammation was scored macroscop-
ically in each paw, using a scale of 0–2 where 0 = not inflamed, 1 = mild, 
1.5 = marked, and 2 = severe. Scoring was performed in a blinded fash-
ion without knowledge of the experimental groups. From day 21, mice 
were scored three times weekly and randomly divided over the treatment 
groups if the arthritis score reached between 0.25 and 1.25. 
Antibody treatment
Mice were injected intraperitoneally with anti-IL-17 (100μg/mouse, clone 
MAB421; R&D Systems), anti-GM-CSF (200μg/mouse, clone 22E9; kind 
gift from Molecular Partners), or isotype control antibody (300μg/mouse, 
Rat IgG) three times weekly from onset of disease.  Total duration of treat-
ment for each mouse was 14 days, corresponding to a total of 6 injections 
(days 0, 2, 4, 7, 9, 11).
Adenoviral vectors
AdIL-17 was kindly provided by Dr. J. K. Kolls (Children’s Hospital of Pitts-
burgh, Pittsburgh, PA). AdGM-CSF was provided by RIKEN BRC, which 
is participating in the National Bio-Resources Project of the MEXT, Japan. 
AdLUC was used as a control vector throughout the study. All vectors 
were replication competent adenovirus (RCA) negative, and had a focus 
forming unit (FFU):particle ratio of < 100:1. The recombinant adenovirus-
es contained less than 1 endotoxin unit/ml, as measured by the Limulus 
amoebocyte lysate test (BioWhittaker).
Intra-articular injection of adenoviral vectors
Mice were injected intra-articularly with 6μl of virus suspension in PBS. 
For the groups treated with AdGM-CSF or AdIL17 alone, 0.5x107 FFU of 
the respective vectors was injected, supplemented with 0.5x107 FFU of 
the control vector AdLUC. For the group receiving both AdGM-CSF and 
AdIL-17, 0.5x107 FFU of each vector was injected. The total viral load in-
jected in each joint was 1x107 FFU. Knee joints were harvested at 4 hours, 
day 1, 4 and 7 after injection for analysis.
RNA purification and quantitative polymerase chain reaction 
(QPCR)
mRNA from synovial tissue was purified using Trizol reagent (Sigma) and 
MagNaLyzer beads (Roche) according to manufacturer’s instructions. 
cDNA was obtained by reverse transcription. Quantitative real-time PCR 
was performed using the ABI Prism 7000 Sequence Detection system 
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(Applied Biosystems) for quantification with SYBR Green and melting 
curve analysis. Fold increase of mRNA transcripts was calculated as fol-
lows: ΔCt = Ct (gene of interest) – Ct (GAPDH). ΔΔCt = ΔCt sample – av-
erage ΔCt control group. Fold difference = 2-ΔΔCt. 
Cell culture
Single cell suspensions from synovial tissue were prepared as described 
previously 31. Synovial cells and lymph node (LN) cells were stimulated 
with PMA (50ng/mL) and ionomycin (1μg/mL), or medium alone (unstim-
ulated). For intracellular flow cytometry, Brefeldin A (5µg/mL, BioLegend) 
and Monensin (2μM, BioLegend) were added for the last 4-6 hours of 
culture.
Patella washouts
Patellae, including attached synovial tissue, were removed from the knee 
joint and cultured in 200μl RPMI supplemented with 10% FCS for 1 hour 
at room temperature.  Supernatant was harvested for cytokine measure-
ment.
Flow cytometry (FACS)
All samples were incubated with Fc-block (BD Pharmingen) before stain-
ing according to the manufacturer’s instructions. Antibodies used were: an-
ti-CD4-Alexa700, anti-CD8-PerCp, anti-IL17-PE-Cy7, anti-IL-21-Alexa647 
(all from BioLegend), anti-GM-CSF-PE and anti-IL-22-FITC (both from 
BD Pharmingen). Fixation and permeabilization for intracellular staining 
was performed according to the manufacturer’s protocol (eBioScience). 
All samples were measured on a Cyan instrument (Beckman Coulter) and 
analysed with FlowJo software version 9.6.2.  
Measurement of cytokines and chemokines
Cytokines and chemokines were measured by Luminex technology, ac-
cording to manufacturer’s instructions (Millipore). Results were analysed 
using BioPlex Manager 4 (BioRad).
X-ray analysis of ankle joints
X-rays from ankle joints were taken using a Faxitron MX20 instrument 
(Faxitron Bioptics) and analysed using Faxitron software. 
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Histology
Joints were fixed for 4 days in 10% formalin and decalcified in 5% formic 
acid, and embedded in paraffin. 7µM sections were stained with hema-
toxylin and eosin (H&E), or Safranin O. Inflammation, chondrocyte death, 
bone destruction, cartilage damage and proteoglycan (PG) depletion 
were scored on a scale of 0–3 by a researcher blinded to the experimen-
tal groups. 
6.3 Results
Combined neutralisation of GM-CSF and IL-17 blocks progres-
sion of CIA
CIA was induced in DBA1/J mice and antibody treatment was started from 
the onset of disease. Mice receiving the isotype control antibody devel-
oped severe arthritis, reaching a macroscopic disease severity score of 
5.55 ± 0.38 after two weeks of treatment (Figure 1A). In contrast, a sig-
nificant reduction in arthritis severity was observed when animals were 
treated with anti-IL-17 or anti-GM-CSF, resulting in end-point scores of 
3.4 ±0.4 and 3.5 ± 0.4 respectively. Combination of these two antibodies 
completely ameliorated disease progression and resulted in an average 
score of 2.0 ± 0.6 after two weeks of treatment. These effects were dose 
dependent, with suboptimal combination therapy (30μg anti-IL-17 + 100μg 
anti-GM-CSF) reaching an end-score of 3.9 ± 0.5, and suboptimal ther-
apy with either antibody alone resulting in end scores of 4.9 ± 0.4 for 
anti-GM-CSF and 3.5 ± 0.4 for anti-IL-17 respectively (not shown). This 
result shows that there is an additive beneficial effect of combined IL-17/
GM-CSF neutralisation. 
Combined neutralisation of GM-CSF and IL-17 protects against 
bone and cartilage damage
Ankle joints were analysed by X-ray to visualize bone destruction and 
changes in joint morphology (Figure 1B). Bone damage in the small joints 
of the ankle and foot was observed in animals treated with anti-IL-17 or 
anti-GM-CSF alone, consistent with an average macroscopic disease 
score of ~3.5 (Figure 1A). The ankles of mice treated with the isotype con-
trol antibody showed severe distortion of joint morphology and extensive 
bone damage. In contrast, ankles from animals treated with a combina-
tion of anti-IL-17 and anti-GM-CSF showed normal joint morphology, and 
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Figure 1: Neutralisation of IL-17 and GM-CSF during established CIA.
(A) Macroscopic disease scores followed over time from day 21 (day 0 of treatment). n=10 mice/
group. Arrows indicate times of antibody treatment. (B) End-point X-ray analysis of ankle joints after 
CIA. Representative ankle joint shown per group (n=20 joints/group). (C) Histological analysis of 
ankle joints. H&E = haematoxylin and eosin. SafO = safranin O stain. Original magnification 50x. (D) 
Detailed histological score of the ankle joints after 14 days of treatment. n=20 joints/group. (E) Total 
histological scores. n=20 joints/group. Mean ± SEM. *p<0.01, Student’s t-test.
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6
minor or no bone degradation (Figure 1B). Other features of joint pathol-
ogy were scored by analysis of histological sections of these ankle joints. 
Sections were stained with H&E or safranin O and scored for features of 
inflammation, cartilage damage and bone degradation (Figure 1C, 1D and 
1E). Treatment of mice with a combination of anti-IL-17 and anti-GM-CSF 
resulted in a marked reduction of each feature scored (exudate and syn-
ovitis, chondrocyte death, cartilage damage, proteoglycan depletion and 
bone degradation), which was reflected in the total histological disease 
score (Figure 1D). Combined treatment was more effective than treatment 
Figure 2: Cytokine measurement in synovial washouts and serum and 
flow-cytometric analysis after 14 days of IL-17 and GM-CSF blockade 
during CIA.
(A) Luminex analysis of cytokines and chemokines in joint washouts (n=6/group). (B) FACS analysis 
of synovial tissue stained with mAbs for CD4 and CD8 after 14 days of treatment. Percentages of 
CD4+ cells of live synoviocytes given. Representative plots shown for n=6 joints/group. (C) Percent-
age of CD4+ cells in synovial tissue after 14 days of treatment. (D) IL-6 levels in serum measured by 
Luminex. n=10 mice/group. Mean ± SEM. *p<0.01, Student’s t-test.
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with the separate antibodies, and resulted in a reduction of the total histo-
logical disease score of ~60% (from a score of 10.3 ± 0.59 to 4.07 ± 1.2, 
respectively, Figure 1E). 
Differential effects on inflammatory mediators by blockade of 
IL-17 or GM-CSF
Local production of cytokines and chemokines was measured by Luminex 
analysis of joint washouts. The major cytokines produced by synoviocytes 
were IL-6, KC, CCL2 and CCL3 (Figure 2A). We observed a slight reduc-
tion in the production of IL-6 and KC in the washouts from mice treated 
with anti-IL-17 or anti-GM-CSF alone, however, combination treatment 
caused an increase in these cytokines. Interestingly, anti-IL-17 alone or 
combination treatment led to increased production of IL-17 and CCL2 by 
synoviocytes, whereas this increase was not seen in the anti-GM-CSF 
treated animals (Figure 2A). 
Synovium was also analysed by flow cytometry. Anti-GM-CSF- or combi-
nation treatment caused a reduction in the number of CD4+ T cells in the 
synovium (Figure 2B and 2C). This effect was not seen in the synovium 
of mice treated with anti-IL-17 alone, or in the control animals. This result 
suggests that even though anti-IL-17 reduces the severity of arthritis, it 
does not prevent CD4+ T cells from entering the target tissues. The sys-
temic effect of antibody treatment was determined by Luminex analysis 
of serum cytokines. The level of IL-6 was significantly decreased in the 
antibody-treated animals compared to the control group, but did not differ 
between treatment groups (Figure 2D). Systemic GM-CSF or IL-17 could 
not be detected using this technique (not shown).
Neutralisation of GM-CSF, but not IL-17, inhibits production of 
MMPs
Cartilage- and bone degradation is mediated by MMPs and alarmins, such 
as S100A8. MMPs are inhibited by tissue inhibitors of metalloproteinases 
(TIMPs). We determined the transcription of these factors and a number of 
T cell and DC/Mϕ-related mediators by quantitative PCR of synovium (Ta-
ble 1). There was a profound reduction in the expression of MMPs when 
GM-CSF was blocked by antibody treatment. In addition, we observed 
a decrease in the Th17-related factors GM-CSF, Ror-γt and IL-21. IL-17 
could not be detected in the anti-GM-CSF samples, but the expression of 
Proefschrift Annemarie.indb   148 13-10-2013   22:35:56
Page 149
Chapter 6
6
IL-23 was not different from the isotype control group. Although anti-IL-17 
treatment had a clear effect on joint damage, this was not reflected in the 
levels of MMP or TIMP mRNA in the joints of these mice. Expression of 
most genes tested changed less than two-fold compared to the control 
group, with the exception of Ror-γt, IL-21 and IL-23 (5-fold and 2.3-fold 
increase, and 2.2-fold decrease respectively). Combination therapy us-
ing both blocking antibodies led to an overall down-regulation of MMPs, 
where the magnitude of the effect held the middle between the effects of 
anti-IL-17 and anti-GM-CSF. The effect on TIMP expression was modest 
in all treatment groups. Interestingly, IL-1β and IL-23 were up-regulated 
Table 1: Quantitative PCR of synovial tissue after two weeks of antibody 
treatment during CIA.
Fold increase over isotype control treated samples 
(2-ΔΔCt)
Gene Anti-IL-17 Anti-GM-CSF
Anti-IL-17+ 
anti-GM-CSF
D
am
ag
in
g
Pro-inflammatory
T-cell factors
IL-17 1.63 ± 0.56 not detected 1.48 ± 1.0
GM-CSF 1.12 ± 0.73 0.55 ± 0.54 0.55 ± 0.2
Ror-γt 5.06 ± 2.94¶ 0.68 ± 0.30 1.68 ± 0.96§
IL-21 2.30 ± 1.14 0.88 ± 0.61 0.71 ± 0.35
RANKL 0.97 ± 0.49 0.36 ± 0.19 0.80 ± 0.56
Matrix metallo- 
proteinases
MMP3 0.87 ± 0.45 0.24 ± 0.10 0.51 ± 0.26
MMP9 1.18 ± 0.71 0.36 ± 0.18 0.75 ± 0.42
MMP13 0.89 ± 0.38 0.44 ± 0.18 0.60 ± 0.31
MMP14 1.43 ± 0.55 0.58 ± 0.22 0.74 ± 0.32
ADAMTS5 1.34 ± 0.67 0.43 ± 0.24 0.89 ± 0.50
Alarmin S100A8 1.82 ± 0.93 0.56 ± 0.23 1.08 ± 0.58
Pro-inflammatory 
DC/Mϕ-
derived
IL-1β 1.09 ± 0.44 0.85 ± 0.40 1.67 ± 1.03
IL-23 0.45 ± 0.19 1.02 ± 0.56 1.71 ± 0.89
P
ro
te
ct
iv
e
Anti-inflammatory 
T cell factor
IL-10 1.53 ± 0.81 0.62 ± 0.38 0.71 ± 0.35
Matrix metallo- 
proteinase 
inhibitors
TIMP1 1.31 ± 0.56 0.48 ± 0.23 0.85 ± 0.42
TIMP2 1.05 ± 0.39 0.50 ± 0.18 0.58 ± 0.25
TIMP3 0.77 ± 0.09 0.63 ± 0.15 0.70 ± 0.09
TIMP4 0.79 ± 0.19 0.97 ± 0.19 0.91 ± 0.22
Th1/2 
transcription 
factors
T-bet 1.75 ± 0.53 0.77 ± 0.11 0.84 ± 0.18
GATA3 1.87 ± 0.71 0.67 ± 0.27 0.69 ± 0.20
§ p ≤ 0.01 vs anti-IL-17;  ¶ p ≤ 0.01 vs anti-GM-CSF
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after combined neutralisation (Table 1). These results suggest that IL-17 
is more important in the earlier stages of CIA, and that blockade of IL-17 
in the later stages of CIA is less effective. In contrast, GM-CSF still plays 
a major role in the mediation of local joint damage in the later stages of 
disease.
Figure 3: Expression analysis of IL-17 and GM-CSF after adenoviral 
transfer
(A) QPCR for IL-17 on synovial tissue at 4 hours, day 1 and day 4 after transfer. n=6 joints/timepoint. 
(B) QPCR for GM-CSF on synovial tissue at 4 hours, day 1 and day 4 after transfer. n=6 joints/time-
point. (C) Luminex analysis for IL-17 in joint washouts taken on day 1 after transfer. n=6 joints/group. 
(D) Luminex analysis for GM-CSF in joint washouts taken on day 1 after transfer. n=6 joints/group. 
(E) FACS analysis of synovial tissue taken on day 1 after transfer. Cells were gated on single viable 
cells. Percentages of positive cells are given. Representative plots shown from n=6 joints/group.
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Synergistic increase of IL-17 and GM-CSF mRNA in transfected 
joints
We next took a different approach to unravelling the combined role of IL-
17 and GM-CSF in joint damage, by local over-expression in knee joints. 
To determine whether adenoviral transfection successfully increased the 
levels of IL-17 and GM-CSF in the joints, washouts of synovial tissue plus 
patella were collected at 4 hours, day 1 and day 4 after intra-articular injec-
tion. QPCR for IL-17 showed that at 4 hours after AdIL17 or AdIL17+AdGM-
CSF injection, the mRNA levels had increased ~8500 fold and ~3000 fold 
over injection with AdLUC alone respectively (Figure 3A). The expression 
of IL-17 mRNA slowly decreased at day 1 and day 4 in the AdIL-17 group 
(to 2,000-fold and 1,000-fold increase respectively). The increase in IL-17 
mRNA was modest for the joints injected with AdGM-CSF alone (between 
3- and 8-fold increase).
An increase in the level of GM-CSF mRNA was detected in the AdGM-
CSF and AdGM-CSF+AdIL17 groups from 4 hours after injection (~1,000-
fold compared to the AdLUC control group, Figure 3B). This upregula-
tion increased to ~7,500-fold for the AdGM-CSF group by day 4, and to 
~21,000-fold for the combination of AdIL-17+AdGM-CSF. GM-CSF mRNA 
levels increased to a maximum of ~4-fold upon injection of AdIL17 alone. 
Increased production of IL-17 and GM-CSF by synoviocytes of 
transfected joints
Although we detected greatly increased transcription of IL-17 and GM-CSF 
after AdIL17 and AdGM-CSF injection, gene translation was confirmed by 
measuring IL-17 and GM-CSF protein levels. We collected patellae at 4 
hours, 1 day and 4 days after virus injection and performed Luminex anal-
ysis of washouts. Increased IL-17 and GM-CSF was detected in washouts 
from joints injected with the respective viruses, and in joints injected with 
a combination of AdIL17 and AdGM-CSF (Day 1 shown in Figure 3C). In 
agreement with the QPCR data, IL-17 could not be detected in washouts 
from AdLUC or AdGM-CSF injected joints, but was produced at high lev-
els in AdIL17 washouts (Figure 3C). Accordingly, low levels of GM-CSF 
were detected in AdLUC or AdIL17 washouts, but GM-CSF was present in 
AdGM-CSF washouts (Figure 3D). 
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Figure 4: Histological analysis of joint damage after intra-articular in-
jection of adenoviral vectors for IL-17 and GM-CSF
(A) H&E and safranin O (SafO) stained sections of knee joints on days 4 and 7 after adenoviral 
transfer. E = exudate; S = synovitis; CD = cartilage damage; B = bone erosion; PG = proteoglycan de-
pletion. Representative sections shown from n=6 joints/group. (B) Individual (left panels) and total 
(right panels) histological scores for days 4 and 7 after adenoviral transfer. Mean ± SEM. *p<0.01, 
Student’s t-test.
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Overexpression of GM-CSF and IL-17 in the knee joint leads to 
joint destruction 
Joints were taken at day 1, 4 and 7 after injection of adenoviral vectors for 
histological analysis. H&E- or safranin O-stained sections were scored for 
inflammation (synovitis and exudate), chondrocyte death, bone- and car-
tilage erosion and PG depletion (Figure 4A). Injection with AdIL17 caused 
a mild inflammatory reaction in the joint on day 4, which increased to 
severe on day 7 after injection. On this day, these joints also displayed 
moderate bone erosion and moderate to severe PG depletion (Figure 4B). 
In contrast, AdGM-CSF injection led to severe synovitis and exudate on 
day 4, and an increase in bone erosion, PG depletion and cartilage dam-
age on day 7. Injection with AdIL17+AdGM-CSF caused accelerated joint 
damage, with severe inflammation, bone erosion and PG depletion visible 
on day 4. On day 7, these joints had lost normal joint architecture due to 
extensive inflammation (Figure 4A).  Overall, the inflammation and dam-
age caused by AdGM-CSF injection was more severe than the damage 
caused by AdIL17. Combined injection caused complete destruction of the 
joint. Injection with AdLUC caused mild inflammation and damage (Fig-
ures 4A and 4B). For all groups, inflammation was very mild (total scores 
< 5 out of 15 for all groups) on day 1 after injection (not shown).
 
GM-CSF and IL-17 synergism induces production of CXCL-1, 
IL-6, IL-23, RANKL and MMPs in synovial tissue
The expression of inflammatory cytokines, Th17-related transcription 
factor Ror-γt and MMPs was measured in synovial tissue by Luminex 
analysis of joint washouts and QPCR at 4 hours, day 1, and day 4 after 
virus injection (Table 2, Figure 5). By day 4, a strong synergistic effect 
was seen on the production of IL-6 and CXCL-1 in the joints injected with 
AdIL17 and AdGM-CSF (Table 2). Ror-γt mRNA was increased ~10-fold 
in all groups compared to AdLUC injected joints on this day, suggesting 
that Th17 differentiation in the joints was induced by IL-17 as well as by 
GM-CSF (Figure 5A). IL-23, which is induced in DC by GM-CSF and is re-
quired for Th17 maintenance and GM-CSF production by Th17 cells, was 
upregulated on day 4 for the AdIL17 group (Figure 5B). Overexpression 
of GM-CSF induced IL-23 production earlier, from day 1 after injection, in 
keeping with the recently described relationship between GM-CSF and 
IL-23 in autoimmune inflammation 21. Interestingly, combined IL-17/GM-
CSF overexpression caused a modest increase in IL-23 mRNA at 4 hours 
and day 1 after injection, but induced an impressive ~350 fold increase at 
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Figure 5: QPCR analysis of inflammatory and anti-inflammatory me-
diators in synovial tissue after adenoviral transfer into the knee joint
(A) Ror-γt expression in synovial tissue measured at 4 hours, day 1 and day 4 after adenoviral 
transfer. (B) IL-23 expression in synovial tissue measured at 4 hours, day 1 and day 4 after ade-
noviral transfer. (C) IL-1, IL-21 and RANKL expression on day 4 after injection. (D) Expression of 
MMPs on day 4 after injection. (E) Expression of MMP inhibitors, Th1/Th2 transcription factors and 
anti-inflammatory cytokine IL-10 on day 4 after injection. n=6 joints/group. Mean ± SEM. *p<0.05, 
Student’s t-test. TF=transcription factor.
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day 4, suggestive of a synergistic relationship (Figure 5B). Although injec-
tion with AdIL17 or AdGM-CSF alone induced an increase in IL-1β, IL-21, 
RANKL and MMPs, synergism between IL-17 and GM-CSF was mostly 
reflected in the production of RANKL (1500 fold increase), MMP9 (426 fold 
increase), MMP13 (584 fold increase) and S100A8 (1120 fold increase, 
Figure 5C and 5D). TIMP1 and TIMP2 expression was up-regulated in 
all treatment groups, but this was not the case for TIMP3 and TIMP4. Al-
though there was a trend towards increased Th1/Th2 transcription factor 
expression in the AdIL-17 group, this did not reach significance. 
Table 2: Cytokine and chemokine analysis of joint washouts on day 4 
after intra-articular injection of adenoviral vectors (pg/mL).
Adenoviral vector
Cytokine AdLUC AdIL17 AdGM-CSF AdIL17+ AdGM-CSF
IL-1β 10.2 ± 0.0¶ 10.2 ± 0.0¶ 34.9 ± 5.4*§ 44.5 ± 11.1*
IL-6 11.2 ± 6.8§¶ 179.4 ± 63.3*¶ 49.6 ± 13.7*§ 1866.2 ± 366*§¶
IL-17 ND 1.9 ± 0.3 ND 9.3 ± 2.25§¶
GM-CSF 26.7 ± 3.16¶ 24.9 ± 0.0¶ 2756.4 ± 18.8*§ 3122.5 ± 38.6*§¶
CXCL-1(KC) 40.1 ± 13.5 49.0 ± 10.0 28.8 ± 3.7 253.3 ± 51.3*§¶
CCL2 (MCP-1) 242.7 ± 109.9 42.5 ± 5.1¶ 121.6 ± 27.2§ 249.04 ± 15.0§¶
CCL3 (MIP-1α) 61.6 ± 30.0 9.68 ± 0.0¶ 29.4 ± 3.9 72.7 ± 5.4¶
* p ≤ 0.01 vs AdLUC; § p≤ 0.01 vs AdIL17; ¶ p ≤ 0.01 vs AdGM-CSF
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6.4 Discussion
GM-CSF has recently been identified as a key player in Th17-mediated 
inflammation 19,20,25. Both GM-CSF and IL-17 are produced by T cells and 
are critical mediators of experimental arthritis 8,22,25,32-34. GM-CSF is es-
sential for the pathogenicity of Th17 cells and for the CCR4-dependent 
production of IL-23 by DC in EAE 19-21. GM-CSF production by T cells is 
regulated by the transcription factor NF-κB1 25, but also by ROR-γt 19. T 
cells lack GM-CSF receptors 35, so the effect of T cell derived GM-CSF 
on Th17 mediated inflammation occurs via enhancement of IL-6 and IL-23 
production from antigen presenting cells (APC) 20. IL-6 and IL-23 enhance 
GM-CSF production by T cells by binding to the respective receptors, cre-
ating a positive feedback loop 20. In addition, IL-6 induces Th17 differen-
tiation in combination with IL-23 and TGF-β, creating a second feedback 
loop 36. The close relationship between GM-CSF and IL-17 in inflammatory 
conditions suggests that therapeutic inhibition of one of these molecules 
might have an effect on the other. Indeed, blockade of GM-CSF in mice 
deficient for the IL-17 receptor improved disease outcome in a model of 
chronic relapsing arthritis 37. 
In the present paper we show that combined inhibition of IL-17 and GM-
CSF significantly improves the outcome of CIA in mice over inhibition of 
these cytokines separately, by targeting different components of Th17-me-
diated joint-inflammation. IL-17 mediates chondrocyte metabolism and 
can induce the expression of MMPs in synovial explants and fibroblasts 
38,39. In primary cultures of human monocyte and macrophages, IL-17 stim-
ulated the production of MMP-9 39. In addition, IL-17 recruits neutrophils to 
the joint, inhibits the synthesis of chondrocyte proteoglycan and induces 
the loss the loss of proteoglycans from mouse cartilage 11,40. We found that 
inhibition of IL-17 during established arthritis only caused a modest de-
crease in the local expression of MMP3, MMP13 and IL-23, but a marked 
reduction in systemic IL-6 levels, in accordance with previous reports 12. 
In our neutralisation studies during CIA, the beneficial effect of anti-IL-17 
on joint pathology is therefore most likely caused by the direct blockade 
of neutrophil-influx and inhibition of the Th17 feedback loop. Inhibition of 
GM-CSF targets the recruitment and differentiation of IL-6- and IL-23-pro-
ducing myeloid cells, hereby indirectly reducing Th17 differentiation. Anti-
GM-CSF had a pronounced effect on the local expression of MMPs. The 
main producers of MMPs are monocytes and macrophages 41, myeloid 
cells that depend on GM-CSF for proliferation and differentiation 42. There-
fore, blockade of GM-CSF is likely to indirectly inhibit MMP production. 
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This was also true for IL-6, which was reduced in the circulation by both 
treatments, but only anti-GM-CSF inhibited IL-6 production locally in the 
affected joints. Interestingly, joint washouts from mice that received com-
bination therapy contained increased levels of IL-6 and CCL2, and synovi-
al tissue showed increased expression of IL-1β and IL-23 in the absence of 
inflammation. This might be due to increased local production of IL-17, in-
duced by formation of IL-17-anti-IL-17 complexes; reduced consumption of 
these factors due to the lack of inflammatory cells; or to the relatively large 
population of resident macrophages and DC. In addition, mRNA levels are 
compared to animals receiving isotype control antibodies. It is likely that 
these animals are in remission at the time of harvest due to the loss of 
cartilage and a lack of collagen (Figure 1C). Combined blockade of IL-17 
and GM-CSF ameliorated disease progression and significantly reduced 
inflammation and erosion in the ankle joints. In view of the introduction of 
IL-17 and GM-CSF inhibitors in the clinic for auto-inflammatory conditions 
such as rheumatoid arthritis (RA) and multiple sclerosis (MS) (recently 
reviewed in 4,43), this is an important observation. It is possible that some 
patients do not respond to therapeutic inhibition of one of these factors, 
as is the case for TNF-inhibitors 44. Based on the additive beneficial effect 
of IL-17 and GM-CSF inhibition during CIA, combination therapy could be 
considered in these cases. 
The local differential effects of IL-17 and GM-CSF on inflammation and 
production of inflammatory mediators were also studied by overexpres-
sion of these cytokines by adenoviral transfer. Increased production of IL-
17 and GM-CSF was detected in the knee joints. Intra-articularly injected 
adenoviral vectors preferentially transfect fibroblasts and synoviocytes 45, 
and in keeping with this observation, we found increased GM-CSF pro-
duction mainly in CD4- cells. Previous studies found that overexpression 
of IL-17 in joints of mice during CIA increased bone erosion through the 
loss of RANKL/osteoprotegerin (OPG) balance 46, but that IL-17 only in-
duced MMPs in presence of TNF 47. We found indeed that the main ef-
fect of IL-17 overexpression was inflammation, PG depletion and bone 
erosion. Overexpression of GM-CSF had a similar effect to IL-17 on joint 
damage as judged by histology, however combined overexpression of IL-
17 and GM-CSF caused accelerated and more severe pathology. This 
result suggests a qualitative difference between the damage caused by 
each of these cytokines, and/or synergistic action. We show indeed that 
overexpression of each cytokine separately caused an increase in MMPs, 
IL-23 and RANKL, but that this increase was greatly enhanced by com-
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bined over-expression.
Although IL-17 and GM-CSF are both involved in the induction of joint 
pathology, the mechanism through which these factors cause damage 
is different. For the production of IL-23, RANKL and MMPs, there was an 
obvious synergistic effect of IL-17 and GM-CSF. This was partly mirrored 
by a significant reduction of RANKL and MMPs after combined neutral-
isation, but interestingly this led to an increase in IL-1β and IL-23.  We 
hypothesize that the absence of inflammation in the joints from animals 
treated with the combination therapy results in a markedly different com-
position of the cell populations, which is reflected in the QPCR results. In 
addition, mRNA was purified two days after the last antibody treatment, 
when inflammation is slowly returning.
Overall, our results illustrate that complex interactions exist between IL-17 
and GM-CSF during inflammation. Blockade of one of these cytokines 
can take away the synergistic effects, but does not per definition lead to 
inhibition of the other cytokine. Therefore, blocking both IL-17 and GM-
CSF has an advantage over single-molecule inhibition.
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Abstract
Production of the pro-inflammatory cytokine interleukin (IL)-17 by Th17 
cells and other cells of the immune system protects the host against 
bacterial and fungal infections, but also promotes the development of 
rheumatoid arthritis (RA) and other autoimmune and inflammatory disor-
ders. Several biologicals targeting IL-17, the IL-17 receptor, or IL-17-relat-
ed pathways are being tested in clinical trials, and might ultimately lead 
to better treatment for patients suffering from various IL-17-mediated dis-
orders. In this review, we provide a clear overview of current knowledge 
on Th17 cell regulation and the main Th17 effector cytokines in relation 
to IL-17- mediated conditions, as well as on recent IL-17-related drug 
developments. We demonstrate that targeting the Th17 pathway is a 
promising treatment for rheumatoid arthritis and various other autoim-
mune and inflammatory diseases. However, improvements in technical 
developments assisting in the identification of patients suffering from 
IL-17-driven disease are needed to enable the application of tailor-made, 
personalised medicine.
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7.1 Interleukin 17 (IL-17)
The gene encoding the cytokine interleukin-17A, also known as IL-17, 
was originally called the cytotoxic T-lymphocyte-associated antigen 8 
(Ctla8) gene, and cloned for the first time from a murine cytotoxic T 
lymphocyte  (CTL) hybridoma cDNA library. The murine cytokine shares 
63% amino acid identity with human IL-17, and both are secreted as 
homodimers 1. Besides IL-17A, the IL-17 family includes IL-17B, IL-17C, 
IL-17D, IL-17E, and IL-17F. Within this family, IL-17A and IL-17F share the 
highest amino acid sequence identity (50%), and these cytokines bind to 
the same receptor. The IL-17 receptor family consists of five members, IL-
17RA to IL-17RE, which form homo- or heterodimers 2. IL-17 receptors are 
well conserved, with 68–90 % similarity observed between the human 
and mouse homologs 1. IL-17 is important in protection against bacterial 
and fungal infections 2. This protection is mediated by the induction of 
pro-inflammatory cytokines and chemokines and the attraction of neutro-
phils to inflammatory sites. IL-17 also induces the production and release 
of antimicrobial peptides from fibroblasts, endothelial cells, and epithelial 
cells 2,3. The cytokine is produced by mast cells 4, cytotoxic CD8+ T cells, 
natural killer cells, neutrophils, and monocytes, but the main producers 
are Th17 cells.
7.2 Th17 cells and Rheumatoid Arthritis (RA)
By producing IL-17, Th17 cells protect the host against bacterial and fungal 
infections, but also promote the development of autoimmune diseases 5. 
The role of IL-17 in rheumatoid arthritis (RA) has been studied extensively. 
Expression levels were significantly increased in RA synovium 6,7, and 
CD4+ IL-17+ cell numbers were increased in peripheral blood mononuclear 
cells of patients with RA compared with healthy controls. Those numbers 
correlated with the number of swollen joints and C-reactive protein levels 
of RA patients. Concentrations of IL-17 in peripheral blood mononuclear 
cell (PBMC) supernatants from RA patients were also significantly high-
er compared with healthy controls 8. The cytokine is involved in different 
processes of arthritis development, for instance in increasing the pro-
duction of pro-inflammatory cytokines, chemokines, and matrix-degrad-
ing enzymes in a range of cell types 3. By the increased production of 
chemokines like CCL2 and CCL7, IL-17 promotes the rapid recruitment 
of monocytes and neutrophils 9. During the process of bone destruction, 
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IL-17 stimulates RANK ligand (RANKL) expression by osteoblasts and 
synovial fibroblasts, thereby promoting osteoclastogenesis 10 (Fig. 1), a 
process that might also be relevant in other diseases like osteoporosis 
11. In addition, the aforementioned IL-17-induced upregulation of pro-in-
flammatory cytokines such as IL-1 and TNF-α in macrophages, synovio-
cytes, chondrocytes, and osteoblasts also stimulates osteoclastogenesis. 
As with IL-17, those pro-inflammatory cytokines upregulate RANKL ex-
IL-17
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IL-21
IFNγ
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Th1
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Figure 1: Regulation of osteoclastogenesis by Th17 cells in rheuma-
toid arthritis synovial tissue. 
Expression of RANKL by osteoblasts or synovial fibroblasts is stimulated by IL-17 and 
other pro-inflammatory cytokines. RANK-mediated signalling is upregulated, promot-
ing osteoclastogenesis. Secretion of IFN-γ and IL-4 by, respectively, Th1 and Th2 cell 
subsets inhibits osteoclastogenesis. Th: T-helper cell; IL: interleukin; RANKL: receptor 
activator of nuclear factor kappa B ligand; IFNγ: interferon γ.
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pression, enhancing RANK-mediated signalling between osteoblasts or 
synovial fibroblasts and osteoclast precursor cells, and promoting osteo-
clastogenesis 10.
Furthermore, the combination of IL-17 and TNF-α enhanced degradation 
of cartilage in foetal mouse bones in vitro 12, and more interestingly, had 
strong synergistic effects on cartilage destruction in vivo 13. In contrast, 
other T-helper subsets inhibit osteoclastogenesis through the production 
of either IFN-γ or IL-4 7,10. In mice, IL-17 was demonstrated to promote 
bone erosion by changing the RANKL/OPG balance 14, and neutralisation 
of IL-17 by an anti-IL-17 antibody effectively suppressed arthritic flares 15 
and reduced local and systemic bone loss by blocking osteoclast differ-
entiation in vivo 16,17.
Two other cytokines produced by Th17 cells, IL-21 and IL-22, also promote 
bone erosion during RA 18,19. Elevated expression of IL-21 was detected in 
the synovium and synovial fluid of arthritic mice, and in synovium, synovial 
fluid, and serum from RA patients compared to healthy controls. Thus, 
RANKL expression is enhanced and osteoclastogenesis is subsequently 
stimulated, indicating that IL-21 promotes osteoclastogenesis in RA and 
contributes to bone destruction in inflamed joints 19. Besides its role in os-
teoclastogenesis, IL-21 is involved in other pathways in the pathogenesis 
of RA. For example, the cytokine can enhance the proliferative response 
of naïve mouse T cells to T-cell receptor (TCR) stimulation. Hence, it was 
suggested that IL-21 might contribute to the initial expansion of pathogen-
ic T-cell populations 20. In addition, IL-21 is able to induce the recruitment 
of both neutrophil and monocytic cell populations through an unknown 
mechanism 21. Furthermore, IL-21 is known to counteract the effects of 
regulatory T-cells (Tregs) by decreasing the sensitivity of Th17 cells to 
suppression by those cells 22. IL-21-receptor-deficient (IL-21R-/-) mice are 
completely resistant to the development of spontaneous arthritis 23, which 
is partly due to the sensitivity of their Th17 cells to suppression by Tregs. 
Administration of a potent neutralising agent to IL-21 in two distinct ani-
mal RA models resulted in amelioration or reversal of the RA phenotype, 
which was correlated with enhanced IFN-γ production and suppression 
of serum IL-6 levels. Since inhibition of IL-21 resulted in a reduction of 
the phenotype of the animals in which the disease process had already 
been initiated, a role mainly in the progression phase was implied for this 
cytokine 20.
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As stated before, IL-22 is, like IL-17 and IL-21, capable of promoting oste-
oclastogenesis 24. IL-22 might perform a pro-inflammatory role in RA, re-
sulting in the aforementioned promotion through the stimulation of RANKL 
expression 18. Mice deficient for IL-22 were shown to be less susceptible 
to experimental arthritis compared to wild-type mice 25, and elevated IL-22 
baseline levels in RA patients were associated with erosive RA 26. These 
findings indicate that Th17 cells are crucial immune cells that are required 
for the initiation of arthritis and contribute to the augmentation of chronic 
and destructive inflammation in joints.
7.3 Regulation of the Th17 cell subset
The way in which Th17 cells are regulated has been a source of 
debate in recent years. The consensus was initially that, in contrast to 
Th17 differentiation in mice, human Th17 differentiation is not dependent 
on TGF-β signalling. It was suggested that TGF-β might act indirectly on 
Th17 differentiation rather than directly, favouring Th17 cell expansion by 
suppressing T-bet expression. Thus, the generation of Th1 cells is sup-
pressed, while Th17 cells are less susceptible to the suppressive effects 
of TGF-β 27. In addition, naïve human T cells were proposed to be able 
to differentiate into Th17 cells by stimulation with a combination of IL-1 
and IL-6/IL-23, or solely by IL-23 28,29. However, in those studies, the en-
dogenous source of TGF-β (e.g. serum and platelets) was not carefully 
controlled. Subsequently performed studies using serum-free medium 
and in which naïve T cells were carefully sorted resolved these issues, 
showing that TGF-β was indispensable in human Th17 differentiation as 
well 30-32. Thus, the regulation of Th17 differentiation from naïve T cells 
appears to be quite similar in both humans and mice after all.
Differentiation of Th17 cells is stimulated by the enhanced expression 
of the orphan nuclear receptor γt (RORγt), induced by TGF-β and IL-6 
or IL-21 acting in synergy 33,34. TGF-β is produced by multiple lineages of 
leukocytes and stromal cells, but might also be secreted by Tregs. Addi-
tionally, Th17 cells can express high amounts of TGF-β themselves, with 
the growth factor acting in an autocrine manner to maintain Th17 cells 
33,35,36. IL-6 is secreted in high amounts by cells of the innate immune sys-
tem, B cells, and subsets of activated T cells, but also by resident cells 
in the joints like fibroblasts. Receptors for IL-6 (IL-6R) are expressed on 
naïve T cells, and the binding of its ligand activates signal transducer 
and activator of transcription 3 (STAT3). This phosphorylation step is 
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necessary, but not sufficient to induce RORγt expression. TGF-β sig-
nalling activates the Smad2 pathway, leading to the expression of both 
Foxp3 (stimulating Treg differentiation) and RORγt (for Th17 induction) 37. 
IL-6 and IL-21-induced expression of suppressor of cytokine signalling 
3 (SOCS3) is inhibited upon TGF-β signalling through Smad2/3, leading 
to enhanced and prolonged activation of STAT3 in naïve T cells 37,38. This 
STAT3 activation in the presence of IL-6 and TGF-β relieves Foxp3-me-
diated suppression of RORγt, thereby enhancing RORγt expression 
and facilitating the Th17 transcriptional program (Fig. 2).
SMAD3
SMAD2
SOCS3 STAT3
TGF-β IL-6 IL-21
FOXP3 RORγt
IFNγ IL-4
Th17Treg
Th1 Th2
Chapter 7 Figu  2
Figure 2: Regulation of Th17 cell differentiation.
Th17 differentiation is stimulated by the TGF-β- and IL-6- or IL-21-enhanced expression 
of RORγt. Binding of TGF-β to its receptor activates the Smad2 pathway, inducing 
both Foxp3 and RORγt expression. Activation of STAT3 by IL-6 and IL-21 receptor bind-
ing relieves the Foxp3-mediated suppression of RORγt, enhancing RORγt expression 
and inducing Th17 differentiation. TGF-β: transforming growth factor β; IL: interleukin; 
SOCS3: suppressor of cytokine signalling 3; STAT3: signal transducer and activator 
of transcription 3; Foxp3: forkhead box p3; RORγt: retinoic acid-related orphan recep-
tor-γt; Th: T helper cell; IFNγ: interferon-γ
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The TGF-β- and IL-6/IL-21-mediated Th17-cell differentiation is enhanced 
by TNF-α and IL-1β, important pro-inflammatory cytokines involved in RA 
pathogenesis 34. Although naïve T cells do not express receptors for IL-1 
and IL-23, they are induced after exposure to TGF-β and IL-6/IL-21 32,39. 
Hence, differentiating Th17 cells become responsive to these cytokines 
required for the maintenance of Th17 cells 36,40-43. IL-23 synergises with 
IL-6, enhancing the differentiation, survival, and stabilisation of Th17 cells 
41,43,44. Despite this support by IL-23 and IL-6, Th17 cells are still quite un-
stable. Various mixed Th17 cell phenotypes have been observed, and 
are likely determined by their inflammatory environment. Th17 cells 
may transform into Th1-like cells and start to produce IFN-γ and other 
inflammatory cytokines under chronic inflammatory conditions 45. IFN-γ 
is able to upregulate IL-12Rβ2 on Th17 cells, enhancing their sensitivity to 
IL-12, resulting in a Th17/Th1 phenotype that stably co-expresses RORγt 
and T-bet 46.
Differentiation of Th17 cells can be inhibited by cytokines secreted by 
Th1 and Th2 T cell subsets. In addition, the development of Tregs in-
hibits Th17 differentiation. Both Tregs and Th17 cells are regulated by 
TGF-β, which maintains a balance between the two T-cell subsets. In 
RA patients that balance is broken in peripheral blood. Patients with RA 
showed increased levels of Th17 cells, whereas their Treg numbers 
were decreased 47. Furthermore, the functional capability of Tregs in RA 
patients was limited 48. A balance between Treg and Th17 levels seems 
crucial for immune homeostasis, and a T-cell imbalance might lead to 
the development of autoimmune disorders. Once more, this shows the 
importance of cytokine regulation in maintaining homeostasis of the 
immune system.
7.4 Clinical use of IL-17-related biologicals in RA
Cytokines contribute to autoimmunity, maintain chronic synovitis, and 
drive bone damage during RA pathogenesis. Therefore, it became a 
therapeutic priority to antagonise their effects by targeting specific cy-
tokines and their receptors in RA patients 49. The first clinically success-
ful, cytokine-specific  therapies  for the  treatment  of RA were the an-
ti-TNF-α agents. Currently, five different TNF- blockers are used to treat 
patients with RA: infliximab, etanercept, adalimumab, golimumab, and 
certolizumab. In clinical trials, TNF-blockers were shown to be safe as 
well as very  efficient, comparable to methotrexate (MTX). However, the 
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efficacy was greater when combining the two drugs. TNF-blockers cost 
over US$13,000 per year, as compared to less than US$130 for MTX treat-
ment. Therefore, it was suggested that treatment of RA should be initiated 
with MTX. In patients responding insufficiently to MTX, TNF-blockers can 
be added to the therapy 50. Since etanercept and infliximab were first 
introduced in 1998 and 1999, respectively, almost 2 million RA patients 
have been treated with anti-TNF-α agents. Although the use of TNF-α 
inhibitors was shown to be very efficient in RA treatment, approximately 
30% of all patients still fail to respond adequately 49. Therefore, agents 
blocking other pathways of RA pathogenesis are required. It was ob-
served that circulating Th17-cell numbers were significantly higher in 
patients who did not respond to treatment with TNF-α inhibitors during 
RA therapy as compared to patients who did respond to treatment 51,52. 
In addition, preclinical studies showed that IL-17 also promotes arthritis 
pathology independently of TNF 53. Once more, this emphasises the im-
portance of Th17 cells and Th17-derived cytokines in RA pathology, and 
these might therefore be potential additional therapeutic targets in RA. 
The main Th17 cell cytokine, IL-17, has been targeted in several clinical 
studies for RA. In human Th17 cells, the IL-17 production can be reduced 
in vitro by a T-cell-specific and anti-inflammatory agent tacrolimus 54. In 
addition, two monoclonal antibodies (mAbs) against IL-17, secukinumab 
and ixekizumab, have been developed, and clinical trials are currently 
performed. The safety, tolerability, pharmacokinetics, pharmacodynam-
ics, and efficacy of ixekizumab have already been evaluated in a first 
in-human trial in RA patients taking disease-modifying anti-rheumatic 
drugs (DMARDs) such as MTX and sulfasalazine (SSZ). The disease 
activity score in 28 joints (DAS28) was significantly reduced in the ixeki-
zumab-receiving groups compared with the placebo group. In addition, 
the percentages of the patients achieving American College of Rheu-
matology (ACR) improvement criteria 20, 50, and 70% responses were 
greater in the groups treated with the mAb than in the placebo-receiving 
group at multiple time points. No apparent dose–response relationship 
in treatment-emergent adverse events was observed 55. Recently, the 
safety, efficacy, and optimal dose of ixekizumab administration were as-
sessed in a phase II trial. The results are, unfortunately, not published 
yet 56. Currently, a phase II study is being performed to assess whether 
patients with a specific biomarker have a better response to secuki-
numab treatment, enabling the optimisation of RA treatment 57. Preclini-
cal research using SCID mice engrafted with human RA synovial tissue 
demonstrated that secukinumab shows the best therapeutic effects when 
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targeting inflammation characterised by high CD3+ T-cell numbers 58. 
This indicates that further profiling of RA patients using local or systemic 
biomarkers will help to realise more effective personalised medicine. 
The long-term efficacy, safety, and tolerability of syringes pre-filled with 
secukinumab were also tested in RA patients in a phase III trial 59.
In addition to the biologicals targeting IL-17, an anti-IL-17 receptor mAb, 
brodalumab, has been developed and is currently being tested in clin-
ical trials for RA 60. This mAb has already shown spectacular efficacy in 
psoriasis treatment 61.
Furthermore, biologicals targeting different pathways have been shown 
to (indirectly) reduce IL-17 production in preclinical studies and in RA 
patients. Experiments using tofacitinib (a JAK inhibitor) treatment in 
SCID-HuRAg mice showed reduced synovial inflammation and invasion 
of the implanted cartilage 62. Although inhibition of the JAK pathway by 
tofacitinib in other disease models has demonstrated enhancement of 
Th17 differentiation and even acceleration of experimental autoimmune 
encephalomyelitis (EAE) development 63,64, tofacitinib reduced Th17 de-
velopment and inhibited inflammation and destruction of the joint during 
collagen-induced arthritis (CIA). In this model, tofacitinib reduced RA 
severity by decreasing phosphorylation of STAT3, thereby reducing 
the expression of several cytokines, such as the IL-6 family, and subse-
quently reducing Th17 differentiation 65. In a phase II double-blind study 
using tofacitinib in patients with active RA, severity was reduced as well, 
as represented by a significant increase in the percentage of ACR20 
responses compared to controls 62. Additionally, rituximab, which is suc-
cessful in RA treatment, reduces Th17 cell numbers and the expression 
of RORγt and IL-22 in synovial tissue, which correlates with reduced in-
flammation and improved clinical outcome 66. Digoxin, a RORγt antag-
onist that directly binds RORγt, suppresses Th17 cell differentiation in 
vitro 67,68 and ex vivo 68 as  well.  Moreover, the RORγt- and RORα-binding 
and -inhibiting high-affinity synthetic ligand SR1001 suppressed Th17 
development as well as the clinical severity of EAE 69. Clinical effects of 
RORγt inhibitors in RA patients remain to be determined.
Agents inhibiting IL-12 and IL-23 have also been developed. As stated 
before, IL-23 is an important mediator of Th17 responses. It is a heterod-
imer consisting of a p19 and a p40 subunit, with the latter also being an 
IL-12 subunit. IL-12 is an important mediator of Th1 responses, and con-
sists of both the p40 subunit and a p35 subunit. This latter subunit shares 
40% homology with the IL-23 subunit p19 49. A study in RA patients as-
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sessing the safety and efficacy of the small molecule apilimod mesylate, 
which inhibits IL-12/IL-23, has shown that this inhibitor is unable to induce 
robust clinical improvement of the phenotype. ACR20 response was 
achieved in only 6% of patients on day 29 and in 25% of patients on 
day 57, similar to the percentage of responders in the control group. It 
was suggested that this failure was due to insufficient levels of the agent 
at the site of inflammation. Therefore, apilimod mesylate was unable to 
mediate its inhibitory effect, leading to unreduced expression levels of 
IL-12 and IL-23 70. However, psoriatic patients receiving ustekinumab, 
an anti-p40 antibody, significantly benefited from the treatment 71. Since 
this agent also targets IL-12 because of the shared p40 subunit, a drug 
targeting p19 would provide more specific IL-23 inhibition and would the-
oretically be safer 72. Therefore, it would possibly also be profitable to 
start testing anti-p19 agents in patients with RA.
Targeting the IL-1 pathway has unfortunately evoked only marginal 
clinical responses 73. Although several agents targeting the IL-1 path-
way have been developed, including anakinra (recombinant IL-1 receptor 
antagonist), rilonacept (IL-1β inhibitor), canakinumab (anti-IL-1β antibody), 
AMG108 (fully human anti-IL1 receptor mAb), soluble IL-1 receptor, and 
pralnacasan (synthetic caspase 1 inhibitor), anakinra is currently the only 
agent approved by the Food and Drug Administration for the treatment 
of RA. Since only modest benefits of this drug were observed, its use-
fulness in RA treatment is limited 49,74. Monoclonal antibodies targeting 
IL-6 were ineffective in clinical trials, causing the formation of immune 
complexes that prolong the serum half-life of the cytokine 75. In contrast, 
IL-6-mediated effects were more efficiently suppressed using antibod-
ies targeting the IL-6 receptor. Tocilizumab is such an antibody, as it is 
administered to RA patients with inadequate responses to anti-TNF-α 
agents. Treatment with tocilizumab restores the disturbed Th17/Treg bal-
ance in patients with RA by suppressing Th17 development 76,77. Even 
though the disease phenotype is significantly improved by the agent, the 
antibody causes an increase in serum IL-6 and soluble IL-6 receptor (sIL-
6R) levels. The serum IL-6 increase is possibly a result of decreased in-
ternalisation of ligated IL-6/ IL-6 receptor, whereas the increase in sIL-6R 
is caused by decreased clearance of the sIL-6R/tocilizumab complexes 
78. In addition to the promising tocilizumab monotherapy, clinical tests 
using both MTX and tocilizumab showed that this combination is very 
effective at achieving rapid and sustained improvements in RA disease 
severity 79. Furthermore, another human IL-6 receptor-specific mAb and 
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a highly specific anti-IL-6 receptor nanobody that exert inhibitory effects 
on IL-6 activity are in the preclinical testing phase 80.
Since TGF-β is important in Th17 development and consequently in RA 
pathogenesis, it is an interesting growth factor to target in RA treatment. 
TGF-β is abundantly expressed in the human body, where it is involved 
in several important growth processes and in maintaining homeostasis. 
Therefore, serious concerns have been expressed regarding the safety 
of TGF-β blocking in human patients. Until now, no studies testing the 
safety and efficacy of TGF-β inhibitors in patients with RA have been 
reported. However, the use of TGF-β-blocking agents in other diseas-
es has been tested in mice, monkeys, and patients. Surprisingly, those 
inhibitors were tolerated well in most cases, suggesting that TGF-β in-
hibitors might be safe and useable in RA treatment as well 81-83.
7.5 IL-17 in other autoimmune and inflammatory 
disorders
In addition to RA, IL-17 plays an important role in the pathogenesis of 
various other autoimmune and inflammatory diseases, such as psoriasis, 
asthma, and inflammatory bowel disease.
7.5.1. Psoriasis
Serum levels of two Th17-related cytokines, IL-17 and IL-22, are higher 
in psoriatic patients than in healthy controls, and correlate with disease 
severity 84. IL-1 induces expression of psoriasin (S100A7) and koeb-
nerisin (S100A15) in patients with psoriasis. This expression is further 
amplified by Th17 cytokines in the micromilieu of psoriatic skin. Both 
psoriasin and koebnerisin are antimicrobial peptides that can act syn-
ergistically as chemoattractants and alarmins to amplify inflammation in 
psoriasis 85. In addition to psoriasin and koebnerisin, IL-17 enhances the 
expression of three other antimicrobial peptides; β-defensin 2, S100A8, 
and S100A9 86. Expression of the neutrophil chemoattractants CXCL1, 
CXCL3, CXCL5, CXCL6, and CXCL8 and the chemokine CCL20 is also 
upregulated by IL-17 87.
Ixekizumab, one of the humanised anti-IL-17 mAbs, has been tested 
for psoriasis treatment in a phase I trial. After 2 weeks of treatment, 
quantitative RT-PCR and microarray results showed an ablation of the 
disease-defining mRNA expression profile. After four more weeks of 
ixekizumab administration, the skin of psoriatic patients appeared nor-
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mal. Together, these results indicated that IL-17 is an important driving 
cytokine in psoriasis, activating pathogenic inflammation in patients 88. 
Recently, the safety and efficacy of ixekizumab was assessed in pa-
tients with moderate to severe psoriasis in a phase II trial. After 12 weeks 
of treatment, the percentage of patients with a reduction in the psoriasis 
area-and-severity index (PASI) score of at least 75% was significantly 
greater for patients treated with ixekizumab compared with those receiv-
ing a placebo, as was the percentage of patients with a reduction in PASI 
score of at least 90%. Even though 63% of the patients developed minor 
adverse events (such as upper respiratory infections and headaches), 
no serious adverse events were observed  89.  Currently, a  phase III trial 
is being performed to assess the safety and efficacy of ixekizumab 
compared to etanercept and placebo in patients with moderate to severe 
chronic plaque psoriasis 90. Recently, the efficacy and safety of another 
anti-IL-17 mAb, secukinumab, were also assessed in patients with mod-
erate to severe plaque psoriasis. PASI 75 responses were significantly 
higher in patients receiving high-dose (3x75 or 3x150 mg) secukinumab 
compared with the placebo-receiving group (57 and 82% versus 9%). A 
higher PASI 90 response rate was only found in the group receiving 3x150 
mg secukinumab compared with the placebo group (52 versus 5%). The 
drug was well tolerated, although neutropenia was reported in 2 patients 
in the 3x150 mg group (n=27) 91. In another study assessing the efficacy 
and safety of secukinumab, 150 mg of the drug were administered to the 
patients either once, weekly (weeks 0, 1, 2, 4), or monthly (weeks 0, 
4, 8). Higher PASI 75 responses were observed at week 12 in patients 
receiving weekly or monthly secukinumab compared with placebo (54 
and 42% versus 1%). Only mild- to-moderate cases of neutropenia were 
reported, and no immunogenicity was observed 92. Currently, the in vivo 
skin distribution properties of subcutaneously administered secukinumab 
in patients with psoriasis is being assessed in a phase I trial, to develop 
a technique that allows the in vivo distribution of the drug and its metab-
olites in human dermal interstitial fluid (ISF) to be assessed 93. A phase II 
trial is being performed to study the proportion of patients achieving re-
versal of chronic plaque psoriasis following secukinumab administration 
compared to placebo 94. Furthermore, phase II trials are being conducted 
to assess the safety and efficacy of two different doses and regimens of 
subcutaneous secukinumab administration 95 and to study the efficacy of 
auto-injector-administered secukinumab 96 in patients with moderate to 
severe chronic plaque-type psoriasis. Finally, a phase III study to assess 
the safety and efficacy of secukinumab compared to placebo in moder-
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ate to severe psoriasis patients 97 as well as  a phase III trial to test the 
long-term efficacy, safety, and tolerability of secukinumab in continuous 
or interrupted therapy in moderate to severe chronic plaque psoriasis 
patients showing at least partial response to the drug 98 are being per-
formed. In addition to the anti-IL-17 mAbs, the efficacy and safety of 
the human anti-IL-17-receptor mAb brodalumab in treating moderate to 
severe psoriasis was recently assessed. The study showed that after 12 
weeks of brodalumab administration, histologic and diagnostic features 
of psoriasis were no longer detectable in 11 of 12 biopsy specimens from 
patients receiving 140, 210, or 280 mg of the drug. Among the group 
of patients receiving 210 mg brodalumab (n=40), 2 patients developed 
grade 3 asymptomatic neutropenia 91. Currently, a phase III trial is being 
conducted to assess the safety and efficacy of brodalumab at two dif-
ferent doses compared with ustekinumab and placebo in moderate to 
severe plaque psoriasis patients 99. Additionally, the safety and effica-
cy of brodalumab administered every 2 weeks at two different doses in 
patients with moderate to severe plaque psoriasis is being studied in a 
phase III trial 100.
7.5.2. Asthma
In severe asthma exacerbations, IL-17-induced neutrophilic infiltration into 
the airways is prominent and may contribute to airway gland hyperse-
cretion, bronchial hyperreactivity, and airway wall remodelling in asthma. 
The IL-17 mRNA expression level is significantly elevated in sputum of 
asthma patients compared with healthy controls. This level correlates 
with sputum neutrophil counts, as high levels are present in patients with 
moderate to severe asthma 101. In addition, a single nucleotide poly-
morphism (SNP) in the IL-17 gene was found to be significantly more 
prevalent in asthma patients compared with healthy controls 102. Further-
more, IL-17 levels in serum are increased in severe asthma patients 
compared with patients suffering from a milder form of asthma 103-105 
or with healthy controls 102,104,106,107. In line with this, Th17 cell numbers 
in peripheral blood 105,106, sputum, and broncho-alveolar lavage fluids 
are significantly higher in patients with allergic asthma compared 
with controls 108. Levels of Th17 cells and the severity of airway remod-
elling are positively correlated 109. As opposed to Th17 cell levels, 
the frequency of Treg cells is significantly lower in asthma pa-
tients compared with healthy controls 105,110. In T-bet-/- mice, increased 
IL-17 levels are present that can be neutralised by an IL-17 mAb 111. 
Neutralisation of pulmonary IL-17 in those mice decreased neutrophilic 
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infiltration into the airways and decreased airway inflam- mation, re-
versing the development of allergic asthma 111. Furthermore, IL-23-de-
pendent IL-17 production can be inhibited by an IL-23p40 peptide-based 
virus-like particle vaccine, inducing autoantibodies to IL-23. This inhi-
bition resulted in reduced inflammation in the lung and skin tissues in a 
mouse model for asthma 112, once more showing the importance of 
the cytokine. In humans, expression of IL-17 in severe asthma patients 
can be reduced to levels comparable with those seen in patients with 
mild asthma and in healthy controls after oral administration of corti-
costeroids 104. No data are available concerning in-human trials testing 
antibodies that target IL-17 or its receptor in asthma, and there are no 
registered clinical trials.
7.5.3. Inflammatory bowel disease
In patients with Crohn’s disease (CD), the number of IL-17-positive cells in 
the lamina propria and in blood is significantly higher than it is in healthy 
controls 113-115. A marked decrease in the Crohn’s disease endoscopic 
index of severity (CDEIS) upon anti-TNF-α treatment in patients with CD 
is associated with a decreased ratio of intestinal IL-17 positive cells 116. 
Furthermore, mRNA expression of IL-17A in the intestine is significantly 
increased in patients with active disease and in those in remission as 
compared with healthy controls. In addition, the IL-17 concentrations in 
both faeces and sera of patients with active disease have been shown 
to be increased 113,114. In active ulcerative colitis (UC), the average 
IL-17-positive cell number and the IL-17 serum levels are significantly in-
creased compared with inactive patients 114. IL-17 mRNA and protein ex-
pression is significantly increased in lamina propria CD4+ cells of active 
UC patients compared to UC patients in remission and healthy controls 
117-119. Polymorphisms in IL-17 alleles were shown to significantly cor-
relate with the development of UC, as higher frequencies of the mutated 
genotypes were observed in the UC patient group compared with healthy 
controls 120. Treatment of naïve T cells with exogenous IL-27 inhibited 
Th17 differentiation in vitro 121 by repressing the expression of RORγt 
and RORαt, two transcription factors directing Th17 lineage commitment 
122. Furthermore, administration of IL-27 in an acute colitis mouse model 
significantly improved colon length and decreased the extent of necro-
sis, ulceration, and thickened epithelium as well as several pathological 
scores in a dose-dependent manner 123. Recently, the safety and effica-
cy of the anti-IL-17 mAb secukinumab was tested in patients with active 
Crohn’s disease. Serious adverse events were reported in seven patients 
Proefschrift Annemarie.indb   181 13-10-2013   22:36:04
Page 182
Chapter 7
receiving the drug (n=39) and three in patients receiving a placebo (n=20). 
In addition, 20 infections were seen in the secukinumab-receiving group 
versus none in placebo-receiving patients. Analysis showed that the prob-
ability that the drug reduces the Crohn’s disease activity index (CDAI) by 
≥50 points more than placebo was <0.1% 124. Furthermore, an oral im-
munomodulator inhibiting both dihydroorotate dehydrogenase (DHODH) 
and IFNγ and IL-17 expression, vidofludimus, was tested for its safety 
and efficacy. 57.1% of CD patients (n=18) and 50% of UC patients (n=16) 
were complete responders after 12 weeks of 35 mg of vidofludimus daily, 
administered orally. Fifty-three mild, 18 moderate, and 4 severe adverse 
events were reported. In addition, 2 patients developed serious adverse 
events (SAEs) with hospital admission. However, those SAEs were not re-
lated to vidofludimus. Therefore, no drug-related SAEs were reported, and 
the drug is considered to be safe and tolerable 125. Currently, no clinical 
trials testing drugs targeting IL-17 or its receptor in CD or UC are reported.
7.5.4. Other autoimmune and inflammatory disorders
A role for IL-17 was also suggested in various other autoimmune and 
inflammatory disorders. In multiple sclerosis (MS), Th17 cell numbers 
and IL-17 levels in serum and cerebrospinal fluid (CSF) significant-
ly increased compared with those in healthy controls or patients with 
inactive disease 126-129. In addition, increased IL-17 mRNA expression 
levels in blood mononuclear cells (MNC) have been found in MS patients 
compared to controls and patients in remission 130. Increases in Th17 cell 
numbers and IL-17 levels were also found in patients with autoimmune 
haemolytic anaemia (AIHA), the levels closely correlating with disease 
activity in patients. In vivo neutralisation of IL-17 in an AIHA mouse 
model abrogated disease development 131. Furthermore, a strong IL-
17 phenotype was found in patients with cystic fibrosis (CF) 132. In 
Sjögren’s syndrome IL-17 production is enhanced in salivary gland infil-
trates, and this is possibly involved in the pathogenesis of salivary gland 
damage 133. Recently, IL-17-producing T cells were shown to be present 
at significantly higher levels in mice with severe autoimmune gastritis 
compared to control subjects. Absence of CD4+ T-cell-derived IL-17 pre-
vents T cells for causing severe damage 134. In idiopathic pulmonary fi-
brosis, IL-17 was shown to play a critical role, inducing neutrophilia and 
pulmonary fibrosis 135. In addition to the role of IL-17 in these autoimmune 
and inflammatory disorders, a role for this cytokine was suggested in 
several other diseases, for example in skin tumour development 136 and 
Graves’ ophthalmopathy 137. In addition, IL-17 has been shown to play im-
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Table 1: Clinical trials targeting IL-17 and IL-17-related pathways
Disease Drug Target Potency Ref
Rheumatoid 
arthritis
Secukinumab IL-17 Currently in trial for patients with specific 
biomarker
Efficient when targeting inflammation with high 
CD3+ T-cell numbers
Efficacy, safety and tolerability of pre-filled 
syringes being tested
57-59
Disease phenotype reduced
Ixekizumab IL-17 No short-term adverse events
Safety and efficacy being tested
55,56
Brodalumab IL-17R Currently in trial 60
Tofacitinib JAK Reduced disease 62
Apilimod mesylate IL-12/IL-23 No disease reduction 70
Anakinra IL-1R Slightly reduced disease 74
Rilonacept IL-1β Not approved by the FDA
Canakinumab IL-1β Not approved by the FDA
AMG108 IL-1R Not approved by the FDA
Soluble IL-1 
receptor
IL-1β Not approved by the FDA
Pralnacasan IL-1β 
pathway
Not approved by the FDA
Tocilizumab IL-6R Reduced disease 77
Psoriasis Ustekinumab IL-12/IL-23 Reduced disease 71
Ixekizumab IL-17 Reduced disease 88,89
Minor adverse events
Secukinumab IL-17 Reduced disease 91,92,98
Mild to moderate neutropenia
Long-term efficacy, safety, and tolerability are 
currently tested
Brodalumab IL-17R Reduced disease 91,99,100
Long-term efficacy, safety, and tolerability are 
currently tested
Crohn’s 
disease
Secukinumab IL-17 Insufficient reduction of disease phenotype
Severe adverse events reported
124
Vidofludimus DHODH-
IFNγ -IL-17
Reduced disease
Adverse events reported
125
Ulcerative 
colitis
Vidofludimus DHODH-
IFNγ -IL-17
Reduced disease 
Adverse events reported
125
IL: interleukin; JAK: janus kinase; DHODH: dihydroorotate dehydrogenase; IFNγ: interferon γ; CD: cluster of 
differentiation; IL-1R: IL-1 receptor; IL-6R: IL-6 receptor; IL-17R: IL-17 receptor.
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portant roles in acute inflammation, such as in brain ischemia 138-140 and 
heart disease 141.
7.6 Concluding remarks and future prospects
IL-17 is a pro-inflammatory cytokine that is an important player in the 
pathogenesis of various autoimmune and inflammatory disorders. Sev-
eral treatments targeting IL-17 directly or indirectly have been tested in 
clinical trials and are still being tested (Table 1). The use of robust cell-
based assays to identify IL-17 in patients and to further optimise therapies 
would be ultimately useful. The basis for such an assay was provided in 
a study performed by van de Veerdonk et al 142. In that study, increased 
IL-17 production by Th17 cells after stimulation of CD4+ lymphocytes with 
the fungus Candida albicans was observed. These IL-17 levels, which 
were positively correlated with Th17 cell numbers, were subsequently 
measured using ELISA 142. In addition, a two-step assay was recently 
developed consisting of in vitro activation and stimulation of CD4+ T lym-
phocytes by a defined complex of antibodies and cytokines, leading 
to Th17 differentiation and IL-17 production. IL-17 levels in cell superna-
tants were quantified using a homogeneous time-resolved fluorescence 
(HTRF) assay 143. Such technical developments are crucial for the iden-
tification of patients suffering from IL-17-driven disease and may help to 
provide tailor-made, personalised medicine.
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Chapter 8 - Summary and brief discussion
Rheumatoid arthritis (RA) is a common disease which affects 0.5 – 1% 
of the population in developed countries 1. RA is characterised by inflam-
mation of the synovial joints, resulting in cartilage damage, bone erosion 
and subsequent loss of function. Many inflammatory mediators have been 
identified in arthritic joints, including pro-inflammatory cytokines, chemok-
ines, reactive oxygen species and matrix degrading enzymes such as 
matrix metalloproteinases (MMPs) 2. Two important molecules on the list 
of pro-inflammatory cytokines involved in RA are GM-CSF and IL-17. El-
evated levels of both these cytokines were detected in inflamed synovial 
joints, suggesting a role in RA pathogenesis 3,4. However, it was unclear 
whether these factors were connected, and how this could promote in-
flammation. Understanding this mechanism is important in view of the de-
velopment of improved therapies for autoimmune inflammatory diseases. 
We have studied GM-CSF and IL-17 in animal models of inflammation, 
and the results are reported in this thesis.
As an extended introduction to GM-CSF and the main research compo-
nents of this thesis, we have reviewed the literature on the role of GM-CSF 
in inflammatory diseases. We also summarize the findings that have led to 
the development of GM-CSF antagonists for the treatment of autoimmune 
diseases like RA (Chapter 2). The main discoveries that resulted in the in-
troduction of GM-CSF inhibitors into the clinic were made in mice deficient 
for GM-CSF or the GM-CSF receptor. These mice are protected from a 
range of models for autoimmune and inflammatory diseases, suggesting 
that GM-CSF plays a central role in the inflammatory cascade. Human-
ised antibodies have now been developed that effectively neutralise GM-
CSF in the circulation. The first clinical trials in RA patients with one of 
these antibodies (Mavrilimumab) have been finalised, and a promising 
reduction in disease parameters was reported 5,6. Additional GM-CSF in-
hibitors will be tested in the near future, not only in RA patients, but also in 
patients suffering from multiple sclerosis (MS). These novel therapeutics 
are of particular interest for the group of RA patients that do not respond 
to anti-TNF treatment 1,2. TNF inhibition has been used for the treatment 
of RA with great success since the late 1990s 2. Why some patients do 
not respond to anti-TNF is still unclear, but it is possible that RA in these 
patients is mediated by pro-inflammatory molecules different from TNF, 
such as GM-CSF. 
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Recent studies reported that GM-CSF is an important player in Th17-me-
diated pathology. Th17 cells are a specific type of T cells involved in the 
pathogenesis of many inflammatory diseases and are characterised by 
the production of the pro-inflammatory cytokine IL-17. We studied the role 
of GM-CSF in T cells by generating transgenic mice that specifically over-
express GM-CSF in T cells (Chapter 3). Based on recent literature 7,8 we 
hypothesised that increased GM-CSF production by T cells might lead to 
increased Th17 differentiation or increased T cell pathogenicity in models 
of inflammation. Indeed we found increased IL-17, IL-23 and expression of 
the Th17-related transcription factor Ror-γt in these mice. More surprising-
ly, these mice developed a severe condition called histiocytosis. Histiocy-
tosis is characterised by the infiltration of many organs with histiocytes, 
a cell of myeloid origin that displays a mixture of macrophage, dendritic 
cell and monocyte characteristics. In humans, histiocytosis is a hetero-
geneous group of diseases of unknown aetiology, and hence there is no 
rational cure. One of the most well known of the histiocytoses is Langer-
hans cell histiocytosis (LCH), which is characterised by the uncontrolled 
accumulation of Langerhans cells 9. Our transgenic mice displayed a phe-
notype resembling this condition, including increased numbers of Langer-
hans cells in the spleen, suggesting that T cell-derived GM-CSF might 
play an important role in the pathogenesis of this disease. In accordance 
with this, GM-CSF was previously detected in the serum and lesions of 
LCH patients 10,11. Other studies in LCH patients rendered conflicting data 
on the involvement of IL-17 and Th17 cells in this disease 12,13, but our data 
suggests a link exists between the overexpression of GM-CSF in T cells, 
the production of IL-17 and Th17-related molecules, and the accumulation 
of Langerhans cells. The conclusion of our study was that (T cell-derived) 
GM-CSF might be involved in the disease pathogenesis of Langerhans 
cell histiocytosis and that therapeutic inhibition of GM-CSF might be a 
future treatment option for this condition.
The involvement of Th17 cells in RA is now well established. We studied 
Th17 differentiation in a model for acute inflammatory arthritis, the mBSA/
IL-1β model (Chapter 4). We show that administration of anti IL-17 during 
arthritis development reduced disease severity, indicating that this model 
is IL-17 dependent. We also found that Th17 cells were present in inflamed 
synovial tissue, but not in the draining lymph nodes. This is an interesting 
finding in view of the rather unconventional differentiation requirements 
for this cell type (the presence of IL-6, IL-23, TGFβ and the absence of 
IL-4 and IFN-γ) and suggests the requirement for a specific local cytokine 
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milieu. This was confirmed in subsequent co-culture experiments, where 
we showed that macrophages from inflamed synovial tissue induced Th17 
differentiation of naïve T cells, but macrophages from a non-inflamed site 
did not, due to the reduced production of IL-6 and IL-23. 
The same model for acute inflammatory arthritis was used in Chapter 5. 
A previous study from our group reported that mice deficient for one of 
the Rel/NF-κB subunits (NF-κB1 or p50) were markedly protected from 
mBSA/IL-1β induced arthritis, as well as collagen-induced arthritis 14. In 
Chapter 5, we discovered that this protection was due to the relatively 
specific defect in the production of GM-CSF in CD4 T cells. Intriguingly, 
NF-κB1-deficient mice lacked differentiation of monocyte-derived inflam-
matory DC (MoDC), in mBSA/IL-1β induced arthritis as well as in a model 
for acute inflammatory peritonitis. Since GM-CSF production was not im-
paired in other cells, this suggested that there is a specific requirement for 
T-cell derived GM-CSF for the development of MoDC in an inflammatory 
context. 
In Chapter 6, the interplay between GM-CSF and IL-17 was further inves-
tigated by taking two opposite approaches: inhibition of these cytokines 
during established collagen-induced arthritis (CIA); and overexpres-
sion of these cytokines in knee joints by transfer of adenoviral vectors. 
We show that inhibition of GM-CSF or IL-17 during CIA significantly re-
duced disease progression and joint pathology. However, the com-
bined blockade of these two cytokines completely ameliorated disease 
progression. There was no apparent inflammatory infiltrate or cartilage 
and bone damage at the conclusion of the experiment in the joints of 
the ankle and foot. Upon analysis of the inflammatory mediators in the 
joint, we discovered that anti-IL-17 specifically reduced the transcrip-
tion of the Th17 differentiation factor IL-23 in the synovium, whereas an-
ti-GM-CSF inhibited production of MMPs, Receptor Activator of NF-κB 
Ligand (RANKL), and monocyte-chemotactic protein-1 (MCP-1, CCL2). 
Serum IL-6 was reduced in all treatment groups compared to control mice. 
To provide further insight in local additive or synergistic effects of IL-17 
and GM-CSF, overexpression of IL-17, GM-CSF or the combination was 
achieved by injection of adenoviral vectors into naïve knee joints. Inflam-
matory infiltrate and cartilage- and bone damage developed in all groups 
from day 1 after adenoviral transfer, with the most severe effect observed 
in the combination group. On day 7, partial destruction of joint architec-
ture was apparent in knee joints after combined overexpression of IL-17 
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and GM-CSF. Overexpression of IL-17 alone caused a specific increase 
in synovial IL-6 production. Overexpression of GM-CSF alone induced 
IL-1β, S100A8 and MMP13 in synoviocytes. A strong synergistic effect of 
combined overexpression was seen on the production of the endogenous 
damage-associated molecular patterns (DAMP) ligand S100A8, the os-
teoclast activator RANKL and IL-23. In addition, both GM-CSF and IL-17 
induced an increase in MMP inhibitors TIMP1 and TIMP2, thereby mod-
ulating the MMP/TIMP balance at the site of inflammation. We conclud-
ed from these experiments that IL-17 and GM-CSF cause joint damage 
through synergistic effects on inflammatory mediators in synovial joints. 
In view of the moderate success of therapeutic IL-17 or GM-CSF blockade 
in clinical trials in RA, combined inhibition of IL-17 and GM-CSF might be 
an option for patients that do not fully respond to inhibition of the separate 
cytokines.
In summary, we conclude that both GM-CSF and IL-17 play prominent 
roles in the pathogenesis of inflammatory arthritis. Although the pathways 
through which these cytokines work are intertwined, our results indicate 
that blockade of one of these cytokines may not necessarily affect the ac-
tions of the other. Even though both cytokines are excellent candidates for 
therapeutic targeting in inflammatory diseases, combined inhibition could 
well be superior to blockade of each cytokine separately.
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Figure 1: The many effector functions of GM-CSF and IL-17 during 
joint inflammation.
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Chapter 9 - Nederlandse samenvatting
Reumatoïde artritis (RA) is een veelvoorkomende ziekte. In ontwikkel-
de landen is ongeveer 0.5 – 1% van de populatie aangedaan. RA wordt 
gekarakteriseerd door ontsteking van de synoviale gewrichten, met als 
resultaat kraakbeenschade, boterosie, en uiteindelijk verlies van mobili-
teit. In artritische gewrichten zijn vele ontstekingsfactoren geïdentificeerd, 
waaronder pro-inflammatoire cytokines, chemokines, reactieve zuurstof 
radicalen en enzymen die de weefselmatrix kunnen aantasten, zoals ma-
trix-metalloproteinases (MMPs). Twee belangrijke moleculen die behoren 
tot de pro-inflammatoire cytokines, zijn granulocyte-macrophage colony 
stimulating factor (GM-CSF) en interleukine 17 (IL-17). Deze twee cyto-
kines zijn in verhoogde gehaltes aangetroffen in ontstoken synoviale ge-
wrichten, wat suggereert dat ze een rol spelen in de pathogenese van 
RA. Het was echter niet duidelijk of deze factoren met elkaar in verband 
stonden, en hoe dit van invloed kon zijn op de ontstekingsreactie. Het is 
belangrijk om dit soort mechanismen te begrijpen, vooral met het oog op 
de ontwikkeling van verbeterde therapeutische middelen voor auto-immu-
ne ontstekingsziekten. In dit proefschrift staan de resultaten beschreven 
van onze studies naar de rol van GM-CSF en IL-17 in diermodellen voor 
(autoimmune) ontsteking. 
In hoofdstuk 2 wordt een extra introductie voor GM-CSF gegeven. Dit is 
gedaan door middel van een overzicht van de gepubliceerde literatuur 
over de rol van GM-CSF in ontstekingsziekten. In dit hoofdstuk worden 
ook de bevindingen besproken die hebben geleid tot de recente ontwikke-
ling van GM-CSF remmers, die gebruikt kunnen worden voor de behan-
deling van auto-immuunziekten zoals RA. De belangrijkste ontdekkingen 
die hebben geleid tot de introductie van GM-CSF remmers in de kliniek 
zijn gedaan in muizen die zelf geen GM-CSF kunnen maken, of die de 
receptor voor GM-CSF niet bezitten. Deze muizen zijn niet vatbaar voor 
een groot aantal diermodellen voor auto-immuunziekten en ontstekings-
ziekten. Dit suggereert dat GM-CSF een centrale rol speelt in het ontste-
kingsproces.
Er zijn inmiddels gehumaniseerde antilichamen ontwikkeld die GM-CSF 
in de circulatie effectief kunnen neutraliseren. De eerste klinische testen 
in RA patiënten met één van deze antilichamen (Mavrilimumab), zijn re-
cent succesvol beëindigd. Er werd een veelbelovende verbetering van 
klinische parameters gerapporteerd. Additionele GM-CSF remmers zul-
len in de nabije toekomst worden getest. Deze testen zullen niet alleen 
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plaatsvinden in RA patiënten, maar ook in patiënten met multiple sclerose 
(MS). De ontwikkeling van deze nieuwe therapieën is met name belangrijk 
voor de groep RA patiënten die geen baat hebben bij behandeling met 
tumor-necrosis factor (TNF) remmers. Het blokkeren van TNF wordt met 
veel succes toegepast bij de behandeling van RA sinds de negentiger 
jaren. Het is niet duidelijk waarom sommige patiënten niet reageren op 
TNF-remmers, maar het is mogelijk dat de RA in deze patiënten geme-
dieerd wordt door andere pro-inflammatoire moleculen, zoals GM-CSF.
Recente studies tonen aan dat GM-CSF een belangrijke rol speelt in T 
helper cell 17 (Th17)-gemedieerde pathologie. Th17 cellen zijn een speci-
fiek soort T cellen die betrokken zijn bij de pathogenese van vele ontste-
kingsziekten. Deze cellen produceren grote hoeveelheden van het pro-in-
flammatoire interleukine 17 (IL-17). Wij bestudeerden de rol van GM-CSF 
in T cellen, door muizen te genereren met een specifieke overproductie 
van GM-CSF in T cellen (Hoofdstuk 3). Onze hypothese voor deze studie 
was dat toegenomen productie van GM-CSF door T cellen zou leiden 
tot een toename in de ontwikkeling van Th17 cellen, en/of een toename 
van pathogene T cellen tijdens ontsteking. We vonden inderdaad een 
toename in IL-17, maar ook in IL-23 (een cytokine dat vereist is voor de 
uiteindelijke ontwikkeling van Th17 cellen) en de Th17-gerelateerde tran-
scriptiefactor Ror-γt. Een onverwachte bevinding was dat deze muizen 
histiocytose ontwikkelden. Histiocytose is een ernstige aandoening die 
wordt gekarakteriseerd door de infiltratie van vele organen met histiocy-
ten: cellen van myeloide oorsprong, die de fenotypische eigenschappen 
bezitten van dendritische cellen, macrofagen en monocyten. Bij de mens 
is histiocytose een heterogene groep van ziekten, waarvoor geen gene-
zing bestaat. Eén van de bekendste vormen van histiocytose is Langer-
hans cel histiocytose (LCH), dat wordt gekarakteriseerd door de onge-
controleerde ophoping van Langerhans cellen. Onze transgene muizen 
ontwikkelden een fenotype dat vele kenmerken deelde met deze ziekte, 
zoals de ophoping van Langerhans cellen in de milt. Dit wees erop dat 
GM-CSF, afkomstig van T cellen, een belangrijke rol zou kunnen spelen in 
de pathogenese van deze ziekte. In ander onderzoek was al een link ge-
vonden tussen GM-CSF en LCH, waar verhoogde concentraties van GM-
CSF waren gemeten in het serum en laesies van LCH patiënten. Over 
de rol van IL-17 in LCH zijn de meningen verdeeld, maar onze resultaten 
wijzen op een verband tussen verhoogde productie van GM-CSF door T 
cellen, de productie van IL-17 en Th17-gerelateerde moleculen, en de op-
hoping van Langerhans cellen. Onze conclusie was dat GM-CSF, al dan 
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niet afkomstig van T cellen, een rol speelt bij LCH en dat therapeutische 
blokkade van GM-CSF een mogelijke toekomstige behandelingsmethode 
zou kunnen zijn voor deze ziekte.
Dat Th17 cellen een belangrijke rol spelen in RA is door vele groepen 
bevestigd. Wij bestudeerden Th17 differentiatie in een model voor acu-
te artritis: het mBSA/IL-1β model (Hoofdstuk 4). Hier laten we zien dat 
behandeling met neutraliserende anti-IL-17 antilichamen de ernst van de 
ontsteking vermindert, en dat dit model dus gemedieerd wordt door IL-
17. We vonden dat Th17 cellen aanwezig waren in ontstoken synoviaal 
weefsel, maar niet in de drainerende lymfeklier. Dit was een interessante 
bevinding, vooral met het oog op de nogal onconventionele eisen voor 
de ontwikkeling van Th17 cellen (aanwezigheid van IL-6, IL-23, TGFβ en 
de afwezigheid van IL-4 en IFN-γ), en wekt de suggestie dat er in het 
synoviaal weefsel een zeer specifiek cytokine milieu heerst. Dit toonden 
wij aan in vervolgexperimenten, waar macrofagen afkomstig uit ontstoken 
synoviaal weefsel Th17 differentiatie konden induceren in naïeve T cellen. 
Macrofagen afkomstig van een niet-ontstoken locatie (de peritoneale hol-
te) konden dit niet, vanwege de verminderde productie van IL-6 en IL-23.
Het mBSA/IL-1β model werd ook gebruikt in Hoofdstuk 5. Een eerdere 
studie van onze groep rapporteerde dat muizen die deficiënt zijn voor 
één van de Rel/NF-κB subunits (NF-κB1 or p50), beschermd waren tegen 
mBSA/IL-1β artritis. Ook voor collageen-geïnduceerde artritis (CIA) waren 
deze muizen niet vatbaar. Wij ontdekten dat deze bescherming werd ver-
oorzaakt door een relatief specifiek defect in CD4+ T cellen: deze kunnen 
geen of nauwelijks GM-CSF produceren. In de NF-κB1-deficiënte muizen 
konden we tijdens het artritis model, en ook tijdens een model voor acute 
peritoneale ontsteking, geen differentiatie aantonen van pro-inflammatoi-
re dendritische cellen (MoDC). Omdat GM-CSF wél gemaakt kan worden 
door andere cellen in deze muizen, suggereert deze data dat T cellen een 
specifieke bron zijn van GM-CSF voor de ontwikkeling van MoDC tijdens 
ontstekingsreacties.  
In Hoofdstuk 6 werd de relatie tussen GM-CSF en IL-17 verder onderzocht 
door het uitvoeren van twee tegenovergestelde experimenten: remming 
van deze cytokines tijdens CIA; en overexpressie van deze cytokines in 
kniegewrichten door injectie van adenovirale vectoren. We toonden aan 
dat het blokkeren van GM-CSF of IL-17 tijdens CIA een significante ver-
traging van het ziekteproces en vermindering van de gewrichtsschade tot 
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gevolg had. De gecombineerde remming van deze twee cytokines blok-
keerde het ziekteproces volledig, en er was geen of nauwelijks schade 
aan de gewrichten van de enkel en voet na afloop van het experiment. 
De analyse van de ontstekingsfactoren in de gewrichten toonde aan dat 
anti-IL-17 de transcriptie remt van de Th17-differentiatie factor IL-23. An-
ti-GM-CSF remde de productie van MMPs, Receptor Activator of NF-κB 
Ligand (RANKL), en monocyte-chemotactic protein-1 (MCP-1, CCL2). Se-
rum IL-6 was verminderd in alle behandelingsgroepen, vergeleken met 
de controlegroep. De lokale additieve en/of synergistische effecten van 
GM-CSF en IL-17 werden bestudeerd in een overexpressie systeem. 
Overexpressie van GM-CSF, IL-17, of een combinatie van de twee, werd 
bewerkstelligd door injectie van adenovirale vectoren in naïeve kniege-
wrichten bij de muis. Ontstekingsinfiltraat, kraakbeenschade en boterosie 
ontwikkelden zich in alle behandelingsgroepen vanaf de eerste dag na 
virusinjectie. Het meest ernstige effect werd waargenomen in de groep 
die geïnjecteerd was met een combinatie van de twee adenovirussen. 
Destructie van de gewrichtsstructuur was te zien op dag zeven na in-
jectie van beide virussen. Overexpressie van GM-CSF induceerde IL-1β, 
S100A8 en MMP13 in synoviocyten. Overexpressie van IL-17 induceer-
de een specifieke toename in IL-6 productie. Er was een sterke synergie 
waar te nemen in de productie van endogenous damage-associated mo-
lecular patterns (DAMP) ligand S100A8, de osteoclast activator RANKL, 
en IL-23. We concludeerden uit deze experimenten dat GM-CSF en IL-17 
gewrichtsschade veroorzaken door synergistische werking op de pro-in-
flammatoire factoren in synoviale gewrichten. Met het oog op het matige 
succes van therapeutische GM-CSF of IL-17 blokkade tijdens klinische 
testen in RA patiënten, zou combinatie therapie een optie kunnen zijn 
voor patiënten die geen baat hebben bij de remming van de afzonderlijke 
cytokines.
Samenvattend kunnen we concluderen dat GM-CSF en IL-17 een pro-
minente rol spelen in de pathogenese van artritis. Hoewel de werkings-
mechanismen van deze cytokines met elkaar in verbinding staan, wijzen 
onze resultaten erop dat het blokkeren van één van deze cytokines niet 
per definitie ook de acties van de ander beïnvloedt. Beide cytokines zijn 
zeer geschikte therapeutische targets in ontstekingsziekten, maar ge-
combineerde blokkade zou een superieure behandelingsmethode kun-
nen blijken te zijn.
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